Researcher Profile and Settings

Master

Affiliation (Master)

• Faculty of Medicine　Specialized Medicine　Reproductive and Developmental Medicine

Affiliation (Master)

• Faculty of Medicine　Specialized Medicine　Reproductive and Developmental Medicine

researchmap

Profile and Settings

Affiliation

• Hokkaido University

Profile and Settings

• Name (Japanese)

  Watari

• Name (Kana)

  Hidemichi

• Name

  201401064784256134

Alternate Names

http://kaken.nii.ac.jp/d/r/10344508.ja.html

Affiliation

• Hokkaido University

Achievement

Research Interests

• 抗癌剤耐性   卵巣癌   MET   clusterin   抗がん剤耐性   micfroRNA   micro RNA   アポトーシス   子宮体がん   医学   婦人科腫瘍学   分子標的治療   dominant negative   p53がん抑制遺伝子   p53癌抑制遺伝子   遺伝子変異   子宮体癌   悪性腫瘍   浸潤能   運動能   gain-of-function   p53変異   

Research Areas

• Life sciences / Obstetrics and gynecology

Research Experience

• 2010 - 2013 Hokkaido University

Published Papers

• Molecular-targeted therapies and precision medicine for endometrial cancer.

  Takashi Mitamura, Peixin Dong, Kei Ihira, Masataka Kudo, Hidemichi Watari

  Japanese journal of clinical oncology 49 (2) 108 - 120 0368-2811 2019/02/01 [Refereed][Not invited]
   

  The overall survival rate of patients with early-stage endometrial cancer is relatively high; however, there are few treatment options for patients with advanced or recurrent endometrial cancer, and the prognosis of such patients remains poor. Recent progress in molecular-targeted therapies demonstrated that they have the potential to improve the long-term survival of cancer patients with appropriate biomarkers. However, the median progression-free survival of patients who received single-agent molecular-targeted therapy was <5 months, and the development of molecular-targeted therapies for endometrial cancer patients is urgently needed. This review highlights the previous efforts, including antiangiogenesis therapy, PI3K/AKT/mTOR pathway inhibitor treatment and epidermal growth factor receptor inhibitor treatment and reports on ongoing phase 2 clinical trials, including immune checkpoint inhibitor and PARP inhibitor. We also summarized the genetic background of endometrial cancer according to The Cancer Genome Atlas data and considered the theoretical background for future efforts to prolong the survival of patients with refractory endometrial cancer and for other interesting challenges.
• Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.

  Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, Hanley SJB, Yue J, Watari H, Sakuragi N

  Oncogene 37 (39) 5257 - 5268 0950-9232 2018/09 [Refereed][Not invited]
  
• miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway.

  Wang B, Li X, Zhao G, Yan H, Dong P, Watari H, Sims M, Li W, Pfeffer LM, Guo Y, Yue J

  Journal of experimental & clinical cancer research : CR 37 (1) 235  0392-9078 2018/09 [Refereed][Not invited]
  
• miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2.

  Zeinab Mohamed, Mohamed Kamel Hassan, Safwat Okasha, Takashi Mitamura, Sarah Keshk, Yusuke Konno, Tatsuya Kato, Sherif F El-Khamisy, Yusuke Ohba, Hidemichi Watari

  Oncotarget 9 (53) 30053 - 30065 2018/07/10 [Refereed][Not invited]
   

  Ovarian cancer is the most aggressive female reproductive tract tumours. Taxane (paclitaxel; TX) is widely used for ovarian cancer treatment. However, ovarian cancers often acquire chemoresistance. MicroRNAs (miR) have been reported to mediate many tumours'chemoresistance. We investigated the role of miR-363 in the chemoresistance of the ovarian cancer cell line, KF, and its TX-resistant derivative (KF-TX) cells. QRT-PCR indicated that miR-363 was upregulated in KF-TX cells, and introduction of miR-363 into sensitive ovarian cancer cells confers TX-resistance and significantly inhibited the expression of the Hippo member, LATS2, as indicated by viability, clonogenic assay and expression analysis. Furthermore, we validated the role of LATS2 in TX-response by sh-based silencing, which also confers TX-resistance to the ovarian cancer cells. On the other hand, specific inhibitor against miR-363 restored the response to TX in the resistant cells. In addition, miR-363 was found to bind to the 3'-UTR of LATS2 mRNA, confirming that miR-363 directly targets LATS2 as indicated by dual luciferase assay. RT-PCR-based evaluation of miR-363 in a panel of human ovarian tumours revealed its upregulation in most of the tumour tissues identified as resistant while it was downregulated in most of the tissues identified as sensitive ones. Moreover, higher levels of miR-363 in human ovarian cancer specimens were significantly correlated with TX chemoresistance. Taken together, our study reveals the involvement of miR-363 in chemoresistance by targeting LATS2 in ovarian cancers, raising the possibility that combination therapy with a miR-363 inhibitor and TX may increase TX efficacy and reduce the chance of TX-resistance.
• Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.

  Satomi Aoyama-Kikawa, Hiromasa Fujita, Sharon J B Hanley, Mitsunori Kasamo, Kokichi Kikuchi, Toshihiko Torigoe, Yoshihiro Matsuno, Akiko Tamakoshi, Takayuki Sasaki, Motoki Matsuura, Yasuhito Kato, Peixin Dong, Hidemichi Watari, Tsuyoshi Saito, Kazuo Sengoku, Noriaki Sakuragi

  Cancer science 109 (6) 2003 - 2012 1347-9032 2018/06 [Refereed][Not invited]
   

  Although cytology-based screening programs have significantly reduced mortality and morbidity from cervical cancer, the global consensus is that primary human papillomavirus (HPV) testing for cervical screening increases detection of high-grade cervical intraepithelial neoplasia (CIN) and invasive cancer. However, the optimal triage strategy for HPV-positive women to avoid over-referral to colposcopy may be setting specific. As Japan requires data that have been generated domestically to modify screening guidelines, we conducted a 3-year prospective study, COMparison of HPV genotyping And Cytology Triage (COMPACT), to evaluate the potential role of HPV16/18 partial genotyping and cytology for primary HPV screening. In total, 14 642 women aged 20 to 69 years undergoing routine screening at 3 centers in Hokkaido were enrolled. Conventional cytology and HPV testing were carried out. Women with abnormal cytology or HPV16/18 positivity underwent colposcopy. Those with 12 other high-risk (hr) HPV types underwent repeat cytology after 6 months. Primary study endpoints were detection of high-grade cervical disease defined as CIN2/CIN3 or greater as determined by consensus pathology. Prevalence of cytological abnormalities was 2.4%. hrHPV, HPV 16, and HPV 18 were detected in 4.6%, 0.9%, and 0.3% of women, respectively. HPV16/18 were detected in all (8/8) invasive cervical cancers and in all (2/2) adenocarcinomas in situ. Both cytological abnormalities and hrHPV positivity declined with increasing age. This is the first Japanese study to investigate the role of partial genotyping and cytology in an HPV-based screening program. Results should help policy-makers develop guidelines for future cervical screening programs and management of cervical abnormalities based on HPV genotype.
• miR-34a, miR-424 and miR-513 inhibit MMSET expression to repress endometrial cancer cell invasion and sphere formation.

  Peixin Dong, Ying Xiong, Junming Yue, Sharon J B Hanley, Hidemichi Watari

  Oncotarget 9 (33) 23253 - 23263 2018/05/01 [Refereed][Not invited]
   

  Although the oncogene MMSET (also known as NSD2 or WHSC1) has an essential role in malignancies, its impact on human endometrial cancer (EC) metastasis and the molecular mechanism of MMSET regulation are largely unknown. We report that MMSET was markedly upregulated in EC cell lines and EC tissues, and was significantly associated with poor survival in EC. MMSET overexpression greatly promoted EC cell invasion and sphere formation, whereas inhibition of MMSET reduced EC cell invasion and sphere formation. Importantly, Twist1 was required for MMSET-induced EC cell invasion and sphere formation. Moreover, we demonstrate that miR-34a, miR-424 and miR-513 directly modulate MMSET expression to attenuate the invasion and sphere formation capacity of EC cells. miR-34a, miR-424 and miR-513 were down-regulated in EC compared with normal tissue, and reduced expression of miR-34a, miR-424 and miR-513 was clinically associated with a poorer prognosis in EC patients. Furthermore, specific inhibition of MMET with BIX-01294 led to decreased EC cell invasion and impaired sphere formation. These findings suggest a pro-metastatic role for MMSET in EC and reveal that the repression of miR-34a, miR-424 and miR-513 contributes to the overexpression of MMSET during EC metastasis.
• Lentiviral vector mediated-ASAP1 expression promotes epithelial to mesenchymal transition in ovarian cancer cells

  Tao Zhang, Guannan Zhao, Chuanhe Yang, Peixin Dong, Hidemichi Watari, Lin Zeng, Lawrence M. Pfeffer, Junming Yue

  Oncology Letters 15 (4) 4432 - 4438 1792-1082 2018/04/01 [Refereed][Not invited]
   

  Ovarian cancer is one of the most common malignancies in women and has a high mortality rate due to metastatic progression and tumor recurrence. ASAP1 (ArfGAP with SH3 Domain, Ankyrin Repeat and PH Domain 1) is an ADP-ribosylation factor GTPase-activating protein, which is involved in tumor metastasis. However, the role of ASAP1 in ovarian cancer is completely unknown. The present study reported that ASAP1 was highly expressed in ovarian carcinoma, and expression positively-correlated with overall poor survival and prognosis of patients. Lentiviral vector mediated ASAP1 expression promoted cell migration and invasion in ovarian cancer cell lines SKOV3 and OVCAR3. In addition, ASAP1 promoted cell proliferation, survival and inhibited chemotherapy drug paclitaxel-induced cell apoptosis. Furthermore, ASAP1 expression promoted epithelial to mesenchymal transition (EMT) by upregulating the mesenchymal cell markers N-cadherin and vimentin, and downregulating epithelial cell marker E-cadherin in the ovarian cancer cell lines. The data indicate for the first time that ASAP1 exhibits an oncogenic role by promoting EMT in ovarian cancer cells.
• B7H3 As a Promoter of Metastasis and Promising Therapeutic Target.

  Peixin Dong, Ying Xiong, Junming Yue, Sharon J B Hanley, Hidemichi Watari

  Frontiers in oncology 8 264 - 264 2018 [Refereed][Not invited]
   

  B7H3 (also known as CD276, an immune checkpoint molecule) is aberrantly overexpressed in many types of cancer, and such upregulation is generally associated with a poor clinical prognosis. Recent discoveries indicate a crucial role for B7H3 in promoting carcinogenesis and metastasis. This review will focus on the latest developments relating specifically to the oncogenic activity of B7H3 and will describe the upstream regulators and downstream effectors of B7H3 in cancer. Finally, we discuss the emerging roles of microRNAs (miRNAs) in inhibiting B7H3-mediated tumor promotion. Excellent recent studies have shed new light on the functions of B7H3 in cancer and identified B7H3 as a critical promoter of tumor cell proliferation, migration, invasion, epithelial-to-mesenchymal transition, cancer stemness, drug resistance, and the Warburg effect. Numerous miRNAs are reported to regulate the expression of B7H3. Our meta-analysis of miRNA database revealed that 17 common miRNAs potentially interact with B7H3 mRNA. The analysis of the TCGA ovarian cancer dataset indicated that low miR-187 and miR-489 expression was associated with poor prognosis. Future studies aimed at delineating the precise cellular and molecular mechanisms underpinning B7H3-mediated tumor promotion will provide further insights into the cell biology of tumor development. In addition, inhibition of B7H3 signaling, to be used alone or in combination with other treatments, will contribute to improvements in clinical practice and benefit cancer patients.
• Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.

  Peixin Dong, Ying Xiong, Junming Yue, Sharon J B Hanley, Hidemichi Watari

  Frontiers in oncology 8 386 - 386 2018 [Refereed][Not invited]
   

  Although the role of PD-L1 in suppressing the anti-tumor immune response is extensively documented, recent discoveries indicate a distinct tumor-intrinsic role for PD-L1 in modulating epithelial-to-mesenchymal transition (EMT), cancer stem cell (CSC)-like phenotype, metastasis and resistance to therapy. In this review, we will focus on the newly discovered functions of PD-L1 in the regulation of cancer development, describe underlying molecular mechanisms responsible for PD-L1 upregulation and discuss current insights into novel components of PD-L1 signaling. Furthermore, we summarize our current understanding of the link between PD-L1 signaling and the EMT program as well as the CSC state. Tumor cell-intrinsic PD-L1 clearly contributes to cancer stemness, EMT, tumor invasion and chemoresistance in multiple tumor types. Conversely, activation of OCT4 signaling and upregulation of EMT inducer ZEB1 induce PD-L1 expression in cancer cells, thereby suggesting a possible immune evasion mechanism employed by cancer stem cells during metastasis. Our meta-analysis demonstrated that PD-L1 is co-amplified along with MYC, SOX2, N-cadherin and SNAI1 in the TCGA endometrial and ovarian cancer datasets. Further identification of immune-independent PD-L1 functions and characterization of crucial signaling events upstream or downstream of PD-L1 in diverse cancer types and specific cancer subtypes, would provide additional targets and new therapeutic approaches.
• Long Non-coding RNA NEAT1: A Novel Target for Diagnosis and Therapy in Human Tumors.

  Peixin Dong, Ying Xiong, Junming Yue, Sharon J B Hanley, Noriko Kobayashi, Yukiharu Todo, Hidemichi Watari

  Frontiers in genetics 9 471 - 471 2018 [Refereed][Not invited]
   

  The nuclear paraspeckle assembly transcript 1 (NEAT1, a long non-coding RNA) is frequently overexpressed in human tumors, and higher NEAT1 expression is correlated with worse survival in cancer patients. NEAT1 drives tumor initiation and progression by modulating the expression of genes involved in the regulation of tumor cell growth, migration, invasion, metastasis, epithelial-to-mesenchymal transition, stem cell-like phenotype, chemoresistance and radioresistance, indicating the potential for NEAT1 to be a novel diagnostic biomarker and therapeutic target. Mechanistically, NEAT1 functions as a scaffold RNA molecule by interacting with EZH2 (a subunit of the polycomb repressive complex) to influence the expression of downstream effectors of EZH2, it also acts as a microRNA (miRNA) sponge to suppress the interactions between miRNAs and target mRNAs, and affects the expression of miR-129 by promoting the DNA methylation of the miR-129 promoter region. Knockdown of NEAT1 via small interfering RNA or short hairpin RNA inhibits the malignant behavior of tumor cells. In this review, we highlight the latest insights into the expression pattern, biological roles and mechanisms underlying the function and regulation of NEAT1 in tumors, and especially focus on its clinical implication as a new diagnostic biomarker and an attractive therapeutic target for cancers.
• The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma In Vitro and In Vivo

  Makiko Nakatani, Hidemichi Watari, Takashi Mitamura, Lei Wang, Yutaka Hatanaka, Kanako C. Hatanaka, Kohei Honda, Toshiyuki Nomura, Hiroshi Nishihara, Shinya Tanaka, Noriaki Sakuragi

  ANTICANCER RESEARCH 37 (11) 6125 - 6132 0250-7005 2017/11 [Refereed][Not invited]
   

  Background: Several reports have shown that the overexpression of the MET proto-oncogene, receptor tyrosine kinase (MET), was more frequently observed in clear cell carcinoma (CCC) than in non-CCC. We evaluated the antitumor activity of cabozantinib, that targets MET. Materials and Methods: A gene expression analysis of tumors from human ovarian cancers was carried out by transcriptome sequencing. An in vitro 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide assay (MTT assay) and in vivo experiments were performed to determine the activity of cabozantinib. Results: The MET levels were higher in tumors with CCC than high-grade serous carcinoma (2.2-fold). Cabozantinib inhibited cell viability and phosphorylation of AKT and MAPK under the treatment of hepatocyte growth factor in RMG-I CCC cells. The tumors removed from mice given cabozantinib of 10 mg/kg weighed 70% less than control on day 15, and the immunohistochemical reactivity of phosphorylated MET was reduced compared with control mice. Conclusion: Cabozantinib contributes to tumor reduction, and phosphorylated MET represents an attractive target of CCC.
• Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells

  Guannan Zhao, Qinghui Wang, Qingqing Gu, Wenan Qiang, Jian-Jun Wei, Peixin Dong, Hidemichi Watari, Wei Li, Junming Yue

  ONCOTARGET 8 (55) 94666 - 94680 1949-2553 2017/11 [Refereed][Not invited]
   

  BIRC5 encodes the protein survivin, a member of the inhibitor of apoptosis family. Survivin is highly expressed in a variety of cancers but has very low expression in the corresponding normal tissues, and its expression is often associated with tumor metastasis and chemoresistance. We report that survivin was highly expressed in ovarian cancer and strongly correlated with patient overall poor survival. For the first time, we provide experimental evidence that survivin is involved in epithelial to mesenchymal transition (EMT) in ovarian cancer cells. Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 gene editing led to the inhibition of EMT by upregulating epithelial cell marker, cytokeratin 7 and downregulating mesenchymal markers: snail2, beta-catenin, and vimentin in both ovarian cancer SKOV3 and OVCAR3 cells. Consistent with this molecular approach, pharmacological treatment of ovarian cancer cells using a small molecule survivin inhibitor, YM155 also inhibited EMT in these ovarian cancer cell lines. Overexpression of BIRC5 promoted EMT in SKOV3 cells. Using molecular or pharmacological approaches, we found that cell proliferation, migration, and invasion were significantly inhibited following BIRC5 disruption in both cell lines. Inhibition of BIRC5 expression also sensitized cell responses to paclitaxel treatment. Moreover, loss of BIRC5 expression attenuated TGF beta signaling in both SKOV3 and OVCAR3 cells. Collectively, our studies demonstrated that disruption of BIRC5 expression inhibited EMT by attenuating the TGF beta pathway in ovarian cancer cells.
• Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3)

  Hidemichi Watari, Hiroshi Katayama, Taro Shibata, Kimio Ushijima, Toyomi Satoh, Takashi Onda, Daisuke Aoki, Haruhiko Fukuda, Nobuo Yaegashi, Noriaki Sakuragi

  JAPANESE JOURNAL OF CLINICAL ONCOLOGY 47 (10) 986 - 990 0368-2811 2017/10 [Refereed][Not invited]
   

  To prospectively investigate the survival benefit of para-aortic lymphadenectomy, we launched a new study, the JCOG1412. This is a randomized Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone. Patients corresponding to possible FIGO Stage IB, II, IIIA, IIIB, and a part of IIIC1 are eligible for the first registration before surgery. Next, those patients without evidence of para-aortic lymph node metastasis and multiple pelvic lymph node metastasis during surgery will be included in the second registration and randomized to either the pelvic lymphadenectomy alone arm or the pelvic and para-aortic lymphadenectomy arm. After the initial surgery, patients with post-operative recurrence risks receive adjuvant chemotherapy. The primary endpoint is overall survival. Secondary endpoints include relapse-free survival, short-term surgical outcomes, adverse events related to adjuvant chemotherapy and recurrence patterns. This trial has been registered at the UMIN Clinical Trials Registry [http://www.umin.ac.jp/ctr/index.htm] as UMIN000025399.
• Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation.

  Dong P, Xiong Y, Hanley SJB, Yue J, Watari H

  Journal of experimental & clinical cancer research : CR 36 (1) 150  0392-9078 2017/10 [Refereed][Not invited]
  
• Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02)

  Shunsuke Ohnishi, Hidemichi Watari, Maki Kanno, Yoko Ohba, Satoshi Takeuchi, Tempei Miyaji, Shunsuke Oyamada, Eiji Nomura, Hidenori Kato, Toru Sugiyama, Masahiro Asaka, Noriaki Sakuragi, Takuhiro Yamaguchi, Yasuhito Uezono, Satoru Iwase

  JOURNAL OF GYNECOLOGIC ONCOLOGY 28 (5) e44  2005-0380 2017/09 [Refereed][Not invited]
   

  Objective: Rikkunshito, an herbal medicine, is widely prescribed in Japan for the treatment of anorexia and functional dyspepsia, and has been reported to recover reductions in food intake caused by cisplatin. We investigated whether rikkunshito could improve chemotherapy-induced nausea and vomiting (CINV) and anorexia in patients treated with cisplatin. Methods: Patients with uterine cervical or corpus cancer who were to receive cisplatin (50 mg/m(2) day 1) and paclitaxel (135 mg/m2 day 0) as first-line chemotherapy were randomly assigned to the rikkunshito group receiving oral administration on days 0-13 with standard antiemetics, or the control group receiving antiemetics only. The primary endpoint was the rate of complete control (CC: no emesis, no rescue medication, and no significant nausea) in the overall phase (0-120 hours). Two-tailed p<0.20 was considered significant in the planned analysis. Results: The CC rate in the overall phase was significantly higher in the rikkunshito group than in the control group (57.9% vs. 35.3%, p=0.175), as were the secondary endpoints: the CC rate in the delayed phase (24-120 hours), and the complete response (CR) rates (no emesis and no rescue medication) in the overall and delayed phases (63.2% vs. 35.3%, p=0.095; 84.2% vs. 52.9%, p=0.042; 84.2% vs. 52.9%, p=0.042, respectively), and time to treatment failure (p=0.059). Appetite assessed by visual analogue scale (VAS) appeared to be superior in the rikkunshito group from day 2 through day 6. Conclusion: Rikkunshito provided additive effect for the prevention of CINV and anorexia.
• Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma

  Hiroaki Itamochi, Tetsuro Oishi, Nao Oumi, Satoshi Takeuchi, Kosuke Yoshihara, Mikio Mikami, Nobuo Yaegashi, Yasuhisa Terao, Kazuhiro Takehara, Kimio Ushijima, Hidemichi Watari, Daisuke Aoki, Tadashi Kimura, Toshiaki Nakamura, Yoshihito Yokoyama, Junzo Kigawa, Toru Sugiyama

  BRITISH JOURNAL OF CANCER 117 (5) 717 - 724 0007-0920 2017/08 [Refereed][Not invited]
   

  Background: Ovarian clear cell carcinoma (OCCC) is mostly resistant to standard chemotherapy that results in poor patient survival. To understand the genetic background of these tumours, we performed whole-genome sequencing of OCCC tumours. Methods: Tumour tissue samples and matched blood samples were obtained from 55 Japanese women diagnosed with OCCC. Whole-genome sequencing was performed using the Illumina HiSeq platform according to standard protocols. Results: Alterations to the switch/sucrose non-fermentable (SWI/SNF) subunit, the phosphatidylinositol-3-kinase (PI3K)/Akt signalling pathway, and the receptor tyrosine kinase (RTK)/Ras signalling pathway were found in 51%, 42%, and 29% of OCCC tumours, respectively. The 3-year overall survival (OS) rate for patients with an activated PI3K/Akt signalling pathway was significantly higher than that for those with inactive pathway (91 vs 40%, hazard ratio 0.24 (95% confidence interval (CI) 0.10-0.56), P = 0.0010). Similarly, the OS was significantly higher in patients with the activated RTK/Ras signalling pathway than in those with the inactive pathway (91 vs 53%, hazard ratio 0.35 (95% CI 0.13-0.94), P = 0.0373). Multivariable analysis revealed that activation of the PI3K/Akt and RTK/Ras signalling pathways was an independent prognostic factor for patients with OCCC. Conclusions: The PI3K/Akt and RTK/Ras signalling pathways may be potential prognostic biomarkers for OCCC patients. Furthermore, our whole-genome sequencing data highlight important pathways for molecular and biological characterisations and potential therapeutic targeting in OCCC.
• iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling.

  Xiong Y, Sun F, Dong P, Watari H, Yue J, Yu MF, Lan CY, Wang Y, Ma ZB

  Journal of experimental & clinical cancer research : CR 36 (1) 48  0392-9078 2017/04 [Refereed][Not invited]
  
• KLF4 expression enhances the efficacy of chemotherapy drugs in ovarian cancer cells

  Baojin Wang, Airong Shen, Xuan Ouyang, Guannan Zhao, Ziyun Du, Wenying Huo, Tao Zhang, Yinan Wang, Chuanhe Yang, Peixin Dong, Hidemichi Watari, Lawrence M. Pfeffer, Junming Yue

  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 484 (3) 486 - 492 0006-291X 2017/03 [Refereed][Not invited]
   

  KLF4 is a transcriptional factor that can function either as a tumor suppressor or oncogene in cancer based on its cellular context. We recently demonstrated that KLF4 was a tumor suppressor in ovarian cancer cells by inhibiting the epithelial to mesenchymal transition. Here we report that KLF4 expression was downregulated in ovarian cancer tissue compared to normal ovarian tissue, and low KLF4 expression correlated with high risk ovarian carcinoma and poor patient survival. Enforced KLF4 expression by lentiviral transduction sensitized ovarian cancer cells to the effects of the chemotherapy drugs, paclitaxel and cisplatin. Treatment of ovarian cancer cells with APTO-253, a small molecule inducer of KLF4, enhanced the efficacy of both chemotherapy drugs. KLF4 expression mediated by lentiviral vector or induced by APTO-253 resulted in G1 phase arrest in ovarian cancer cells. Our results demonstrate that for the first time that inducing KLF4 expression with APTO-253 is a novel therapeutic strategy for treating ovarian cancer. (C) 2017 Elsevier Inc. All rights reserved.
• EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis

  Kei Ihira, Peixin Dong, Ying Xiong, Hidemichi Watari, Yosuke Konno, Sharon J. B. Hanley, Masayuki Noguchi, Noriyuki Hirata, Futoshi Suizu, Takahiro Yamada, Masataka Kudo, Noriaki Sakuragi

  ONCOTARGET 8 (8) 13509 - 13520 1949-2553 2017/02 [Refereed][Not invited]
   

  EZH2 inhibition and reactivation of tumor suppressor microRNAs (miRNAs) represent attractive anti-cancer therapeutic strategies. We found that EZH2-suppressed let 7b and miR-361, two likely tumor suppressors, inhibited endometrial cancer (EC) cell proliferation and invasion, and abrogated cancer stem cell-like properties. In EC cells, EZH2 induced and functioned together with YY1 to epigenetically suppress miR-361, which upregulated Twist, a direct target of miR361. Treating EC cells with GSK343, a specific EZH2 inhibitor, mimicked the effects of siRNA-mediated EZH2 knockdown, upregulating miR-361 and downregulating Twist expression. Combining GSK343 with 5 AZA-2'-deoxycytidine synergistically suppressed cell proliferation and invasion in vitro, and decreased tumor size and weight in EC cell xenografted mice. Quantitative real-time PCR analysis of 24 primary EC tissues showed that lower let-7b and miR-361 levels were associated with worse patient outcomes. These results were validated in a larger EC patient dataset from The Cancer Genome Atlas. Our findings suggest that EZH2 drives EC progression by regulating miR-361/Twist signaling, and support EZH2 inhibition as a promising anti-EC therapeutic strategy.
• Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells

  Wenying Huo, Guannan Zhao, Jinggang Yin, Xuan Ouyang, Yinan Wang, Chuanhe Yang, Baojing Wang, Peixin Dong, Zhixiang Wang, Hidemichi Watari, Edward Chaum, Lawrence M. Pfeffer, Junming Yue

  JOURNAL OF CANCER 8 (1) 57 - 64 1837-9664 2017 [Refereed][Not invited]
   

  CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats) mediated genome editing is a powerful approach for loss of function studies. Here we report that lentiviral CRISPR/Cas9 vectors are highly efficient in introducing mutations in the precursor miRNA sequence, thus leading to the loss of miRNA expression and function. We constructed four different lentiviral CRISPR/Cas9 vectors that target different regions of the precursor miR-21 sequence and found that these lentiviral CRISPR/Cas9 miR-21 gRNA vectors induced mutations in the precursor sequences as shown by DNA surveyor mutation assay and Sanger sequencing. Two miR-21 lentiviral CRISPR/Cas9 gRNA vectors were selected to probe miR-21 function in ovarian cancer SKOV3 and OVCAR3 cell lines. Our data demonstrate that disruption of pre-miR-21 sequences leads to reduced cell proliferation, migration and invasion. Moreover, CRISPR/Cas9-mediated miR-21 gene editing sensitizes both SKOV3 and OVCAR3 cells to chemotherapeutic drug treatment. Disruption of miR-21 leads to the inhibition of epithelial to mesenchymal transition (EMT) in both SKOV3 and OVCAR3 cells as evidenced by the upregulation of epithelial cell marker E-cadherin and downregulation of mesenchymal marker genes, vimentin and Snai2. The miR-21 target genes PDCD4 and SPRY2 were upregulated in cells transduced with miR-21gRNAs compared to controls. Our study indicates that lentiviral CRISPR/Cas9-mediated miRNA gene editing is an effective approach to address miRNA function, and disruption of miR-21 inhibits EMT in ovarian cancer cells.
• Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells

  Muhammad Baghdadi, Haruka Wada, Sayaka Nakanishi, Hirotake Abe, Nanumi Han, Wira Eka Putra, Daisuke Endo, Hidemichi Watari, Noriaki Sakuragi, Yasuhiro Hida, Kichizo Kaga, Yohei Miyagi, Tomoyuki Yokose, Atsushi Takano, Yataro Daigo, Ken-ichiro Seino

  CANCER RESEARCH 76 (20) 6030 - 6042 0008-5472 2016/10 [Refereed][Not invited]
   

  The ability of tumor cells to escape immune destruction and their acquired resistance to chemotherapy are major obstacles to effective cancer therapy. Although immune checkpoint therapies such as anti-PD-1 address these issues in part, clinical responses remain limited to a subpopulation of patients. In this report, we identified IL34 produced by cancer cells as a driver of chemoresistance. In particular, we found that IL34 modulated the functions of tumor-associated macrophages to enhance local immunosuppression and to promote the survival of chemoresistant cancer cells by activating AKT signaling. Targeting IL34 in chemoresistant tumors resulted in a remarkable inhibition of tumor growth when accompanied with chemotherapy. Our results define a pathogenic role for IL34 in mediating immunosuppression and chemoresistance and identify it as a tractable target for anticancer therapy. (C) 2016 AACR.
• Suppression of iASPP-dependent aggressiveness in cervical cancer through reversal of methylation silencing of microRNA-124

  Peixin Dong, Ying Xiong, Hidemichi Watari, Sharon J. B. Hanley, Yosuke Konno, Kei Ihira, Fumihiko Suzuki, Takahiro Yamada, Masataka Kudo, Junming Yue, Noriaki Sakuragi

  SCIENTIFIC REPORTS 6 35480  2045-2322 2016/10 [Refereed][Not invited]
   

  Derepression of wild-type p53 by suppressing its negative inhibitor iASPP (Inhibitor of apoptosis-stimulating protein of p53) represents a potential therapeutic option for cervical cancer (CC). Here, we reported a novel functional significance of iASPP upregulation in cervical tumorigenesis: iASPP acts as a key promoter of CC cell proliferation, epithelial-mesenchymal transition, invasion and cancer stemness, by interacting with p53 to suppress p53-mediated transcription of target genes and reducing p53-responsive microRNA-34a levels. Moreover, we demonstrate that miR-124, directly targeting iASPP, reduces expression of iASPP and attenuates CC cell growth and invasiveness. Low miR-124 expression is inversely correlated with increased expression of iASPP mRNA in CC tissues. In a cohort of 40 patients with CC, the low miR-124 expression was correlated with poor 5-year overall survival (P = 0.0002) and shorter disease-free survival 5-year (P = 0006). Treatment with the DNA methyltransferase inhibitor Zebularine increases miR-124 expression and retards CC cell growth and invasion with minimal toxicity to normal cells. Even at a non-toxic concentration, Zebularine was effective in suppressing CC cell invasion and migration. Altogether, the restoration of miR-124 reduces iASPP expression and leads to p53-dependent tumor suppression, suggesting a therapeutic strategy to treat iASPP-associated CC.
• HPV self-sampling in Japanese women: A feasibility study in a population with limited experience of tampon use

  Sharon J. B. Hanley, Hiromasa Fujita, Susumu Yokoyama, Shiori Kunisawa, Akiko Tamakoshi, Peixin Dong, Noriko Kobayashi, Hidemichi Watari, Masataka Kudo, Noriaki Sakuragi

  JOURNAL OF MEDICAL SCREENING 23 (3) 164 - 170 0969-1413 2016/09 [Refereed][Not invited]
   

  Objectives: Cervical cancer incidence and mortality is increasing in Japanese women under age 50. Screening uptake is low and proactive recommendations for human papillomavirus vaccination have been suspended. Other cervical cancer prevention initiatives are urgently needed. We assessed whether human papillomavirus self-sampling might be an acceptable alternative to physician-led screening, particularly in women with limited experience of tampon use. We also sought to identify any practical, logistical, or safety issues in women already attending for screening, before carrying out further large-scale studies in non-responders. Methods: In total, 203 women aged 20-49 attending their annual workplace healthcheck in Sapporo, northern Japan, performed unsupervised human papillomavirus self-sampling before undergoing a physician-led cervical smear and human papillomavirus test, and completing a measure of acceptability for both tests. Results: Ninety per cent of participants stated they would use self-sampling again. They found instructions easy to follow and reported no issues with the usability of the self-sampling device. Compared with physician-led testing, women found self-sampling significantly less painful, less embarrassing and could relax more (p < 0.001), regardless of history of tampon use, which was associated with negative experiences in physician sampling (p = 0.034). Women lacked confidence the test had been performed correctly, despite no unsatisfactory samples. No safety issues were reported. Conclusions: Self-sampling was highly acceptable in this population of women. They could perform the test safely unsupervised, but lacked confidence the test has been carried out correctly. Japanese women need to be educated about the accuracy of human papillomavirus self-sampling and further large-scale studies are necessary in non-responders.
• MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells.

  Dong P, Xiong Y, Watari H, Hanley SJ, Konno Y, Ihira K, Yamada T, Kudo M, Yue J, Sakuragi N

  Journal of experimental & clinical cancer research : CR 35 (1) 132  0392-9078 2016/09 [Refereed][Not invited]
  
• Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group

  Kenichi Harano, Akihiro Hirakawa, Mayu Yunokawa, Toshiaki Nakamura, Toyomi Satoh, Tadaaki Nishikawa, Daisuke Aoki, Kimihiko Ito, Kiyoshi Ito, Toru Nakanishi, Nobuyuki Susumu, Kazuhiro Takehara, Yoh Watanabe, Hidemichi Watari, Toshiaki Saito

  GYNECOLOGIC ONCOLOGY 141 (3) 447 - 453 0090-8258 2016/06 [Refereed][Not invited]
   

  Background. The benefits of cytoreductive surgery for uterine carcinosarcoma (UCS) are unknown. The objective of this study was to determine the impact of optimal surgery on advanced UCS patient survival. Methods. We performed a multi-institutional, retrospective study of women diagnosed with stage UCS between 2007 and 2012. Data were obtained retrospectively from medical records, including demographic, clinicopathologic, treatment, and outcome information. Optimal cytoreductive surgery was defined as surgery resulting in a maximum residual tumor of <= 1 cm. The Kaplan-Meier method was used to calculate progression-free survival (PFS) and overall survival (OS), and the Cox regression model was used to examine the impact of selected factors on survival. Results. A total of 225 UCS patients (median age, 63 years) were identified, including 136 (60%) with stage III and 89 (40%) with stage IV disease. Among these patients, 170 (76%) received optimal cytoreductive surgery. The median follow-up time was 19 months. The median PFS was 11.5 months (95% confidence interval ICI], 10.6-13.4) and 8.1 months (95% CI, 5.1-9.5) for patients who received optimal and suboptimal cytoreductive surgery, respectively (P < 0.0001). The median OS was 37.9 months (95% CI, 283-not reached) and 18 months (95% CI, 9.6-21) for patients who received optimal and suboptimal cytoreductive surgery, respectively (P < 0.0001). Residual tumor >1 cm was associated with worse OS while pelvic lymph node dissection was associated with improved OS. Conclusion. Optimal cytoreductive surgery and pelvic lymph node dissection are associated with improved OS in advanced UCS patients. (C) 2016 Elsevier Inc. All rights reserved.
• Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression

  Peixin Dong, Kei Ihira, Ying Xiong, Hidemichi Watari, Sharon J. B. Hanley, Takahiro Yamada, Masayoshi Hosaka, Masataka Kudo, Junming Yue, Noriaki Sakuragi

  ONCOTARGET 7 (15) 20260 - 20270 1949-2553 2016/04 [Refereed][Not invited]
   

  Overexpression of IQGAP1 and microRNA (miRNA) dysregulation are frequent in human tumors, but little is known about the role of IQGAP1 and its relationship to miRNA in endometrial carcinogenesis. We demonstrate that IQGAP1 activates the epithelial-mesenchymal transition (EMT) program and that miR-124 directly represses IQGAP1 expression in endometrial cancer (EC) cells. The overexpression of IQGAP1 stimulates EMT features and enhances migration, invasion and proliferation of EC cells, whereas knocking down IQGAP1 expression reverses EMT and inhibits these malignant properties. Using miRNA microarray profiling, we identified 29 miRNAs (let-7b, let-7f, miR-10b, miR-15b, miR-23a, miR-24, miR-25, miR-27a, miR-29b, miR-30a-5p, miR-34a, miR-124, miR-127, miR-130b, miR-148a, miR-155, miR-191*, miR-194, miR-224, miR-362, miR-409-3p, miR-422b, miR-424, miR-453, miR-497, miR-518d, miR-518f*, miR-526a and miR-656) that are significantly down-regulated in an in vitro-selected highly invasive derivative cell line (HEC-50-HI) relative to the parental HEC-50 cells. We further identified miR-124 as a direct regulator of IQGAP1 in EC cells. Enforced expression of miR-124 suppresses EC cell invasion and proliferation. The expression of IQGAP1 mRNA was significantly elevated in EC tissues, while the expression of miR-124 was decreased. The downregulation of miR-124 correlates with a poor survival outcome for patients with EC. Treating EC cells with the demethylating agent 5-aza-2'-deoxycytidine increased miR-124 expression and down-regulated IQGAP1 levels. Our data suggest that IQGAP1 promotes EMT, migration and invasion of EC cells. MiR-124, a novel tumor suppressor miRNA that is epigenetically silenced in EC, can reverse EMT and the invasive properties, by attenuating the expression of the IQGAP1 oncogene.
• Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups

  Yukiharu Todo, Hidemichi Watari

  CHINESE JOURNAL OF CANCER RESEARCH 28 (2) 221 - 227 1000-9604 2016/04 [Refereed][Not invited]
   

  Concurrent chemoradiotherapy (CCRT) is regarded as the standard treatment for locally advanced uterine cervical cancer (LACC), including stage Ib2-IVa disease [International Federation of Gynecology and Obstetrics (FIGO) staging]. However, approximately a third of eligible patients in previous studies died of LACC despite receiving CCRT. The therapeutic significance of CCRT alone in stage III-IVa disease has not yet been confirmed. Effective treatment of some LACC is beyond the scope of CCRT. The objective of the present review is to highlight some challenging work aimed at overcoming this seemingly intractable disease. CCRT with increased peak concentrations of cisplatin (CDDP), surgery following CCRT, adjuvant chemotherapy (CT) following CCRT, and neoadjuvant CT followed by CCRT are strategies expected to enhance the therapeutic efficacy of CCRT. If patients with LACC were divided into those with low-risk or high-risk systemic disease or prognoses, novel strategies should be assessed in the group with high-risk disease.
• Adjuvant chemotherapy for early-stage cervical cancer

  Hiroshi Asano, Yukiharu Todo, Hidemichi Watari

  CHINESE JOURNAL OF CANCER RESEARCH 28 (2) 228 - 234 1000-9604 2016/04 [Refereed][Not invited]
   

  The aim of this review is to address the current status of adjuvant chemotherapy alone in early-stage cervical cancer treatments in the literature. At present, the therapeutic effect of adjuvant chemotherapy alone after radical surgery (RS) has not yet been established, and radiation therapy (RT) or concurrent chemoradiotherapy (CCRT) is recommended as the standard adjuvant therapy after RS for early-stage cervical cancer in various guidelines. The main purpose of adjuvant therapy after RS, however, should be to reduce extrapelvic recurrence rather than local recurrence, although adjuvant RT or CCRT has survival benefits for patients with intermediate-or high-risk factors for recurrence. Moreover, several studies reported that adjuvant therapies including RT were associated with a higher incidence of complications, such as lymphedema, bowel obstruction and urinary disturbance, and a lower grade of long-term quality of life (QOL) or sexual functioning than adjuvant chemotherapy alone. The effect of adjuvant chemotherapy alone for early-stage cervical cancer with intermediate-or high-risk factors for recurrence were not fully investigated in prospective studies, but several retrospective studies suggest that the adjuvant effects of chemotherapy alone are at least similar to that of RT or CCRT in terms of recurrence rate, disease-free survival, or overall survival (OS) with lower incidence of complications. Whereas cisplatin based combination regimens were used in these studies, paclitaxel/cisplatin (TP) regimen, which is currently recognized as a standard chemotherapy regimen for patients with metastatic, recurrent or persistent cervical cancer by Gynecologic Oncology Group (GOG), had also survival benefit as an adjuvant therapy. Therefore, it may be worth considering a prospective randomized controlled trial (RCT) of adjuvant chemotherapy alone using TP regimen versus adjuvant RT as an alternative adjuvant therapy. Because early-stage cervical cancer is a curable condition, it is necessary that the therapeutic strategies should be improved with considering adverse events and QOL for long-term survivors.
• Neoadjuvant chemotherapy for locally advanced cervical cancer

  Takashi Iwata, Azumi Miyauchi, Yukako Suga, Hiroshi Nishio, Masaru Nakamura, Akiko Ohno, Nobumaru Hirao, Tohru Morisada, Kyoko Tanaka, Hiroki Ueyama, Hidemichi Watari, Daisuke Aoki

  CHINESE JOURNAL OF CANCER RESEARCH 28 (2) 235 - 240 1000-9604 2016/04 [Refereed][Not invited]
   

  Neoadjuvant chemotherapy followed by surgery (NCS) has not been fully evaluated clinically. Currently, the main regimen of neoadjuvant chemotherapy (NAC) used in NCS includes cisplatin. The antitumor effects of NAC reduce lymph node metastasis and the tumor diameter in patients prior to surgery, and this can reduce the number of high risk patients who require postoperative radiation therapy. Many randomized controlled trials (RCTs) have examined the long-term prognosis of NCS compared to primary surgery, but the utility of NCS remains uncertain. The advent of concurrent chemoradiotherapy (CCRT) has markedly improved the outcome of radiotherapy (RT), and CCRT is now used as a standard method in many cases of advanced bulky cervical cancer. NCS gives a better treatment outcome than radiation therapy alone, but it is important to verify that NCS gives a similar or better outcome compared to CCRT.
• Chemotherapy and molecular targeting therapy for recurrent cervical cancer

  Naotake Tsuda, Hidemichi Watari, Kimio Ushijima

  CHINESE JOURNAL OF CANCER RESEARCH 28 (2) 241 - 253 1000-9604 2016/04 [Refereed][Not invited]
   

  For patients with primary stage IVB, persistent, or recurrent cervical cancer, chemotherapy remains the standard treatment, although it is neither curative nor associated with long-term disease control. In this review, we summarized the history of treatment of recurrent cervical cancer, and the current recommendation for chemotherapy and molecular targeted therapy. Eligible articles were identified by a search of the MEDLINE bibliographical database for the period up to November 30, 2014. The search strategy included the following any or all of the keywords: "uterine cervical cancer", "chemotherapy", and "targeted therapies". Since cisplatin every 21 days was considered as the historical standard treatment for recurrent cervical cancer, subsequent trials have evaluated and demonstrated activity for other agents including paclitaxel, gemcitabine, topotecan and vinorelbine among others. Accordingly, promising agents were incorporated into phase III trials. To examine the best agent to combine with cisplatin, several landmark phase III clinical trials were conducted by Gynecologic Oncology Group (GOG) and Japan Clinical Oncology Group (JCOG). Through, GOG204 and JCOG0505, paclitaxel/cisplatin (TP) and paclitaxel/carboplatin (TC) are now considered to be the recommended therapies for recurrent cervical cancer patients. However, the prognosis of patients who are already resistant to chemotherapy, are very poor. Therefore new therapeutic strategies are urgently required. Molecular targeted therapy will be the most hopeful candidate of these strategies. From the results of GOG240, bevacizumab combined with TP reached its primary endpoint of improving overall survival (OS). Although, the prognosis for recurrent cervical cancer patients is still poor, the results of GOG240 shed light on the usefulness of molecular target agents to chemotherapy in cancer patients. Recurrent cervical cancer is generally considered incurable and current chemotherapy regiments offer only modest gains in OS, particularly for patients with multiple poor prognostic factors. Therefore, it is crucial to consider not only the survival benefit, but also the minimization of treatment toxicity, and maximization of quality of life (QOL).
• Comparison between borderline ovarian tumors and carcinomas using semi-automated histogram analysis of diffusion-weighted imaging: focusing on solid components.

  Rie Mimura, Fumi Kato, Khin Khin Tha, Kohsuke Kudo, Yosuke Konno, Noriko Oyama-Manabe, Tatsuya Kato, Hidemichi Watari, Noriaki Sakuragi, Hiroki Shirato

  Japanese journal of radiology 34 (3) 229 - 37 1867-1071 2016/03 [Refereed][Not invited]
   

  PURPOSE: This study aimed to evaluate whether histogram analysis of the apparent diffusion coefficient (ADC) of a solid tumor component could distinguish borderline ovarian tumors from ovarian carcinoma. MATERIALS AND METHODS: Sixteen pathologically proven borderline tumors and 21 carcinomas were retrospectively examined. Magnetic resonance (1.5-T) image data sets were coregistered, and the solid components of each tumor were semiautomatically segmented. ADC histograms of the solid components were extracted; modes, minimums, means, and 10th, 25th, 50th, 75th, and 90th percentiles of the histograms were compared between the two tumor types, and receiver-operating characteristic (ROC) analysis was performed. RESULTS: The mode, minimum, mean, 10th, 25th, 50th, and 75th percentile ADC values of solid components of borderline tumors were significantly larger than those of carcinomas. Among these, the 10th percentile values had the lowest p value (p = 0.0003). At ROC analysis, the area under the curve (AUC) in the 10th percentile was the greatest (0.854), and the best cutoff value in the 10th percentile provided the highest specificity (93.8 %). CONCLUSIONS: ADC histograms of solid tumor components facilitated the distinction between borderline ovarian tumors and carcinoma. The 10th percentile ADC values had the best diagnostic performance.
• Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group

  Kenichi Harano, Akihiro Hirakawa, Mayu Yunokawa, Toshiaki Nakamura, Toyomi Satoh, Tadaaki Nishikawa, Daisuke Aoki, Kimihiko Ito, Kiyoshi Ito, Toru Nakanishi, Nobuyuki Susumu, Kazuhiro Takehara, Yoh Watanabe, Hidemichi Watari, Toshiaki Saito

  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 21 (1) 168 - 176 1341-9625 2016/02 [Refereed][Not invited]
   

  Uterine carcinosarcomas (UCSs) are rare and aggressive tumors. The prognostic factors are not sufficiently known. We performed a multi-institutional, retrospective study of women with stage I-IV UCS, diagnosed between 2007 and 2012. Data obtained from medical records included demographic, clinicopathological, treatment, and outcome information. A total of 486 patients (median age 65 years) were identified-224 (46 %) were stage I, 32 (7 %) were stage II, 139 (28 %) were stage III, and 91 (19 %) were stage IV. Among them, 277 (57 %) had disease recurrence. Median disease-free survival (DFS) was 16.4 months [95 % confidence interval (CI) 15.7-27.2], and median overall survival (OS) was 72.0 months (95 % CI 43.0-not reached). In total, 454 (94 %) patients received adjuvant treatment, and 440 (91 %) received adjuvant chemotherapy. In multivariate analysis, stage III-IV disease, CA-125 level, and lymphovascular space invasion (LVSI) were significantly associated with shorter median DFS. Stage III-IV disease, performance status 2-4, a parts per thousand yen50 % myometrial invasion depth, and postsurgical residual tumor size > 1 cm were significantly associated with shorter median OS. Conversely, pelvic lymph node lymphadenectomy was associated with improved DFS and OS. Stage, performance status, CA-125 level, LVSI, and myometrial invasion were associated with poor prognoses. Pelvic lymphadenectomy was associated with improved survival, and may be necessary for the surgical management of UCS.
• How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey

  Yoshihito Yokoyama, Kiyoshi Ito, Kiyoshi Takamatsu, Kazuhiro Takehara, Toru Nakanishi, Kenichi Harano, Hidemichi Watari, Nobuyuki Susumu, Daisuke Aoki, Toshiaki Saito

  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 20 (5) 997 - 1004 1341-9625 2015/10 [Refereed][Not invited]
   

  This survey sought to determine Japanese gynecologists' attitudes concerning administering hormone replacement therapy (HRT) for patients after surgery for endometrial cancer (EC). Eight hundred and eighty-eight members of the Japanese Gynecologic Oncology Group (JGOG) were asked to respond to an anonymous questionnaire on the JGOG website. The survey asked whether or not HRT was to be administered when surgery was performed (including a hysterectomy and bilateral oophorectomy) to treat EC before or after menopause. If HRT was not to be administered, respondents were asked the reason why. Respondents were presented with the same hypothetical patients that were featured in a previous survey in Germany, and differences in the mindsets of Japanese and German physicians were compared. Responses from 363 individuals (response rate 40.9 %) were analyzed. Seventy-eight percent of physicians considered HRT for patients undergoing surgery before menopause. The most prevalent reason of refusal to prescribe HRT was the risk of EC recurrence. Forty-eight percent of physicians considered HRT for patients undergoing surgery after menopause. The most prevalent reasons of refusal of HRT were its limited benefit and the availability of alternative therapies. Sixty-five percent of Japanese physicians responded that they would administer HRT to patients with low risk of recurrence vs. 46 % of physicians in Germany (P < 0.0002). Forty-nine percent of Japanese physicians approved of prescribing HRT for patients with high risk of recurrence vs. 25 % of physicians in Germany (P < 0.0001). Many Japanese gynecologists have a favorable attitude toward prescribing HRT after treatment of EC.
• Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors

  Peixin Dong, Kei Ihira, Junichi Hamada, Hidemichi Watari, Takahiro Yamada, Masayoshi Hosaka, Sharon J. B. Hanley, Masataka Kudo, Noriaki Sakuragi

  ONCOTARGET 6 (24) 19968 - 19975 1949-2553 2015/08 [Refereed][Not invited]
   

  Although mutational inactivation of p53 is found in 50% of all human tumors, a subset of tumors display defective p53 function, but retain wild-type (WT) p53. Here, direct and indirect mechanisms leading to the loss of WT p53 activities are discussed. We summarize the oncogenic roles of iASPP, an inhibitor of WT p53, in promoting proliferation, invasion, drug or radiation-resistance and metastasis. From the therapeutic view, we highlight promising perspectives of microRNA-124, peptide and small molecules that reduce or block iASPP for the treatment of cancer. High iASPP expression enhances proliferation, aggressive behavior, the resistance to radiation/chemotherapy and correlates with poor prognosis in a range of human tumors. Overexpression of iASPP accelerates tumorigenesis and invasion through p53-dependent and p53-independent mechanisms. MicroRNA-124 directly targets iASPP and represses the growth and invasiveness of cancer cells. The disruption of iASPP-p53 interaction by a p53-derived peptide A34 restores p53 function in cancer cells. The inhibition of iASPP phosphorylation with small molecules induces p53-dependent apoptosis and growth suppression. The mechanisms underlying aberrant expression of iASPP in human tumors should be further investigated. Reactivating WT p53 functions by targeting its novel inhibitor iASPP holds promise for potential therapeutic interventions in the treatment of WT p53-containing tumors.
• Human Papillomavirus Type 16 Sequence Variation in Concurrent Vulvar and Penile Carcinoma in a Married Couple

  Takashi Mitamura, Hidemichi Watari, Katsushige Yamashiro, Tatsuya Kato, Masayoshi Hosaka, Chisa Shimada, Shun Fukumoto, Kiwamu Noshiro, Takayuki Sasaki, Noriaki Sakuragi

  SEXUALLY TRANSMITTED DISEASES 42 (6) 342 - 343 0148-5717 2015/06 [Refereed][Not invited]
   

  We encountered an elderly married couple with concurrent vulvar and penile carcinoma with an Asian variant of human papillomavirus type 16. Asian variants might have an elevated risk of concurrent external genital carcinomas of a male and a female, and analysis of human papillomavirus variants might be important to understand the mechanism of carcinogenesis.
• P18/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxane.

  Mohamed Kamel Hassan, Hidemichi Watari, Takashi Mitamura, Zainab Mohamed, Sherif F El-Khamisy, Yusuke Ohba, Noriaki Sakuragi

  Oncoscience 2 (3) 294 - 308 2331-4737 2015 [Refereed][Not invited]
   

  MicroRNAs (miRNAs) have been reported to regulate the development of chemoresistance in many tumors. Stathmin 1 (STMN1) is a microtubule-depolymerizing molecule, involved in chemo-response; however, the mechanism of its regulation is unknown. Herein, the immunohistochemical study indicated significant upregulation of the STMN1 in the ovarian cancer tissues defined as resistant tumors compared with those defined as responsive tumors. STMN1 level elevated in the chemoresistant ovarian cancer cells, KF-TX, compared with the parental, KF, ones. Targeting STMN1 by siRNA restored taxane-sensitivity of KF-TX cells. Screening miRNA profiles from KF/KF-TX cellular set followed by bioinformatics-based prediction, revealed that miR-31 could be a possible regulator of STMN1. Down-modulation of miR-31 was verified by quantitative RT-PCR in the cellular set used. Overexpression of miR-31 in KF-TX cells (KF-TX-miR-31) significantly restored chemo-response and reduced STMN1 expression as well. STMN1 reduction-associated cellular characteristics such as enhanced microtubule polymerization and stability, as indicated by acetylated tubulin quantification, confocal visualization, and G2 phase delay, were observed in KF-TX-miR-31 cells, indicating the functional reduction of STMN1. miR-31 suppressed the luciferase activity in reporter construct containing the STMN1 3'-untranslated region (3'-UTR), confirming that miR-31 directly targets STMN1. miR-31 has therapeutic potency when introduced into ovarian cancer, in combination with taxane.
• Lymphadenectomy can be omitted for low-risk endometrial cancer based on preoperative assessments

  Takashi Mitamura, Hidemichi Watari, Yukiharu Todo, Tatsuya Kato, Yosuke Konno, Masayoshi Hosaka, Noriaki Sakuragi

  JOURNAL OF GYNECOLOGIC ONCOLOGY 25 (4) 301 - 305 2005-0380 2014/10 [Refereed][Not invited]
   

  Objective: According to the International Federation of Gynecology and Obstetrics staging, some surgeons perform lymphadenectomy in all patients with early stage endometrial cancer to enable the accurate staging. However, there are some risks to lymphadenectomy such as lower limb lymphedema. The aim of this study was to investigate whether preoperative assessment is useful to select the patients in whom lymphadenectomy can be safely omitted.Methods: We evaluated the risk of lymph node metastasis (LNM) using LNM score (histological grade, tumor volume measured in magnetic resonance imaging [MRI], and serum CA-125), myometrial invasion and extrautrerine spread assessed by MRI. Fiftysix patients of which LNM score was 0 and myometrial invasion was less than 50% were consecutively enrolled in the study in which a lymphadenectomy was initially intended not to perform. We analyzed several histological findings and investigated the recurrence rate and overall survival.Results: Fifty-one patients underwent surgery without lymphadenectomy. Five (8.9%) who had obvious myometrial invasion intraoperatively underwent systematic lymphadenectomy. One (1.8%) with endometrial cancer which was considered to arise from adenomyosis had para-aortic LNM. Negative predictive value of deep myometrial invasion was 96.4% (54/56). During the mean follow-up period of 55 months, one patient with deep myometrial invasion who refused an adjuvant therapy had tumor recurrence. The overall survival rate was 100% during the study period.Conclusion: This preoperative assessment is useful to select the early stage endometrial cancer patients without risk of LNM and to safely omit lymphadenectomy.
• Distribution of Lymph Node Metastasis Sites in Endometrial Cancer Undergoing Systematic Pelvic and Para-Aortic Lymphadenectomy: A Proposal of Optimal Lymphadenectomy for Future Clinical Trials

  Tetsuji Odagiri, Hidemichi Watari, Tatsuya Kato, Takashi Mitamura, Masayoshi Hosaka, Satoko Sudo, Mahito Takeda, Noriko Kobayashi, Peixin Dong, Yukiharu Todo, Masataka Kudo, Noriaki Sakuragi

  ANNALS OF SURGICAL ONCOLOGY 21 (8) 2755 - 2761 1068-9265 2014/08 [Refereed][Not invited]
   

  The aim of this study was to demonstrate the precise mapping of lymph node metastasis (LNM) sites in endometrial cancer.A total of 266 patients who underwent primary radical surgery including systematic pelvic and para-aortic lymphadenectomy for endometrial cancer from 1993 to 2010 were enrolled in this study. We removed lymph nodes from the femoral ring to the para-aortic node up to the level of renal veins. We analyzed the distribution of positive-node sites according to their anatomical location.Overall, 42 of 266 patients (15.8 %) showed LNM. The median number of nodes harvested was 62.5 (range 40-119) in pelvic nodes (PLN), and 20 (range 3-47) in para-aortic nodes (PAN). Among 42 cases with positive-nodes, 16 cases (38.1 %) showed positive PLN alone, 7 cases (16.7 %) in PAN alone, and 19 cases (45.2 %) in both PLN and PAN. The most prevalent site of positive-nodes was PAN (9.8 %) followed by obturator nodes (9.4 %), internal iliac nodes (7.1 %), and common iliac nodes (5.6 %). Six of 19 cases (31.6 %) of positive PAN above the inferior mesenteric artery (IMA) showed negative PAN below IMA. Metastasis to the deep inguinal nodes was found to be extremely rare (0.38 %). Single-site LNM was the most frequently observed in obturator nodes, followed by PAN above IMA.Routine resection of deep inguinal nodes is not recommended, whereas para-aortic lymphadenectomy should be extended up to the level of renal veins for endometrial cancer.
• The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer

  Peixin Dong, Yosuke Konno, Hidemichi Watari, Masayoshi Hosaka, Masayuki Noguchi, Noriaki Sakuragi

  JOURNAL OF TRANSLATIONAL MEDICINE 12 231  1479-5876 2014/08 [Refereed][Not invited]
   

  Activation of the PI3K/AKT pathway, a common mechanism in all subtypes of endometrial cancers (endometrioid and non-endometrioid tumors), has important roles in contributing to epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) features. MicroRNAs (miRNAs) are small non-coding RNA molecules that concurrently affect multiple target genes, and regulate a wide range of genes involved in modulating EMT and CSC properties. Here we overview the recent advances revealing the impact of miRNAs on EMT and CSC phenotypes in tumors including endometrial cancer via regulating PI3K/AKT pathway. MiRNAs are crucial mediators of EMT and CSC through targeting PTEN-PI3K-AKT-mTOR axis. In endometrial cancer cells, miRNAs can activate or attenuate EMT and CSC by targeting PTEN and other EMT-associated genes, such as Twist1, ZEB1 and BMI-1. More detailed studies of miRNAs will deepen our understanding of the molecular basis underlying PI3K/AKT-induced endometrial cancer initiation and progression. Targeting key signaling components of PI3K/AKT pathway by restoring or inhibiting miRNA function holds promise as a potential therapeutic approach to suppress EMT and CSC in endometrial cancer.
• MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells

  Yosuke Konno, Peixin Dong, Ying Xiong, Fumihiko Suzuki, Jiabin Lu, Muyan Cai, Hidemichi Watari, Takashi Mitamura, Masayoshi Hosaka, Sharon J. B. Hanley, Masataka Kudo, Noriaki Sakuragi

  ONCOTARGET 5 (15) 6049 - 6062 1949-2553 2014/08 [Refereed][Not invited]
   

  MicroRNA-101 has been implicated as a tumor suppressor miRNA in human tumors. However, its potential functional impact and the underlying mechanisms in endometrial cancer progression have not been determined. Here, we report that in aggressive endometrial cancer cells, re-expression of microRNA-101 leads to inhibition of cell proliferation and induction of apoptosis and senescence. Ectopic overexpression of microRNA-101 attenuates the epithelial-mesenchymal transition-associated cancer cell migration and invasion, abrogates the sphere-forming capacity and enhances chemosensitivity to paclitaxel. Algorithm and microarray-based strategies identifies potential microRNA-101 targets. Among these, we validated EZH2, MCL-1 and FOS as direct targets of miR-101 and silencing of these genes mimics the tumor suppressive effects observed on promoting microRNA-101 function. Importantly, further results suggest an inverse correlation between low miR-101 and high EZH2, MCL-1 and FOS expression in EC specimens. We conclude that, as a crucial tumor suppressor, microRNA-101 suppresses cell proliferation, invasiveness and self-renewal in aggressive endometrial cancer cells via modulating multiple critical oncogenes. The microRNA-101-EZH2/MCL-1/ FOS axis is a potential therapeutic target for endometrial cancer.
• MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines

  Peixin Dong, Masanori Kaneuchi, Hidemichi Watari, Satoko Sudo, Noriaki Sakuragi

  MOLECULAR CARCINOGENESIS 53 (5) 349 - 359 0899-1987 2014/05 [Refereed][Not invited]
   

  Type II endometrial carcinoma is an aggressive subtype of endometrial cancer (EC). TWIST1, a helix-loop-helix transcription regulator, is known to induce epithelial-mesenchymal transition (EMT) and promote tumor metastasis. MicroRNAs (miRNAs) also serve as important regulators of EMT and metastasis by regulating EMT-related genes. In this study, we sought to explore the role of TWIST1 in inducing EMT in representative type II EC cell lines, and to determine the miRNAs involved in regulating TWIST1 gene expression. Functional analysis suggested that TWIST1 contributes to the EMT phenotypes of EC cells, as evidenced by the acquisition of fibroblast-like properties, enhanced invasiveness, and induction of an EN-switch (downregulation of epithelial marker E-cadherin and upregulation of mesenchymal marker N-cadherin). Conversely, silencing of TWIST1 by siRNA inhibited cell invasion and the mesenchymal phenotype, which was accompanied by a reversion of the EN-switch. We also observed a novel post-transcriptional regulatory mechanism of TWIST1 expression mediated by miR-106b via its direct interaction with TWIST1 mRNAs at the 3 '-untranslated region. Our data suggest that TWIST1 is a critical inducer of EMT in invasive EC cells and that miR-106b could suppress EC cell invasion by downregulating TWIST1 expression. (c) 2013 Wiley Periodicals, Inc.
• Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer

  Peixin Dong, Masanori Kaneuchi, Ying Xiong, Liping Cao, Muyan Cai, Xishi Liu, Sun-Wei Guo, Jingfang Ju, Nan Jia, Yosuke Konno, Hidemichi Watari, Masayoshi Hosaka, Satoko Sudo, Noriaki Sakuragi

  CARCINOGENESIS 35 (4) 760 - 768 0143-3334 2014/04 [Refereed][Not invited]
   

  Krppel-like factor 17 (KLF17), a member of the KLF transcription factor family, is elevated in endometrial cancer tissues, and KLF17 induces the epithelialmesenchymal transition (EMT) of endometrial cancer cells via direct activation of key EMT inducer TWIST1.Krppel-like factor 17 (KLF17), a member of the KLF transcription factor family, has been shown to inhibit the epithelialmesenchymal transition (EMT) and tumor growth. However, the expression, the cellular function and the mechanism of KLF17 in endometrioid endometrial cancer (EEC; a dominant type of endometrial cancer) remain elusive. Here, we report that among the KLF family members, KLF17 was consistently upregulated in EEC cell lines compared with immortalized endometrial epithelial cells. Overexpression of KLF17 in EEC cell lines induced EMT and promoted cell invasion and drug resistance, resulting in increased expression of TWIST1. In contrast, KLF17 suppression reversed EMT, diminished cell invasion, restored drug sensitivity and suppressed TWIST1 expression. Luciferase assays, site-directed mutagenesis and transcription factor DNA-binding analysis demonstrated that KLF17 transactivates TWIST1 expression by directly binding to the TWIST1 promoter. Knockdown of TWIST1 prevented KLF17-induced EMT. Consistent with these results, both KLF17 and TWIST1 levels were found to be elevated in EECs compared with normal tissues. KLF17 expression positively correlated with tumor grade but inversely correlated with estrogen and progesterone receptor expression. Thus, KLF17 may have an oncogenic role during EEC progression via initiating EMT through the regulation of TWIST1.
• Histone Deacetylase Inhibitors Sensitize Lung Cancer Cells to Hyperthermia: Involvement of Ku70/SirT-1 in Thermo-Protection

  Mohamed K. Hassan, Hidemichi Watari, Alaa-eldin Salah-eldin, Ahmed S. Sultan, Zainab Mohamed, Yoichiro Fujioka, Yusuke Ohba, Noriaki Sakuragi

  PLOS ONE 9 (4) e94213  1932-6203 2014/04 [Refereed][Not invited]
   

  This study describes the sensitization mechanism to thermal stress by histone deacetylase inhibitors (HDACIs) in lung cancer cells and shows that Ku70, based on its acetylation status, mediates the protection of lung cancer from hyperthermia (42.5 degrees C, 1-6 hrs). Ku70 regulates apoptosis by sequestering pro-apoptotic Bax. However, its role in thermal stress is not fully understood. The findings showed that, pre-treating lung cancer cells with HDACIs, nicotinamide (NM) or Trichostatin A (TsA) or both significantly enhanced hyperthermia-induced Bax-dependent apoptosis in PC-10 cells. We found that hyperthermia induces SirT-1, Sirtuin, upregulation but not HDAC6 or SirT-3, therefore transfection with dominant negative SirT-1 (Y/H) also eliminated the protection and resulted in more cell death by hyperthermia, in H1299 cells through Bax activation. Hyperthermia alone primed lung cancer cells to apoptosis without prominent death. After hyperthermia Bax was upregulated, Bcl-2 was downregulated, the Bax/Bcl-2 ratio was inversed and Bax/Bcl-2 heterodimer was dissociated. Although hyperthermia did not affect total Ku70 expression level, it stimulated Ku70 deacetylation, which in turn could bind more Bax in the PC-10 cells. These findings suggest an escape mechanism from hyperthermia-induced Bax activation. To verify the role of Ku70 in this protection mechanism, Ku70 was silenced by siRNA. Ku70 silencing significantly sensitized the lung cancer cells to hyperthermia. The Ku70 KD cells underwent cytotoxic G1 arrest and caspase-dependant apoptosis when compared to scrambled transfectants which showed only G2/M cytostatic arrest in the cell lines investigated, suggesting an additional cell cycle-dependent, novel, role of Ku70 in protection from hyperthermia. Taken together, our data show a Ku70-dependent protection mechanism from hyperthermia. Targeting Ku70 and/or its acetylation during hyperthermia may represent a promising therapeutic approach for lung cancer.
• microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway

  Takashi Mitamura, Hidemichi Watari, Lei Wang, Hiromi Kanno, Makiko Kitagawa, Mohamed Kamel Hassan, Taichi Kimura, Mishie Tanino, Hiroshi Nishihara, Shinya Tanaka, Noriaki Sakuragi

  MOLECULAR CANCER 13 97  1476-4598 2014/04 [Refereed][Not invited]
   

  Background: We aimed to investigate whether MIR31 is an oncogene in human endometrial cancer and identify the target molecules associated with the malignant phenotype.Methods: We investigated the growth potentials of MIR31-overexpressing HEC-50B cells in vitro and in vivo. In order to identify the target molecule of MIR31, a luciferase reporter assay was performed, and the corresponding downstream signaling pathway was examined using immunohistochemistry of human endometrial cancer tissues. We also investigated the MIR31 expression in 34 patients according to the postoperative risk of recurrence.Results: The overexpression of MIR31 significantly promoted anchorage-independent growth in vitro and significantly increased the tumor forming potential in vivo. MIR31 significantly suppressed the luciferase activity of mRNA combined with the LATS2 3'-UTR and consequently promoted the translocation of YAP1, a key molecule in the Hippo pathway, into the nucleus. Meanwhile, the nuclear localization of YAP1 increased the transcription of CCND1. Furthermore, the expression levels of MIR31 were significantly increased (10.7-fold) in the patients (n = 27) with a high risk of recurrence compared to that observed in the low-risk patients (n = 7), and this higher expression correlated with a poor survival.Conclusions: MIR31 functions as an oncogene in endometrial cancer by repressing the Hippo pathway. MIR31 is a potential new molecular marker for predicting the risk of recurrence and prognosis of endometrial cancer.
• Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer

  Yasuhiko Ebina, Hidemichi Watari, Masanori Kaneuchi, Mahito Takeda, Masayoshi Hosaka, Masataka Kudo, Hideto Yamada, Noriaki Sakuragi

  EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 41 (3) 446 - 451 1619-7070 2014/03 [Refereed][Not invited]
   

  Purpose To investigate the impact of PET and PET/CT scanning on decision-making in management planning and to identify the optimal setting for selecting candidates for surgery in suspicious recurrent ovarian cancer. Methods A retrospective chart review was performed in patients with possible recurrent ovarian cancer after primary optimal cytoreduction and taxane/carboplatin chemotherapy who had undergone FDG PET or FDG PET/CT scans from July 2002 to August 2008 to help make treatment decisions. The analysis included 44 patients who had undergone a total of 89 PET scans. The positive PET scans were classified as follows. (1) localized (one or two localized sites of FDG uptake), (2) multiple (three or more sites of FDG uptake), (3) diffuse (extensive low-grade activity outlining serosal and peritoneal surfaces). Results Of the 89 PET scans, 52 (58.4 %) led to a change in management plan. The total number of patients in whom cytoreductive surgery was selected as the treatment of choice increased from 12 to 35. Miliary disseminated disease, which was not detected by PET scan, was found in 22.2 % of those receiving surgery. Miliary disseminated disease was detected in 6 of the 12 patients with recurrent disease whose treatment-free interval (TFI) was <12 months, whereas none of those with a TFI of >= 12 months had such disease (P = 0.0031). Conclusion PET or PET/CT is useful for selecting candidates for cytoreductive surgery among patients with recurrent ovarian cancer. To avoid surgical attempts in those with miliary dissemination, patients with a TFI of >= 12 months are the best candidates for cytoreductive surgery.
• Risk assessment of lymph node metastasis before surgery in endometrial cancer: Do we need a clinical trial for low-risk patients?

  Sokbom Kang, Yukiharu Todo, Hidemichi Watari

  JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH 40 (2) 322 - 326 1341-8076 2014/02 [Refereed][Not invited]
   

  Due to advances of radiological imaging and tumor biomarkers, the extent of information provided by preoperative assessment is rapidly growing. The Korean Gynecologic Oncology Group (KGOG) recently proposed new preoperative criteria to identify patients at low risk for lymph node metastasis in endometrial cancer. In the multicenter study, serum carbohydrate antigen 125 levels and three magnetic resonance imaging parameters were found to be independent risk factors for nodal metastasis, and classified 53% of patients as part of a low-risk group. The false-negative predictive value (NPV) was 1.7%, and was 1.4% in the validation set. Furthermore, the KGOG low-risk criteria were validated in 319 Japanese patients with endometrial cancer. The criteria identified 181 of 319 patients as a low-risk group (51%), and three false-negative cases were found (1.9%). These results indicate that we are able to identify low-risk patients with a negligible NPV before surgery. In addition, the low false NPV implies that there is great difficulty in performing a randomized trial to determine the efficacy of routine lymphadenectomy in patients at low risk of lymph node metastasis. Based on these data, the challenges and possible solutions for developing a consensus on the optimized management of low-risk endometrial cancer will be discussed in this review.
• Proposal of a concept and design of a randomized phase III trial investigating the survival effect of para-aortic lymphadenectomy in endometrial cancer

  Hidemichi Watari, Yukiharu Todo, Sokbom Kang, Tetsuji Odagiri, Noriaki Sakuragi

  JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH 40 (2) 312 - 316 1341-8076 2014/02 [Refereed][Not invited]
   

  Although prospective studies have failed to show the therapeutic effect of lymphadenectomy in the surgical treatment of endometrial cancer, several retrospective studies including the SEPAL study revealed the survival effect of lymphadenectomy. To prospectively investigate the survival benefit of para-aortic lymphadenectomy shown in the SEPAL study, we are proposing a new concept of a randomized phase III trial. An appropriate study population will be selected according to the preoperative assessments (evaluation of myometrial invasion and cervical invasion with magnetic resonance imaging, extrauterine spread with computed tomography, and histological type and grade by pathological evaluation) to estimate the risk of lymph node metastasis. Patients relevant to potential International Federation of Gynecology and Obstetrics (2008) stage IB, II and III diseases will be eligible, and randomly assigned to two arms: pelvic lymphadenectomy alone (control), or pelvic and para-aortic lymphadenectomy (experimental). After initial surgery, patients with postoperative pathological risk factors for recurrence will receive adjuvant chemotherapy. Because we aim to investigate the therapeutic significance of primary treatments, including surgery and adjuvant chemotherapy, the primary end-point could be recurrence-free survival. One of the most important issues to successfully perform this prospective study is to assure the quality of lymphadenectomy (extent and area), which could be evaluated based on the number of harvested nodes and objective evaluation of dissected area by videos and/or photos.
• Tailoring lymphadenectomy according to the risk of lymph node metastasis in endometrial cancer

  Yukiharu Todo, Hidemichi Watari, Sokbom Kang, Noriaki Sakuragi

  JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH 40 (2) 317 - 321 1341-8076 2014/02 [Refereed][Not invited]
   

  It has been strongly suggested that patients with endometrial cancer with low risk of lymph node metastasis do not benefit from lymphadenectomy and that intermediate-risk/high-risk endometrial cancer patients benefit from complete pelvic and para-aortic lymphadenectomy. This hypothesis needs to be validated by prospective studies. For randomized controlled trials (RCT), heterogeneity of intervention compromises internal validity and non-participation of experienced doctors compromises external validity. As these situations easily occur in randomized surgical trials (RST) intended for high-risk patients, the effects of complicated surgery, such as full lymphadenectomy, might be underestimated in RST. In a famous RST, data for all eligible patients implied that survival outcome for the non-randomized group was significantly better than that for the randomized group. One plausible explanation is that physicians' judgment and experience produce better treatment decisions than do random choices. Although two RCT from European countries showed negative results of lymphadenectomy on prognosis, valuing the care of individual patients may be more important than uncritically adopting the results of RCT. In endometrial cancer, lymphadenectomy must be tailored to maximize the therapeutic effect of surgery and minimize its invasiveness and adverse effects. Two strategies are: (i) to remove lymph nodes most likely to harbor disease while sparing lymph nodes that are unlikely to be affected; and (ii) to perform full lymphadenectomies only on patients who can potentially benefit from them. Here, we focus on the second strategy. Preoperative risk assessments used in Japan and Korea to select low-risk patients who would not benefit from lymphadenectomy are discussed.
• Apoptosis and Molecular Targeting Therapy in Cancer

  Mohamed Hassan, Hidemichi Watari, Ali AbuAlmaaty, Yusuke Ohba, Noriaki Sakuragi

  BIOMED RESEARCH INTERNATIONAL 2014 150845  2314-6133 2014 [Refereed][Not invited]
   

  Apoptosis is the programmed cell death which maintains the healthy survival/death balance in metazoan cells. Defect in apoptosis can cause cancer or autoimmunity, while enhanced apoptosis may cause degenerative diseases. The apoptotic signals contribute into safeguarding the genomic integrity while defective apoptosis may promote carcinogenesis. The apoptotic signals are complicated and they are regulated at several levels. The signals of carcinogenesis modulate the central control points of the apoptotic pathways, including inhibitor of apoptosis (IAP) proteins and FLICE-inhibitory protein (c-FLIP). The tumor cells may use some of several molecular mechanisms to suppress apoptosis and acquire resistance to apoptotic agents, for example, by the expression of antiapoptotic proteins such as Bcl-2 or by the downregulation or mutation of proapoptotic proteins such as BAX. In this review, we provide the main regulatory molecules that govern the main basic mechanisms, extrinsic and intrinsic, of apoptosis in normal cells. We discuss how carcinogenesis could be developed via defective apoptotic pathways or their convergence. We listed some molecules which could be targeted to stimulate apoptosis in different cancers. Together, we briefly discuss the development of some promising cancer treatment strategies which target apoptotic inhibitors including Bcl-2 family proteins, IAPs, and c-FLIP for apoptosis induction.
• Clinical significance of tumor volume in endometrial cancer: A Japan-Korea cooperative study

  Yukiharu Todo, Hyuck-Jae Choi, Sokbom Kang, Jae-Weon Kim, Joo-Hyun Nam, Hidemichi Watari, Akiko Tamakoshi, Noriaki Sakuragi

  GYNECOLOGIC ONCOLOGY 131 (2) 294 - 298 0090-8258 2013/11 [Refereed][Not invited]
   

  Objective. The aim of this study was to elucidate the significance of tumor volume as a risk factor for predicting lymph node metastasis. Methods. We applied the tumor volume index to the data that were collected for 327 Korean patients with endometrial cancer who underwent preoperative assessment including magnetic resonance imaging (MRI) and subsequent surgery including systematic lymphadenectomy. The volume index, which we previously reported in the literature, was defined as the product of maximum longitudinal diameter along the uterine axis, maximum anteroposterior diameter in a sagittal section image, and maximum horizontal diameter in a horizontal section image according to MRI data, from 425 Japanese women with endometrial cancer. Relationships between lymph node metastasis and results of preoperative examinations including volume index were analyzed by logistic regression analysis. Results. The prevalence of affected lymph nodes was 14.2%. Multivariate analysis showed that high-grade histology assessed by endometrial biopsy [odds ratio (OR); 2.9, 95% confidence interval (CI): 1.4-6.4], volume index (OR; 2.4, 95% CI: 1.1-5.3), node enlargement assessed by MRI (OR; 4.2, 95% CI: 1.4-132), and high serum cancer antigen (CA)125 level (OR; 3.6, 95% CI: 1.6-8.1) were significantly and independently related to lymph node metastasis. When volume index was excluded from the analysis, myoinvasion assessed by MRI was an independent risk factor for lymph node metastasis as well as high-grade histology, node enlargement, and high serum CA125 level. Conclusion. Volume index is compatible with myometrial invasion as a factor for predicting lymph node metastasis in endometrial cancer. (C) 2013 Elsevier Inc. All rights reserved.
• Multivariate prognostic analysis of adenocarcinoma of the uterine cervix treated with radical hysterectomy and systematic lymphadenectomy

  Tatsuya Kato, Hidemichi Watari, Mahito Takeda, Masayoshi Hosaka, Takashi Mitamura, Noriko Kobayashi, Satoko Sudo, Masanori Kaneuchi, Masataka Kudo, Noriaki Sakuragi

  JOURNAL OF GYNECOLOGIC ONCOLOGY 24 (3) 222 - 228 2005-0380 2013/07 [Refereed][Not invited]
   

  Objective: The aim of this study was to investigate the prognostic factors and treatment outcome of patients with adenocarcinoma of the uterine cervix who underwent radical hysterectomy with systematic lymphadenectomy. Methods: A total of 130 patients with stage IB to IIB cervical adenocarcinoma treated with hysterectomy and systematic lymphadenectomy from 1982 to 2005 were retrospectively analyzed. Clinicopathological data including age, stage, tumor size, the number of positive node sites, lymphovascular space invasion, parametrial invasion, deep stromal invasion (>2/3 thickness), corpus invasion, vaginal infiltration, and ovarian metastasis, adjuvant therapy, and survival were collected and Cox regression analysis was used to deteitnine independent prognostic factors. Results: An estimated five-year survival rate of stage IB1 was 96.6%, 75.0% in stage IB2, 100% in stage IIA, and 52.8% in stage IIB. Prognosis of patients with one positive-node site is similar to that of those with negative-node. Prognosis of patients with multiple positive-node sites was significantly poorer than that of negative and one positive-node site. Multivariate analysis revealed that lymph node metastasis, lymphovascular space invasion, and parametrial invasion were independent prognostic factors for cervical adenocarcinoma. Survival of patients with cervical adenocarcinoma was stratified into three groups by the combination of three independent prognostic factors. Conclusion: Lymph node metastasis, lymphovascular space invasion, and parametrial invasion were shown to be independent prognostic factors for cervical adenocarcinoma treated with hysterectomy and systematic lymphadenectomy.
• Tumor volume successively reflects the state of disease progression in endometrial cancer

  Yukiharu Todo, Hidemichi Watari, Kazuhira Okamoto, Hitoshi Hareyama, Shinichiro Minobe, Hidenori Kato, Noriaki Sakuragi

  GYNECOLOGIC ONCOLOGY 129 (3) 472 - 477 0090-8258 2013/06 [Refereed][Not invited]
   

  Objective. This study aimed to clarify the clinical significance of tumor volume in endometrial cancer. Methods. A total of 667 patients with endometrial cancer who underwent preoperative MRI and surgical treatment including lymphadenectomy were enrolled. As the surrogate marker of actual tumor volume, the volume index was defined as the product of the maximum longitudinal diameter along the uterine axis, the maximum intersecting anteroposterior diameter of the sagittal section image, and the maximum horizontal diameter of the horizontal section image from the MRI data. The volume index was divided into five categories: Group 1 (<8), Group 2 (8 to <27), Group 3 (27 to <64), Group 4 (64 to <125), and Group 5 (125 or more). The relationships between various clinicopathologic factors and volume index were investigated, and Cox regression analysis was conducted to assess the significance of volume index with respect to prognosis. Results. High-risk clinicopathologic findings increased with tumor volume. The lymph node metastasis rate was 3% in Group 1,9% in Group 2, 17% in Group 3,25% in Group 4, and 53% in Group 5. Cox regression analysis showed that the volume index (>= 36) was a prognostic factor (hazard ratio: 2.0, 95% confidence interval: 13-3.1) independent of older age (>= 58 years), high-risk histological grade/subtype, deep myoinvasion, lymph node metastasis, and type of surgery. Conclusion. Tumor volume successively reflects the state of disease progression in endometrial cancer. The volume index can give information on both the staged prognosis and surgical management. (C) 2013 Elsevier Inc. All rights reserved.
• Human papillomavirus 16-positive uterine cervical squamous cell carcinoma with coinfection with human papillomavirus 34 has a lower incidence in lymph node metastasis than that without coinfection with human papillomavirus 34

  Rie Michimata, Hidemichi Watari, Utano Tomaru, Noriaki Sakuragi, Akihiro Ishizu

  Pathobiology 80 (5) 259 - 264 1015-2008 2013/06 [Refereed][Not invited]
   

  Our earlier study demonstrated high prevalence of multiple human papillomavirus (HPV) infection in patients with invasive uterine cervical cancer, including squamous cell carcinoma (SCC). HPV 16 is the most predominant genotype related to SCC of the uterine cervix. The aim of this study was to reveal the biological significance of multiple HPV infection concerning the tumor progression of invasive uterine cervical SCC. In the present study, the effects of coinfection with genotypes other than HPV 16 on tumor growth and lymph node metastasis of invasive uterine cervical SCC with HPV 16 infection were examined. Although coinfection with most genotypes did not influence tumor progression, the clinical stage of patients coinfected with HPV 16 and HPV 34 was significantly lower than that of those without HPV 34 coinfection (p = 0.0038). Moreover, no patient coinfected with HPV 16 and HPV 34 manifested lymph node metastasis, but about half of the patient population without HPV 34 coinfection did (p = 0.0299). These findings suggested that coinfection with HPV 34 could prevent the tumor progression of invasive uterine cervical SCC with HPV 16 infection. Copyright © 2013 S. Karger AG, Basel.
• A low-risk group for lymph node metastasis is accurately identified by Korean gynecologic oncology group criteria in two Japanese cohorts with endometrial cancer

  Sokbom Kang, Yukiharu Todo, Tetsuji Odagiri, Takashi Mitamura, Hidemichi Watari, Jae-Weon Kim, Joo-Hyun Nam, Noriaki Sakuragi

  GYNECOLOGIC ONCOLOGY 129 (1) 33 - 37 0090-8258 2013/04 [Refereed][Not invited]
   

  Objective. The Korean Gynecologic Oncology Group (KGOG) recently proposed new pre-operative criteria to identify a low-risk group for lymph node metastasis in endometrial cancer. The aim of this study was to test whether the good performance of the criteria can be reproducible in diverse clinical settings.Methods. From two Japanese hospitals, 319 patients with endometrial cancer who underwent systemic lymphadenectomy were retrospectively reviewed. In one hospital, para-aortic lymphadenectomy was routinely performed, but it was selectively performed in the other hospital. The performance of the criteria was determined by adjusting the false-negative rate (FNR) at the given prevalence of nodal metastasis of 10% using Bayes' theorem.Results. Nodal metastasis rate of the study population was 12.9%. The KGOG low-risk criteria identified 181 of 319 patients as a low-risk group (51%), and three false-negative cases were found (1.9%). Despite a significant difference in the nodal metastasis rate (18.2% and 8.8%, P=.012) and the surgical policy for para-aortic lymphadenectomy (100% and 48.9%, P<.001) between the two hospitals, KGOG criteria consistently showed a very low adjusted FNR at the prevalence of 10% in both hospitals (1.8% vs. 1.1%, respectively). Among the entire study population, the adjusted FNR was 1.4% (95% confidence interval, .5% to 4.3%), which was similar to the FNR of 1.3% in our previous study.Conclusion. The KGOG low-risk criteria accurately identified a low-risk group for lymph node metastasis with acceptable false negativity regardless of diverse clinical settings. (C) 2013 Elsevier Inc. All rights reserved.
• Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women

  Masayoshi Hosaka, Hiromasa Fujita, Sharon J. B. Hanley, Takayuki Sasaki, Yozo Shirakawa, Mitsuharu Abiko, Masataka Kudo, Masanori Kaneuchi, Hidemichi Watari, Kohkichi Kikuchi, Noriaki Sakuragi

  INTERNATIONAL JOURNAL OF CANCER 132 (2) 327 - 334 0020-7136 2013/01 [Refereed][Not invited]
   

  We examined incidence probabilities of cervical intraepithelial neoplasia 3 (CIN3) or more severe lesions (CIN3+) in 1,467 adult Japanese women with abnormal cytology in relation to seven common human papillomavirus (HPV) infections (16/18/31/33/35/52/58) between April 2000 and March 2008. Sixty-seven patients with multiple HPV infection were excluded from the risk factor analysis. Incidence of CIN3+ in 1,400 patients including 68 with ASCUS, 969 with low grade squamous intraepithelial lesion (LSIL), 132 with HSIL without histology-proven CIN2 (HSIL/CIN2(-)) and 231 with HSIL with histology-proven CIN2 (HSIL/CIN2(+)) was investigated. In both high grade squamous intraepithelial lesion (HSIL)/CIN2(-) and HSIL/CIN2(+), HPV16/18/33 was associated with a significantly earlier and higher incidence of CIN3+ than HPV31/35/52/58 (p = 0.049 and p = 0.0060, respectively). This association was also observed in LSIL (p = 0.0002). The 1-year cumulative incidence rate (CIR) of CIN3+ in HSIL/CIN2(-) and HSIL/CIN2(+) according to HPV genotypes (16/18/33 vs. 31/35/52/58) were 27.1% vs. 7.5% and 46.6% vs. 19.2%, respectively. In contrast, progression of HSIL/CIN2(+) to CIN3+ was infrequent when HPV DNA was undetected: 0% of 1-year CIR and 8.1% of 5-year CIR. All cervical cancer occurred in HSIL cases of seven high-risk HPVs (11/198) but not in cases of other HPV or undetectable/negative-HPV (0/165) (p = 0.0013). In conclusion, incidence of CIN3+ depends on HPV genotypes, severity of cytological abnormalities and histology of CIN2. HSIL/CIN2(+) associated with HPV16/18/33 may justify early therapeutic intervention, while HSIL/CIN2(-) harboring these HPV genotypes needs close observation to detect incidence of CIN3+. A therapeutic intervention is not indicated for CIN2 without HPV DNA.
• Emerging Therapeutic Biomarkers in Endometrial Cancer

  Peixin Dong, Masanori Kaneuchi, Yosuke Konno, Hidemichi Watari, Satoko Sudo, Noriaki Sakuragi

  BIOMED RESEARCH INTERNATIONAL 2013 130362  2314-6133 2013 [Refereed][Not invited]
   

  Although clinical trials of molecular therapies targeting critical biomarkers (mTOR, epidermal growth factor receptor/epidermal growth factor receptor 2, and vascular endothelial growth factor) in endometrial cancer show modest effects, there are still challenges that might remain regarding primary/acquired drug resistance and unexpected side effects on normal tissues. New studies that aim to target both genetic and epigenetic alterations (noncoding microRNA) underlying malignant properties of tumor cells and to specifically attack tumor cells using cell surface markers overexpressed in tumor tissue are emerging. More importantly, strategies that disrupt the cancer stem cell/epithelial-mesenchymal transition-dependent signals and reactivate antitumor immune responses would bring new hope for complete elimination of all cell compartments in endometrial cancer. We briefly review the current status ofmolecular therapies tested in clinical trials and mainly discuss the potential therapeutic candidates that are possibly used to develop more effective and specific therapies against endometrial cancer progression and metastasis.
• New revised FIGO 2008 staging system for endometrial cancer produces better discrimination in survival compared with the 1988 staging system

  Tatsuya Kato, Hidemichi Watari, Daisuke Endo, Takashi Mitamura, Tetsuji Odagiri, Yousuke Konno, Masayoshi Hosaka, Noriko Kobayashi, Yukiharu Todo, Satoko Sudo, Mahito Takeda, Peixin Dong, Masanori Kaneuchi, Masataka Kudo, Noriaki Sakuragi

  JOURNAL OF SURGICAL ONCOLOGY 106 (8) 938 - 941 0022-4790 2012/12 [Refereed][Not invited]
   

  Background and Objectives The aim of this study was to analyze the stage migration and survival of endometrial cancer by the revised FIGO 2008 staging system compared with the 1988 staging system. Methods A total of 355 patients with endometrial cancer, who underwent complete surgical staging, were enrolled. We compared the surgical stages and survival by FIGO 1988 staging system with those by FIGO 2008 staging system. Results 2008 FIGO staging system resulted in an increase of stage I patients and decrease of stage II and IIIa patients. The 5-year overall survival (OS) rates for patients with 2008 FIGO stage IA and IB disease were 98.2% and 91.9%, respectively (P?=?0.004). Five-year OS rate of new stage II (82.6%) was significantly worse than that of new stage IA (98.2%, P?=?0.003). Patients with positive washing cytology alone revealed a 5-year OS rate similar to that of patients with new stage IIIA disease (96.2% vs. 90.9%, respectively; P?=?0.53). The 5-year OS rate for patients with stage IIIC1 disease was improved compared with that for patients with stage IIIC2 disease (85.7% vs. 63.0%, respectively; P?=?0.08). Conclusion New revised FIGO 2008 staging system for endometrial cancer produced better discrimination in OS outcomes compared with the 1988 system. J. Surg. Oncol. 2012; 106: 938941. (c) 2012 Wiley Periodicals, Inc.
• Ultrastaging of para-aortic lymph nodes in stage IIIC1 endometrial cancer: A preliminary report

  Yukiharu Todo, Yoshihiro Suzuki, Manabu Azuma, Yutaka Hatanaka, Yosuke Konno, Hidemichi Watari, Hidenori Kato, Yoshihiro Matsuno, Katsushige Yamashiro, Noriaki Sakuragi

  GYNECOLOGIC ONCOLOGY 127 (3) 532 - 537 0090-8258 2012/12 [Refereed][Not invited]
   

  Objective. The aim of this study was to determine the rate of occult metastasis, including isolated tumor cells, in para-aortic lymph nodes of patients with stage IIIC1 endometrial cancer who underwent pelvic and para-aortic lymphadenectomy. Methods. A series of 15 patients who had undergone combined pelvic and para-aortic lymphadenectomy during the period from 2004 to 2010 and who were diagnosed as being positive for pelvic node metastasis but negative for para-aortic node metastasis were included in this study. Ultra-staging by multiple slicing, staining with hematoxylin/eosin and cytokeratin, and microscopic inspection was performed on a total of 242 para-aortic lymph nodes. Results. Eleven (73.3%) of the 15 patients had occult para-aortic lymph node metastasis. Two patients (13.3%) had macrometastasis and nine patients (60.0%) had isolated tumor cells. Type 2 endometrial cancer tended to have a higher rate of occult metastasis than that of type 1 cancer (90% vs. 40%, P=0.07). The rate of occult para-aortic node metastasis was not related to the number of metastatic pelvic nodes. Five patients suffered recurrence in the lung or in the intraabdomen, but lymph node recurrence was not found in any case. Conclusion. Patients with stage IIIC1 endometrial cancer have a potentially high rate of occult para-aortic node metastasis. Local treatment of the para-aortic region should be considered in patients with stage IIIC1 endometrial cancer until effective adjuvant therapy is established. (C) 2012 Elsevier Inc. All rights reserved.
• Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy

  Masayoshi Hosaka, Hidemichi Watari, Tatsuya Kato, Tetsuji Odagiri, Yousuke Konno, Daisuke Endo, Takashi Mitamura, Satomi Kikawa, Yoshihiro Suzuki, Noriaki Sakuragi

  JOURNAL OF SURGICAL ONCOLOGY 105 (6) 612 - 616 0022-4790 2012/05 [Refereed][Not invited]
   

  Background and Objectives The aim of this study was to compare the clinical efficacy of paclitaxel/cisplatin (TP) as an adjuvant chemotherapy to adjuvant radiotherapy (RT) after radical hysterectomy and systematic lymphadenectomy for patients with cervical cancer.Methods: A total of 125 patients with early-stage cervical cancer, who underwent radical hysterectomy, and received adjuvant therapy due to recurrent risk factors were retrospectively analyzed. Forty-nine patients were treated with RT, and 32 received paclitaxel/ cisplatin (TP) for three to six cycles at 4-week interval. Survival and postoperative complications were compared between two modalities.Results: There was no significant difference of 3-year disease-free survival between two groups (P 0.23), while significantly better 3-year overall survival in TP group than RT group (P 0.02). Seven of 32 patients (21.9%) treated with adjuvant TP, 16 of 49 patients (32.7%) treated with RT showed disease recurrence. Median of survival time after recurrence in RT group and TP group was 8.5 months, 12.0 months, respectively. Postoperative bowel obstruction was significantly more frequent in the RT group compared to the TP group (P 0.01).Conclusions: Postoperative chemotherapy using TP might be more beneficial for survival than adjuvant RT and can reduce postoperative complications for cervical cancer patients treated with radical hysterectomy. J. Surg. Oncol. 2012; 105: 612-616. (C) 2011 Wiley Periodicals, Inc.
• A Prospective Study on the Efficacy of Octreotide in the Management of Malignant Bowel Obstruction in Gynecologic Cancer

  Hidemichi Watari, Masayoshi Hosaka, Yukio Wakui, Eiji Nomura, Hitoshi Hareyama, Fumie Tanuma, Rifumi Hattori, Masaki Azuma, Hidenori Kato, Naoki Takeda, Satoshi Ariga, Noriaki Sakuragi

  INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 22 (4) 692 - 696 1048-891X 2012/05 [Refereed][Not invited]
   

  Objective: Malignant bowel obstruction (MBO), of which symptoms lead to a poor quality of life, is a common and distressing clinical complication in advanced gynecologic cancer. The aim of this study was to prospectively assess the clinical efficacy of octreotide to control vomiting in patients with advanced gynecologic cancer with inoperable gastrointestinal obstruction. Methods: Patients with advanced gynecologic cancer, who presented at least one episode of vomiting per day due to MBO, were enrolled in this prospective study from 2006 to 2009. Octreotide was administered when necessary at doses starting with 300 Kg up to 600 Kg a day by continuous infusion for 2 weeks. Primary end point was vomiting control, which was evaluated by common terminology criteria for adverse events version 3 (CTCAE v3.0). Adverse events were also evaluated by CTCAE v3.0. Results: Twenty-two cases were enrolled in this study. Octreotide controlled vomiting in 15 cases (68.2%) to grade 0 and 3 cases (13.6%) to grade 1 on CTCAE v3.0. Overall response rate to octreotide treatment was 81.8% in our patients' cohort. Among 14 cases without nasogastric tube, the overall response rate was 93.1% (13/14). Among 8 cases with nasogastric tube, 4 cases were free of tube with decrease of drainage, and overall response rate was 62.5% (5/8). No major adverse events related to octreotide were reported. Conclusions: We conclude that 300-Kg/d dose of octreotide was effective and safe for Japanese patients with MBO by advanced gynecologic cancer. Octreotide could contribute to better quality of life by avoiding placement of nasogastric tube.
• Prognostic Significance of Clusterin Expression in Advanced-Stage Cervical Cancer Treated With Curative Intended Radiotherapy

  Hidemichi Watari, Rumiko Kinoshita, Yimin Han, Lei Wang, Masayoshi Hosaka, Hiroshi Taguchi, Kazuhiko Tsuchiya, Shinya Tanaka, Hiroki Shirato, Noriaki Sakuragi

  INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 22 (3) 465 - 470 1048-891X 2012/03 [Refereed][Not invited]
   

  Objective: Overexpression of clusterin (CLU), an antiapoptotic molecule, has been reported to induce resistance to radiotherapy (RT) in a variety of cancer cell types. The aim of this study was to evaluate the significance of CLU expression to predict survival of patients with advanced-stage cervical cancer who received curative intended RT. Methods: Biopsy tissue specimens of advanced-stage cervical cancer before curative intended RT were obtained from 34 patients who were treated at Hokkaido University Hospital between 1998 and 2008 and whose complete medical records were available. The expression of CLU protein was analyzed by immunohistochemistry. Findings were evaluated in relation to several clinicopathological factors. Survival analyses were performed using the Kaplan-Meier curves and the log-rank test. Independent prognostic factors were determined by multivariate Cox regression analysis. Results: Clusterin protein was mainly present in the cytoplasm of cervical cancer cells. The expression of CLU protein in cervical cancer tissues before curative intended RT was not significantly related to any clinicopathological factors analyzed, including age, clinical stage, histologic type, and response to RT. Univariate analysis on prognostic factors showed that histologic type (P = 0.001), and CLU expression (P = 0.02) were related to survival. Multivariate analysis revealed that both histologic type (P = 0.002), and CLU expression (P = 0.02) were independent prognostic factors for overall survival. Conclusion: We conclude that CLU could be a new molecular marker to predict overall survival of patients with advanced-stage cervical cancer treated with curative intended RT.
• Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.

  Mohamed K Hassan, Hidemichi Watari, Yimin Han, Takashi Mitamura, Masayoshi Hosaka, Lei Wang, Shinya Tanaka, Noriaki Sakuragi

  Journal of experimental & clinical cancer research : CR 30 113 - 113 0392-9078 2011/12/20 [Refereed][Not invited]
   

  BACKGROUND: Clusterin is a cytoprotective chaperone protein involved in numerous physiological processes, carcinogenesis, tumor growth and tissue remodelling. The purpose of this study was to investigate whether clusterin (CLU), an antiapoptotic molecule, could be a potential predictor molecule for ovarian cancer and whether or not targeting this molecule can improve survival of ovarian cancer patients. METHODS: Clusterin expression was compared between ten primary and their recurrent tumors from same patients immunohistochemically. We analyzed prognostic significance of CLU expression in another 47 ovarian cancer tissue samples by immunohistochemistry. We used small interference RNA to knock down CLU in the chemo-resistant ovarian cancer cell lines. KF-TX and SKOV-3-TX, paclitaxel-resistant ovarian cancer cells, were established from parental KF and SKOV-3 chemo-sensitive cell lines, respectively. Either siRNA or second generation antisense oligodeoxynucleotide against CLU (OGX-011), which is currently evaluated in clinical phase II trials in other cancer s, was used to modulate sensitivity to paclitaxel (TX) in ovarian cancer cells in vitro. Cellular viability assay, FACS analysis and annexin V staining were used to evaluate the comparative effect of CLU knocking down in ovarian cancer cells. RESULTS: Immunohistochemical analysis of CLU expression in primary ovarian cancer tissue specimens and their recurrent counterparts from same patients demonstrated higher expression of CLU in the recurrent resistant tumors compared with their primary tumors. High expression of CLU by immunohistochemistry among 47 surgical tissue specimens of early-stage (stage I/II) ovarian cancer, who underwent complete cytoreduction as a primary surgery, significantly related to poor survival, while none of other clinicopathological factors analyzed were related to survival in this patient cohort. Secretory CLU (s-CLU; 60 KDa) expression was upregulated in TX-resistant ovarian cancer cells compared to parental cells. Transfection of siRNA or OGX-011 clearly reduced CLU expression. Cell viability assay, FACS analysis and annexin V staining demonstrated that targeting CLU expression by siRNA or OGX-011 sensitized ovarian cancer cells to TX. CONCLUSION: We conclude that CLU could be a potential molecular target to predict survival while targeting this s-CLU may improve survival of patients with ovarian cancer.
• Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel

  Mohamed Kamel Hassan, Hidemichi Watari, Lane Christenson, Saverio Bettuzzi, Noriaki Sakuragi

  TUMOR BIOLOGY 32 (5) 1031 - 1047 1010-4283 2011/10 [Refereed][Not invited]
   

  Understanding the molecular events that lead to paclitaxel (TX) resistance is necessary to identify effective means to prevent chemoresistance. Previously, results from our lab revealed that secretory clusterin (CLU) form positively mediates TX response in ovarian cancer cells. Thus, we had interest to study the role of another non-secreted form (intracellular clusterin (i-CLU)) in chemo-response. Here, we provide evidences that i-CLU form localizes mainly in the nucleus and differentially expressed in the TX-responsive KF cells, versus TX-resistant, KF-TX, ovarian cancer cells and negatively regulate cellular chemo-response. I-CLU was cloned, by deleting the secretion-leading signaling peptide from full-length CLU cDNA, and transiently over-expressed in OVK-18 cells. Forced expression of truncated i-CLU was mainly detectable in the nuclei and significantly reduced cellular growth, accumulating cells in G1 phase which finally died through apoptosis. Importantly, compromised expression of i-CLU under an inducible promoter was tolerated and did not induce apoptosis but sensitized ovarian cancer cells to TX. We then demonstrated that this sensitization mechanism was cell cycle independent and relied on i-CLU/Ku70 binding probably due to controlling the free amount of Ku70 available for DNA repair in the nucleus. Results from CLU immunehistochemistry in ovarian tumor tissues verified the retardation of nuclear CLU staining in the recurrent tumor even though their primary counterparts showed nuclear CLU staining. Thus, the controversial data on CLU function in chemo-response/resistance may be explained by a shift in the pattern of CLU expression and intracellular localization as well when tumor acquires chemoresistance.
• MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1

  Peixin Dong, Masanori Kaneuchi, Hidemichi Watari, Junichi Hamada, Satoko Sudo, Jingfang Ju, Noriaki Sakuragi

  MOLECULAR CANCER 10 99  1476-4598 2011/08 [Refereed][Not invited]
   

  Background: Epithelial-mesenchymal transition (EMT) is the key process driving cancer metastasis. Oncogene/self renewal factor BMI-1 has been shown to induce EMT in cancer cells. Recent studies have implied that noncoding microRNAs (miRNAs) act as crucial modulators for EMT. The aims of this study was to determine the roles of BMI-1 in inducing EMT of endometrial cancer (EC) cells and the possible role of miRNA in controlling BMI-1 expression. Methods and results: We evaluated the expression of BMI-1 gene in a panel of EC cell lines, and detected a strong association with invasive capability. Stable silencing of BMI-1 in invasive mesenchymal-type EC cells up-regulated the epithelial marker E-cadherin, down-regulated mesenchymal marker Vimentin, and significantly reduced cell invasion in vitro. Furthermore, we discovered that the expression of BMI-1 was suppressed by miR-194 via direct binding to the BMI-1 3'-untranslated region 3'-UTR). Ectopic expression of miR-194 in EC cells induced a mesenchymal to epithelial transition (MET) by restoring E-cadherin, reducing Vimentin expression, and inhibiting cell invasion in vitro. Moreover, BMI-1 knockdown inhibited in vitro EC cell proliferation and clone growth, correlated with either increased p16 expression or decreased expression of stem cell and chemoresistance markers (SOX-2, KLF4 and MRP-1). Conclusion: These findings demonstrate the novel mechanism for BMI-1 in contributing to EC cell invasion and that repression of BMI-1 by miR-194 could have a therapeutic potential to suppress EC metastasis.
• Incidence of metastasis in circumflex iliac nodes distal to the external iliac nodes in intermediate- and high-risk endometrial cancer

  Yukiharu Todo, Hidenori Kato, Kazuhira Okamoto, Shinichiro Minobe, Yoshihiro Suzuki, Yoko Ohba, Mahito Takeda, Hidemichi Watari, Masanori Kaneuchi, Noriaki Sakuragi

  GYNECOLOGIC ONCOLOGY 122 (1) 55 - 58 0090-8258 2011/07 [Refereed][Not invited]
   

  Objective. The aim of this study was to elucidate the incidence of metastasis in circumflex iliac nodes distal to the external iliac nodes (CINDEIN), which are also called suprainguinal nodes, in intermediate- and high-risk endometrial cancer. Removal of these nodes needs to be discussed from the viewpoint of patient's quality of life because removal of CINDEIN is strongly related to lower extremity lymphedema. Methods. A retrospective chart review was carried out for 508 patients with intermediate- and high-risk endometrial cancer who were included in this study. We identified patients with lymph node metastasis. Lymph node sites were classified into four groups: (1) CINDEIN, (2) external iliac nodes, (3) Group A consisting of circumflex iliac nodes to the distal obturator nodes, internal iliac nodes, obturator nodes, cardinal ligament nodes (including deep obturator nodes), and sacral nodes, and (4) Group B consisting of common iliac nodes and para-aortic nodes. Logistic regression analysis was used to select risk factors for CINDEIN metastasis. Results. In an analysis of 508 patients with intermediate- and high-risk disease, CINDEIN metastasis was found in fourteen (2.8%) of the patients. Multivariate analysis confirmed that high-risk histology (OR = 5.7, 95% CI = 1.2-16.1) and Group A node metastasis (OR = 9.7, 95% CI = 2.9-31.4) were independent risk factors for CINDEIN metastasis. None of the patients with G1 endometrioid adenocarcinoma had CINDEIN metastasis. Three (2.5%) of the patients with G2 endometrioid adenocarcinoma had CINDEIN metastasis and all of these three patients had other pelvic node metastasis. Conclusion. Removal of CINDEIN can be eliminated in patients with G1 endometrial cancer and patients with G2 endometrial cancer who have no pelvic node metastasis. (C) 2011 Elsevier Inc. All rights reserved.
• Risk factors for lower-limb lymphedema after surgery for cervical cancer

  Yoko Ohba, Yukiharu Todo, Noriko Kobayashi, Masanori Kaneuchi, Hidemichi Watari, Mahito Takeda, Satoko Sudo, Masataka Kudo, Hidenori Kato, Noriaki Sakuragi

  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 16 (3) 238 - 243 1341-9625 2011/06 [Refereed][Not invited]
   

  Lower-limb lymphedema (LLL) is a prevalent complication that is encountered after treatment for gynecological malignancies. The aim of this study was to evaluate the risk factors for postoperative LLL in patients with cervical cancer. We conducted a retrospective chart review for patients who had undergone surgery, including systematic lymphadenectomy, for cervical cancer. Patients who died of cancer, were evaluated for short periods of time (< 2 years), had missing medical records, or were suffering from deep venous thrombosis were excluded. We utilized the International Society of Lymphology staging of lymphedema severity as the diagnostic criteria for LLL, and patients with stage II or III lymphedema, as objectively determined by physicians, were included in the group of patients with LLL. Multivariate analysis was performed to confirm independent risk factors. A total of 155 patients with cervical cancer were evaluated. Thirty-one patients (20.0%) contracted LLL with a median follow-up of 6.1 years. Suprafemoral node dissection (odds ratio, 9.5; 95% confidence interval, 1.2-73.3; P = 0.031) and adjuvant radiotherapy (3.7; 1.2-10.9; P = 0.019) were identified as independent risk factors. Given that the effectiveness of the above two therapeutic options for cervical cancer is currently controversial, the clinical benefits of these therapies should be reevaluated specifically to conserve the quality of life for patients with this disease.
• Initial failure site according to primary treatment with or without para-aortic lymphadenectomy in endometrial cancer

  Yukiharu Todo, Hidenori Kato, Shinichiro Minobe, Kazuhira Okamoto, Yoshihiro Suzuki, Satoko Sudo, Mahito Takeda, Hidemichi Watari, Masanori Kaneuchi, Noriaki Sakuragi

  GYNECOLOGIC ONCOLOGY 121 (2) 314 - 318 0090-8258 2011/05 [Refereed][Not invited]
   

  Objective. The objective of this study was to compare the initial failure sites in patients with endometrial cancer who underwent surgical treatment including pelvic lymphadenectomy with or without para-aortic lymphadenectomy. Methods. A retrospective chart review was carried out for 657 endometrial cancer patients with no residual disease after initial treatments including lymphadenectomy at two tertiary centers between 1987 and 2004. Surgical treatment at one institute included pelvic lymphadenectomy (PLX) without para-aortic lymphadenectomy (PALX), while surgical treatment including PLX + PALX was routinely performed at the other institute. We identified patients with recurrence and evaluated initial failure sites. Rates of recurrence in the respective sites were compared according to the type of lymphadenectomy. Results. Of the 657 patients, 103 (15.7%) suffered recurrence. There was no significant difference between the rate of intrapelvic recurrence in the PLX alone group and that in the PLX + PALX group (4.7% vs. 2.9%, p = 0.22). The rate of extrapelvic recurrence in the PLX alone group was significantly higher than that in the PLX + PALX group (16.1% vs. 6.2%, p < 0.0001), and the rate of para-aortic node (PAN) recurrence in the PLX alone group was also significantly higher than that in the PLX + PALX group (5.1% vs. 0.6%, p = 0.0004). In the analysis of patients who received adjuvant chemotherapy, the rate of PAN recurrence in the PLX alone group was significantly higher than that in the PLX + PALX group (9.5% vs. 1.3%, p = 0.0036). Conclusion. PAN recurrence was a failure pattern peculiar to the PLX alone group. Adjuvant chemotherapy might not be able to replace surgical removal as a treatment for metastatic lymph nodes. (C) 2011 Elsevier Inc. All rights reserved.
• A validation study of the new revised FIGO staging system to estimate prognosis for patients with stage IIIC endometrial cancer

  Yukiharu Todo, Hidenori Kato, Shinichiro Minobe, Kazuhira Okamoto, Yoshihiro Suzuki, Yosuke Konno, Mahito Takeda, Hidemichi Watari, Masanori Kaneuchi, Noriaki Sakuragi

  GYNECOLOGIC ONCOLOGY 121 (1) 126 - 130 0090-8258 2011/04 [Refereed][Not invited]
   

  Objective. The aim of this study was to validate the role of the new FIGO staging system for estimating prognosis for patients with stage IIIC endometrial cancer. Methods. A total of 93 cases with stage IIIC were entered in this study and classified into three groups: one group of patients who underwent pelvic lymphadenectomy (PLX) and para-aortic lymphadenectomy (PALX) and who were for positive for pelvic node metastasis (PLNM) and negative for para-aortic node metastasis (PANM) (Group 1), one group of patients who underwent PLX alone and were positive for PLNM (Group 2) and one group of patients who underwent PLX and PALX and were positive for PANM (Group 3). Information on clinicopathologic findings and treatments was obtained from medical charts. Cox regression analysis was used to select prognostic factors. Results. The 5-years survival rates were 89.3% in Group 1, 46.5% in Group 2 and 59.9% in Group 3. The overall survival rate in Group 1 was significantly better than that in Group 2 (p = 0.0001) and Group 3 (p = 0.0016). No significant difference in overall survival was found between Group 2 and Group 3. Age, number of metastatic lymph nodes, type of lymphadenectomy and type of adjuvant therapy were significantly and independently related to overall survival. Only when patients received PALX, PANM was a prognostic risk factor. Conclusion. Sub-classification of stage IIIC would be functional for estimating prognosis in the revised FIGO staging system. Systematic lymphadenectomy including PALX has therapeutic significance for patients with stage IIIC endometrial cancer. Prognosis of patients with stage IIIC endometrial cancer would depend much more on application of lymphadenectomy including PALX than nodal status. (C) 2010 Elsevier Inc. All rights reserved.
• Multivariate survival analysis of the patients with recurrent endometrial cancer

  Tetsuji Odagiri, Hidemichi Watari, Masayoshi Hosaka, Takashi Mitamura, Yousuke Konno, Tatsuya Kato, Noriko Kobayashi, Satoko Sudo, Mahito Takeda, Masanori Kaneuchi, Noriaki Sakuragi

  JOURNAL OF GYNECOLOGIC ONCOLOGY 22 (1) 3 - 8 2005-0380 2011/03 [Refereed][Not invited]
   

  Objective: Few studies on the prognosticators of the patients with recurrent endometrial cancer after relapse have been reported in the literature. The aim of this study was to determine the prognosticators after relapse in patients with recurrent endometrial cancer who underwent primary complete cytoreductive surgery and adjuvant chemotherapy.Methods: Thirty-five patients with recurrent endometrial cancer were included in this retrospective analysis. The prognostic significance of several clinicopathological factors including histologic type, risk for recurrence, time to relapse after primary surgery, number of relapse sites, site of relapse, treatment modality, and complete resection of recurrent tumors were evaluated. Survival analyses were performed by Kaplan-Meier curves and the log-rank test. Independent prognostic factors were determined by multivariate Cox regression analysis.Results: Among the clinicopathological factors analyzed, histologic type (p=0.04), time to relapse after primary surgery (p=0.03), and the number of relapse sites (p=0.03) were significantly related to survival after relapse. Multivariate analysis revealed that time to relapse after primary surgery (hazard ratio, 6.8; p=0.004) and the number of relapse sites (hazard ratio, 11.1; p=0.002) were independent prognostic factors for survival after relapse. Survival after relapse could be stratified into three groups by the combination of two independent prognostic factors.Conclusion: We conclude that time to relapse after primary surgery, and the number of relapse sites were independent prognostic factors for survival after relapse in patients with recurrent endometrial cancer.
• Survival and prognosticators of node-positive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy

  Masayoshi Hosaka, Hidemichi Watari, Takashi Mitamura, Yousuke Konno, Tetsuji Odagiri, Tatsuya Kato, Mahito Takeda, Noriaki Sakuragi

  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 16 (1) 33 - 38 1341-9625 2011/02 [Refereed][Not invited]
   

  Lymph node metastasis (LNM) is known to be the most important prognostic factor in cervical cancer. We analyzed the number of positive lymph nodes and other clinicopathological factors as prognostic factors for survival in node-positive patients with cervical cancer.Node-positive cervical cancer patients (n = 108) who underwent radical hysterectomy and systematic lymphadenectomy in Hokkaido University Hospital from 1982 to 2002 were enrolled. Clinicopathological data including age, stage, histologic subtype, and the number of LNM sites were collected. The main outcome was the overall survival (OS) rate for Stage Ib-IIb patients treated with surgery and postoperative radiotherapy.The 5-year OS rate of patients with 1 positive node was 93.3%, that for 2 nodes was 77.3%, for 3 nodes it was 33.3%, and for 4 or more it was 13.8%. The OS rate of patients with 1 or 2 LNM sites was significantly better than that for patients with more than 2 LNM sites. The OS rate of patients with adenocarcinoma (Ad) (28.6%) was significantly lower than that for patients with other histologic subtypes (squamous cell carcinoma; 66.7%, adenosquamous carcinoma; 75.0%, p = 0.0003). Multivariate analysis revealed that > 2 LNM sites and Ad were independent prognostic factors for survival. The 5-year OS rate of patients with 1 or 2 LNM sites was 86.8%, a more favorable prognosis than the OS rates in other reports.More than two LNM sites and adenocarcinoma were independent prognostic factors for node-positive patients with cervical cancer.
• A Retrospective Analysis of Postoperative Complications With or Without Para-aortic Lymphadenectomy in Endometrial Cancer

  Yosuke Konno, Yukiharu Todo, Shinichiro Minobe, Hidenori Kato, Kazuhira Okamoto, Satoko Sudo, Mahito Takeda, Hidemichi Watari, Masanori Kaneuchi, Noriaki Sakuragi

  INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 21 (2) 385 - 390 1048-891X 2011/02 [Refereed][Not invited]
   

  Introduction: Although para-aortic lymphadenectomy (PALX) has not been accepted as a standard treatment for patients with endometrial cancer, it is possible that systematic lymphadenectomy including PALX has therapeutic significance for patients with intermediate-/high-risk endometrial cancer. On the other hand, a consensus regarding the safety of PALX has not been reached. The aim of this study was to compare the incidence rates of postoperative complications after pelvic lymphadenectomy (PLX) with or without PALX in patients with uterine corpus cancer. Methods: A retrospective chart review was carried out for all patients with endometrial cancer treated at 2 tertiary centers between 1998 and 2004. Surgery at one institute included both PLX and PALX, whereas PLX alone was routinely performed at the other institute. A total of 142 patients underwent PLX + PALX and 138 patients underwent PLX alone. We evaluated postoperative complications including intraoperative injury, ileus, lymphedema, lymphocyst, and thrombosis. Results: There was no fatal accident associated with surgery. Lymphedema was the most frequent complication. Comparing the PLX + PALX group and the PLX group, there were no significant differences in the rate of cases of lymphedema (23.2% vs 28.3%), lymphocyst (9.2% vs 9.4%), and thrombosis (4.9% vs 2.2%). The rate of cases of mild/moderate ileus in the PLX + PALX group was significantly higher than that in the PLX group (10.5% vs 2.9%; P = 0.011). However, no significant difference in the rates of cases of severe ileus was found between the 2 groups (1.4% vs 0.7%). There were also no significant differences between the 2 groups in the rates of intraoperative organ injury (2.8% vs 2.2%) and secondary operation for postoperative complications (4.9% vs 4.3%). Conclusions: Para-aortic lymphadenectomy can be performed with an acceptable morbidity under the conditions in which it is performed by experienced surgeons, and measures to prevent complications are properly taken.
• Risk Factors for Persistent Low Bladder Compliance After Radical Hysterectomy

  Yasunari Oda, Yukiharu Todo, Sharon Hanley, Masayoshi Hosaka, Mahito Takeda, Hidemichi Watari, Masanori Kaneuchi, Masataka Kudo, Noriaki Sakuragi

  INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 21 (1) 167 - 172 1048-891X 2011/01 [Refereed][Not invited]
   

  Introduction: Bladder compliance deteriorates immediately after radical hysterectomy (RH), and low bladder compliance causes upper urinary tract dysfunctions such as progressive hydronephrosis. The aims of this study were to clarify risk factors for persistent low bladder compliance after RH and to propose a postsurgical management protocol for improved recovery of bladder function. Methods: A total of 113 consecutive patients who underwent RH with the intention to preserve the pelvic autonomic nerve system were included in this prospective study. Urodynamic studies were performed according to a planned schedule: presurgery and 1, 3, 6, and 12 months after surgery. Autonomic nerves were preserved at least unilaterally in 95 (84.1%) of the 113 patients, but this was not possible in the remaining 18 patients (15.9%). Postoperative adjuvant radiation therapy (RT) was performed in 14 patients. The relationships between bladder compliance and various clinical factors were investigated using logistic regression analysis. Covariates included age, nerve-sparing procedure, adjuvant RT, and maximum abdominal pressure during the voiding phase. Bladder compliance at 12 months after surgery was used as the dependent variable. Results: Radical hysterectomy with a non-nerve-sparing procedure (odds ratio [OR], 3.4; 95% confidence interval [CI], 1.1-11.0), adjuvant RT (OR, 10.3; 95% CI, 2.5-43.5), and voiding with abdominal pressure at 3 months after surgery (OR, 2.9; 95% CI, 1.1-7.2) were risk factors for persistent low bladder compliance. Conclusions: A nerve-sparing procedure and prohibition of voiding with abdominal strain during the acute and subacute phases after RH resulted in improved recovery of bladder compliance. Adjuvant RT should be avoided in patients who undergo nerve-sparing RH if an alternative postoperative strategy is possible.
• High Prevalence of Multiple Human Papillomavirus Infection in Japanese Patients with Invasive Uterine Cervical Cancer

  Hidemichi Watari, Rie Michimata, Motoaki Yasuda, Akihiro Ishizu, Utano Tomaru, Ying Xiong, Mohamed K. Hassan, Noriaki Sakuragi

  PATHOBIOLOGY 78 (4) 220 - 226 1015-2008 2011 [Refereed][Not invited]
   

  Objective: Multiple human papillomavirus (HPV) infection of the uterine cervix has been suggested as a risk factor for persistent HPV infection, resulting in the development of invasive cervical cancer. The aim of this study was to reveal the actual state of multiple HPV infection in Japanese patients with invasive cervical cancer. Methods: Sixty fresh-frozen invasive cervical cancer tissues were examined for genotyping of HPV. The presence of HPV genotypes was determined with an HPV-DNA array, which can discriminate 25 different HPV genotypes with high sensitivity and specificity. Results: Among 60 samples, 59 (96.7%) were positive for HPV. The three common genotypes were HPV-16 (83.3%), HPV-18 (45.0%) and HPV-52 (28.3%). Multiple HPV infection was observed in 47 of 60 samples (78.3%), among which 42 were infected with more than one high-risk genotype (70.0%). Multiple high-risk HPV infection was significantly more prevalent in patients below 40 years old (14/15, 93.3%) than in patients 40 years of age and over (28/45, 62.2%). Conclusion: The HPV-DNA array is the preferred method to detect HPV genotypes. Multiple HPV infection in Japanese patients with invasive cervical cancer seemed to be more frequent than reported in the literature. Copyright (C) 2011 S. Karger AG, Basel
• Clusterin Expression Inversely Correlates with Chemosensitivity and Predicts Poor Survival in Patients with Locally Advanced Cervical Cancer Treated with Cisplatin-Based Neoadjuvant Chemotherapy and Radical Hysterectomy

  Hidemichi Watari, Tatsuya Kanuma, Yoko Ohta, Mohamed Kamel Hassan, Takashi Mitamura, Masayoshi Hosaka, Takashi Minegishi, Noriaki Sakuragi

  PATHOLOGY & ONCOLOGY RESEARCH 16 (3) 345 - 352 1219-4956 2010/09 [Refereed][Not invited]
   

  Overexpression of clusterin, an antiapoptotic molecule, has been reported to induce resistance to chemotherapy in a variety of cancer cell types. The aim of this study was to evaluate the significance of clusterin expression to predict response to platinum-based neoadjuvant chemotherapy and survival of patients with invasive cervical cancer who subsequently underwent radical hysterectomy. Biopsy specimens of invasive cervical cancer before neoadjuvant chemotherapy were obtained from 46 patients who subsequently underwent radical hysterectomy at Hokkaido University Hospital and Gunma University Hospital from 1994 to 2007. The expression of clusterin protein was analyzed by immunohistochemistry. Findings were evaluated in relation to several clinicopathological factors. Survival analyses were performed by the Kaplan-Meier curves and the log-rank test. Independent prognostic factors were determined by multivariate Cox regression analysis. Clusterin protein was mainly present in the cytoplasm of cervical cancer cells. The expression of clusterin protein in cervical cancer tissues before neoadjuvant chemotherapy was significantly related to poor response to chemotherapy among factors analyzed. Univariate analysis on prognostic factors showed that response to chemotherapy (p=0.01), lymph node metastasis (p=0.02), and clusterin expression (p=0.02) were related to survival. Multivariate analysis revealed that lymph node metastasis (p=0.03), and clusterin expression (p=0.03) were independent prognostic factors for survival of cervical cancer patients. We conclude that clusterin expression could be a new molecular marker to predict response to platinum-based chemotherapy and survival of patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy.
• Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis

  Yukiharu Todo, Hidenori Kato, Masanori Kaneuchi, Hidemichi Watari, Mahito Takeda, Noriaki Sakuragi

  LANCET 375 (9721) 1165 - 1172 0140-6736 2010/04 [Refereed][Not invited]
   

  Background In response to findings that pelvic lymphadenectomy does not have any therapeutic benefit for endometrial cancer, we aimed to establish whether complete, systematic lymphadenectomy, including the para-aortic lymph nodes, should be part of surgical therapy for patients at intermediate and high risk of recurrence. Methods We selected 671 patients with endometrial carcinoma who had been treated with complete, systematic pelvic lymphadenectomy (n=325 patients) or combined pelvic and para-aortic lymphadenectomy (n=346) at two tertiary centres in Japan (January, 1986 June, 2004). Patients at intermediate or high risk of recurrence were offered adjuvant radiotherapy or chemotherapy. The primary outcome measure was overall survival. Findings Overall survival was significantly longer in the pelvic and para-aortic lymphadenectomy group than in the pelvic lymphadenectomy group (HR 0.53, 95% CI 0.38-0.76; p=0.0005). This association was also recorded in 407 patients at intermediate or high risk (p=0.0009), but overall survival was not related to lymphadenectorny type in low-risk patients. Multivariate analysis of prognostic factors showed that in patients with intermediate or high risk of recurrence, pelvic and para-aortic lymphadenectomy reduced the risk of death compared with pelvic lymphadenectomy (0.44, 0.30-0.64; p<0.0001). Analysis of 328 patients with intermediate or high risk who were treated with adjuvant radiotherapy or chemotherapy showed that patient survival improved with pelvic and para-aortic lymphadenectomy (0.48, 0.29-0.83; p=0.0049) and with adjuvant chemotherapy (0.59, 0.37-1.00; p=0.0465) independently of one another. Interpretation Combined pelvic and para-aortic lymphadenectomy is recommended as treatment for patients with endometrial carcinoma of intermediate or high risk of recurrence. If a prospective randomised or comparative cohort study is planned to validate the therapeutic effect of lymphadenectomy, it should include both pelvic and para-aortic lymphadenectomy in patients of intermediate or high risk of recurrence.
• Survival and Failure Pattern of Patients With Endometrial Cancer After Extensive Surgery Including Systematic Pelvic and Para-Aortic Lymphadenectomy Followed by Adjuvant Chemotherapy

  Hidemichi Watari, Takashi Mitamura, Masashi Moriwaki, Masayoshi Hosaka, Yoko Ohba, Satoko Sudo, Yukiharu Todo, Mahito Takeda, Yasuhiko Ebina, Noriaki Sakuragi

  INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 19 (9) 1585 - 1590 1048-891X 2009/12 [Refereed][Not invited]
   

  We investigated the survival and the failure pattern of 288 patients with endometrial cancer treated with extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by cisplatin-based chemotherapy from 1982 to 2002. We correlated the failure pattern with various clinicopathologic factors to find the predictors of recurrence sites. The 5-year overall survival rates were 97.5% for stage I, 87.5% for stage II, 85.2% for stage III, and 12.5% for stage IV Notably, the 5-year survival rate was 76.5% for patients with stage IIIC disease. Among patients with a low risk (n = 92) for recurrence who received no adjuvant chemotherapy, 2 (2.2%) showed recurrent disease. Among those with intermediate (n 98) and high (n = 98) risks for recurrence who received adjuvant chemotherapy, 9 (9.2%) and 20 (20.4%) showed recurrent disease, respectively. The recurrence sites were described as follows: distant (n = 12), vaginal (n = 8), peritoneal (n = 7), pelvic (n = 2), and lymphatic (n = 2). Lymphatic failure was found beyond the area of lymphadenectomy. Architectural and nuclear grades; myometrial, lymph-vascular space, and cervical invasions; and lymph node metastasis were predictors of distant failure. Cervical invasion and lymph node metastasis were predictors of vaginal failure. For patients with stage I/II cancer, the architectural and nuclear grades were related to distant failure. Seven (63.6%) of 11 patients with a low or intermediate risk survived after relapse, whereas only 1 (4.8%) of 21 patients with a high risk survived after a recurrence. We conclude that we need to further test the efficacy of systemic adjuvant therapy using new chemotherapeutic regimens to prevent distant failure and to improve the survival of patients with endometrial cancer.
• A 14-Year-Old Female Patient With FIGO Stage IB Endometrial Carcinoma A Case Report

  Takashi Mitamura, Hidemichi Watari, Yukiharu Todo, Takayuki Koshida, Noriaki Sakuragi

  INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 19 (5) 896 - 897 1048-891X 2009/07 [Refereed][Not invited]
   

  Introduction: This is the second report on the conservative treatment of endometrial carcinoma in a female patient younger than fifteen years. Case A, a 14-year-old teenager, presented with menorrhagia. An endometrial biopsy revealed grade 2 endometrioid adenocarcinoma. The estrogen receptor and progesterone receptor were strongly positive in 60% and 90% of the tumor, respectively. Although she was administered medroxyprogesterone acetate for a month, it was not effective. She underwent standard Surgery including a hysterectomy. She was thereafter free of disease 1 year after Surgery. No estrogen receptor staining of the Surgical specimen was observed, and 30% of the tumor was strongly positive for progesterone receptor. Direct DNA sequencing of exons 7 and 8 of PTEN and the K-ras codon 12 demonstrated the presence of no mutation. In addition, no dominant-negative p53 mutation was found by a yeast functional assay.Conclusion: A uterine malignancy should therefore be included in the differential diagnosis in a young female patient complaining of abnormal genital bleeding.
• Intrathoracic injection of paclitaxel for a patient with stage IV serous ovarian cancer: a case report

  Takashi Mitamura, Masayoshi Hosaka, Mahito Takeda, Hidemichi Watari, Noriaki Sakuragi

  CANCER CHEMOTHERAPY AND PHARMACOLOGY 64 (1) 169 - 170 0344-5704 2009/06 [Refereed][Not invited]
   

  There have so far only been few reports on the intrathoracic injection (IT) of paclitaxel for ovarian cancer.The patient was treated with IT paclitaxel to control a large volume of pleural effusion as neoadjuvant chemotherapy. A total of 220 mg (110 mg in each thoracic cavity) of paclitaxel was administrated and the pleural effusion dramatically decreased. The intrathoracic concentration of paclitaxel was 1,524.0, 107.5, 8.1, 11.0 and 3.8 mu m/l at 0, 24, 48, 72 and 96 h, respectively. The plasma concentration was 0.05, 0.11, 0.07, 0.04 and 0.02 mu m/l, respectively.An extremely high concentration was maintained over 96 h and there was slight transition into general circulation following IT administration. IT paclitaxel might be effective in some patients with ovarian serous adenocarcinoma who have a refractory tumor in the thoracic cavity.
• Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype

  Hidemichi Watari, Ying Xiong, Mohamed K. Hassan, Noriaki Sakuragi

  GYNECOLOGIC ONCOLOGY 112 (1) 229 - 234 0090-8258 2009/01 [Refereed][Not invited]
   

  Objectives. It has been reported that expression of Cyr61 decreased in endometrial cancers and cancer cell lines compared with normal endometrium, and forced expression of Cyr61 could suppress the growth of human endometrial cancer cells. However, in another report, Cyr61 was immunostained in most of endometrial cancer tissues analyzed. Thus, the aim of this study was to examine the expression of Cyr61 in endometrial cancer and to correlate Cyr61 expression with cinicopathologic factors in a larger cohort. Methods. We used immunohistochemistry and RT-PCR to examine the expression of Cyr61 in 92 endometrial carcinomas of endometrioid subtype. We correlated the expression of Cyr61 with various clinicopathologic factors in patients with endometrioid adenocarcinoma. Survival analyses were performed by the Kaplan Meier Curves and the log-rank test. Independent prognostic factors were determined by multivariate Cox regression analysis. Results. Cyr61 expression was high in 21 of 92 cases of endometrioid adenocarcinoma (22.8%). High expression of Cyr61 was related to poor survival of patients with endometrioid adenocarcinoma. Multivariate analysis including Cyr61 expression revealed that Cyr61 expression and positive lymph node metastasis (LNM) were independent prognostic factors for Survival. Survival of patients with endometrioid adenocarcinoma could be stratified into three groups by combination of Cyr61 expression and positive LNM with an estimated 5-year survival rate of 96.5% for no LNM irrespective of Cyr61 expression (group A), 85.7% for positive LNM with low/moderate expression of Cyr61 (group B), and 0% for positive LNM with high expression of Cyr61 (group C)(p=0.18 for group A vs group B, p=0.008 for group B vs group C, and p < 0.0001 for group A vs group C). Conclusions. Cyr61 is highly expressed in some endometrial cancer of endometrioid subtype. Cyr61 expression and positive LNM were independent prognostic factors for patients with endometrioid adenocarcinoma. Cyr61 might be a new molecular marker to predict the prognosis of patients with endometrioid adenocarcinoma. (c) 2008 Elsevier Inc. All rights reserved.
• Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymphadenectomy

  Masayoshi Hosaka, Hidemichi Watari, Mahito Takeda, Masashi Moriwaki, Yoko Hara, Yukiharu Todo, Yasuhiko Ebina, Noriaki Sakuragi

  JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH 34 (4) 552 - 556 1341-8076 2008/08 [Refereed][Not invited]
   

  Aim: To compare the clinical efficacy focused on post-treatment morbidity between adjuvant chemotherapy (CT) and pelvic radiotherapy (RT) after radical hysterectomy for patients with cervical cancer. Methods: A total of 125 patients with cervical squamous cell carcinoma who underwent radical hysterectomy and pelvic lymphadenectomy at Hokkaido University Hospital between 1991 and 2002 were enrolled in the study for retrospective analysis. Seventy patients with recurrent risk factors, including deep stromal invasion, lymph vascular space invasion, parametrial invasion, lymph node metastasis (LNM), and bulky tumor (>= 4 cm), received adjuvant therapy; 42 were treated with RT, and 28 were treated with CT. Almost all patients with multiple LNM received RT. Analyses were also performed on a subgroup of 50 patients without multiple LNM (23 RT, 27 CT). Clinical efficacy of post-treatment morbidity and survival was evaluated. Results: Because there were more patients with multiple LNM in the RT group, we analyzed disease-free survival in 50 patients without multiple LNM. The 3-year disease-free survival rate was 82.6% with RT and 96.3% with CT (P = 0.16). Postoperative bowel obstruction was significantly more frequent in the RT group versus the CT (P = 0.007) and no-therapy (P = 0.0026) groups. Urinary disturbance was also more frequent in the RT group than in the CT (P = 0.0016) and no-therapy (P = 0.089) groups. Conclusion: CT has the equivalent therapeutic effect as RT with fewer postoperative complications for patients with intermediate risks. A prospective randomized trial is needed to compare CT combined with radical hysterectomy and pelvic lymphadenectomy to RT or chemoradiotherapy.
• Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy

  Hidemichi Watari, Yoko Ohta, Mohamed Kamel Hassan, Ying Xiong, Shinya Tanaka, Noriaki Sakuragi

  GYNECOLOGIC ONCOLOGY 108 (3) 527 - 532 0090-8258 2008/03 [Refereed][Not invited]
   

  Objectives. The aim of this study was to evaluate the prognostic significance of clusterin expression in invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Methods. Invasive cervical cancer specimens were obtained from 52 patients who underwent radical hysterectomy and systematic lymphadenectomy at Hokkaido University Hospital from 1997 to 2004. The expression of clusterin protein was analyzed by inummohistochemical staining. Findings were evaluated in relation to several clinicopathological factors. Survival analyses were performed by the Kaplan-Meier curves and the log-rank test. Independent prognostic factors were determined by multivariate Cox regression analysis. Results. Clusterin protein was present in the cytoplasm of cervical cancer cells. The expression of clusterin protein in invasive cervical cancer tissues was not related to any clinicopathologic factors analyzed. Patients with positive clusterin expression showed significantly worse prognosis than those with negative clusterin expression (p=0.017). Multivariate analysis including clusterin expression revealed that clusterin expression (p=0.006) and the number of positive node groups (p=0.002) were independent prognostic factors for survival. Survival of patients with invasive cervical cancer could be stratified into three groups by combination of clusterin expression and number of positive node groups with an estimated 5-year survival rate of 100.0% for no or one positive node group irrespective of clusterin expression (group A), 78.7% for multiple node groups with negative clusterin expression (group B), and 14.3% for multiple node groups with positive clusterin expression (group C) (p=0.03 for group A vs. group B, p=0.004 for group B vs. group C, and p<0.0001 for group A vs. group C). Conclusions. Clusterin expression and the number of positive node groups were independent prognostic factors for invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Clusterin might be a new molecular marker to predict the survival of cervical cancer patients with multiple positive node groups. (C) 2007 Elsevier Inc. All rights reserved.
• [Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma].

  Hosaka M, Ebina Y, Moriwaki M, Hara Y, Araki N, Todo Y, Takeda M, Watari H, Sakuragi N

  Gan to kagaku ryoho. Cancer & chemotherapy 34 (9) 1505 - 1508 0385-0684 2007/09 [Refereed][Not invited]
  
• A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial cancer for tailoring the indication of lymphadenectomy

  Yukiharu Todo, Kazuhira Okamoto, Masaru Hayashi, Shinichiro Minobe, Eiji Nomura, Hitoshi Hareyama, Mahito Takeda, Yasuhiko Ebina, Hidemichi Watari, Noriaki Sakuragi

  GYNECOLOGIC ONCOLOGY 104 (3) 623 - 628 0090-8258 2007/03 [Refereed][Not invited]
   

  Objetive. The aim of this study was to verify whether a preoperative scoring system to estimate the risk of lymph node metastasis (LNM) in endometrial carcinoma is clinically useful for tailoring the indication of lymphadenectomy. Study design. LNM score was set up using volume index, serum CA125 level, and tumor grade/histology, which were found to be independent risk factors for LNM in a pilot study. Based on the LNM score before a validation study was started, the estimated rates of LNM (para-aortic LNM) were 3.4% (0.0%) in a low risk group, 7.7% (5.8%) in an intermediate group, 44.4% (30.6%) in a high risk group and 70.0% (50.0%) in an extremely high risk group. The validation study was carried out using data for 211 patients with endometrial carcinoma for whom three risk factors were preoperatively confirmed. Logistic regression analysis was used to determine whether these factors remain valid. The actual rate of LNM was investigated according to the LNM score. Results. Volume index, serum CA125 level, and tumor grade/histology were found to be independent risk factors for LNM in the cohort of this study. The actual rates of LNM (para-aortic LNM) were 3.2% (1.0%) in the low risk group, 15.3% (11.9%) in the intermediate group, 30.2% (23.8%) in the high risk group and 78.6% (57.1%) in the extremely high risk group. Conclusion. The actual rate of LNM for each score was fairly consistent with the estimated rate of LNM. Para-aortic lymphadenectomy may not be necessary in cases of a low risk group. A large prospective multicenter clinical trial needs to be conducted to establish the clinical usefulness of our preoperative scoring system. (c) 2006 Elsevier Inc. All rights reserved.
• A study of oligosaccharide variants of alpha-fetoproteins produced by normal fetuses and fetuses with trisomy 21

  R Yamamoto, T Ohkouchi, K Tabata, Y Ebina, H Watari, M Kudo, K Shimizu, S Satomura, H Minakami, N Sakuragi

  ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA 84 (12) 1145 - 1149 0001-6349 2005/12 [Refereed][Not invited]
   

  Background. The mechanisms of the increase in the percentage of alpha-fetoproteins (AFPs) that strongly binds to Lens culinaris agglutinin (AFP-L3) in pregnancies with a trisomy 21 fetus have not been analyzed. To investigate the oligosaccharide variants of AFP produced by normal fetuses and fetuses with trisomy 21, the lectin reactivity of AFP was analyzed. Methods. Fetal liver tissue, amniotic fluid, and maternal serum were obtained from five normal pregnancies and five pregnancies with a trisomy 21 fetus. The percentages of AFP reactive to lectins were determined by lectin-affinity electrophoresis coupled with antibody-affinity blotting. Results. The percentages of AFP-L3 in the fetal liver and the maternal serum were 23.9 and 27.0%, respectively, in normal pregnancies, and 28.7 and 38.5%, respectively, in pregnancies with a trisomy 21 fetus. There was no statistically significant difference between the percentage in the fetal liver and the percentage in the maternal serum in normal pregnancies; however, a significant difference (P < 0.01) was found in pregnancies with a trisomy 21 fetus. In regard to the percentage of AFP-L3 in the fetal liver, there was no significant difference; however, a significant difference (P < 0.05) was found in the maternal serum between normal pregnancies and pregnancies with a trisomy 21 fetus. Conclusions. The transference of the AFP-L3 fraction might be relatively high in the placentas of women carrying a trisomy 21 fetus, and this could be the one of the reasons for the increase in the percentage of AFP-L3 in the maternal serum in pregnancies with a trisomy 21 fetus.
• Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer

  N Sakuragi, H Watari, Y Ebina, R Yamamoto, E Steiner, H Koelbl, M Yano, M Tada, T Moriuchi

  INTERNATIONAL JOURNAL OF CANCER 116 (4) 514 - 519 0020-7136 2005/09 [Refereed][Not invited]
   

  In addition to the loss of function, mutant p53 can possess a dominant-negative effect on wild-type p53 and may also exert gain-of-function activity. It is not clear whether the functional status of p53 mutation contributes to differences in outcome in endometrial cancer. We collected a total of 92 RNA samples of high quality from endometrial cancer tissues, and the samples were subjected to yeast functional assay and sequencing for p53 mutations. The detected mutant p53 genes were further investigated for their dominant-negative activity using a yeast-based transdominance assay. p53 mutation was found in 24 out of 92 (26.1%) tumors, of which 10 exhibited no dominant-negative activity (recessive mutation) and 14 showed dominant-negative activity. Dominant-negative p53 mutation was related to advanced stages (p = 0.01), non-endometrioid type tumors (p = 0.01) and grade 3 tumors (p = 0.04). The patients with dominant-negative mutation had significantly shorter survival than patients with no mutation (p < 0.0001) and those with a recessive mutation (p = 0.01) in the p53 gene. No difference in survival was found between the patients with tumors harboring a recessive p53 mutation and those with tumors harboring a wild-type p53. Multivariate analysis revealed that dominant-negative p53 mutation (p = 0.019), FIGO stage (p = 0.0037) and histologic subtype (p = 0.014) were independently related to patient survival. Dominant-negative p53 mutation was the most important prognostic factor for stage III/IV endometrial cancer (P = 0.0023). In conclusion, dominant-negative p53 mutation is often found in advanced stages and aggressive histologic subtypes of endometrial cancer and it is a strong predictor of survival of patients with advanced endometrial cancer. To elucidate further the role of p53 mutation in endometrial cancer, it is necessary to investigate gain-of-function activity involving dominant-negative p53 mutant proteins. (c) 2005 Wiley-Liss, Inc.
• Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer

  H Watari, Y Todo, M Takeda, Y Ebina, R Yamamoto, N Sakuragi

  GYNECOLOGIC ONCOLOGY 96 (3) 651 - 657 0090-8258 2005/03 [Refereed][Not invited]
   

  Objective. The aim of this Study was to determine pathologic variables associated with disease-specific survival of node-positive patients with endometrial carcinoma treated with combination of surgery including pelvic and para-aortic lymphadenectomy and adjuvant chemotherapy. Methods. Survival of 55 node-positive endometrial carcinoma patients prospectively treated with Surgery and adjuvant chemotherapy between 1982 and 2002 at Hokkaido University Hospital was compared to various histopathologic variables. All patients underwent primary surgical treatment including pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy consisting of intravenous cisplatin, doxorubicin, and cyclophosphamide. Survival analyses were performed by the Kaplan-Meier curves and the log-rank test. Independent prognostic factors were determined by multivariate Cox regression analysis using a forward stepwise selection. Results. Among 303 consecutive endometrial cancer patients treated during the period of this study, 55 patients (18.2%), including 44 without peritoneal rnetastasis (FIGO stage IIIc) and II with peritoneal metastasis (FIGO stage IV), were found to have retroperitoneal lymph node metastasis. Multivariate Cox regression analysis revealed that peritoneal metastasis and lymph-vascular space invasion (LVSI) were independently related to poor Survival in node-positive endometrial carcinoma. The estimated 5-year survival rate of stage IIIc patients with or without moderate/prominent LVSI was 50.9% and 93.3%, respectively with statistically significant difference (P = 0.0024). The estimated 5-year survival rate of stage IV patients was 20.0%. Prognosis of stage IIIc patients could be stratified into three groups by the number of positive para-aortic node (PAN) with an estimated 5-year survival rate of 86.4% for no positive PAN (n = 23), 60.4% for one positive PAN (n = 13), and 20.0% for >= 2 positive PAN (n = 8). The difference of survival rate between no or one positive PAN and >= 2 positive PAN was statistically significant (P = 0.0007 for no positive PAN vs. >= 2 positive PAN, P = 0.0319 for one positive PAN vs. >= 2 positive PAN). Multivariate analysis including number of positive PAN groups showed that LVSI, number of positive PAN groups were independent prognostic factors for survival. Survival of patients with stage IIIc disease could be stratified into three groups by combination of LVSI and number of positive PAN groups with an estimated 5-year Survival rate of 93.3% for no or one positive PAN group with nil or minimal LVSI, 62.6% for no or one positive PAN group with intermediate or prominent LVSI, and 20.0% for 2 positive PAN groups irrespective of LVSI (P = 0.0002 for no or one positive PAN group with nil or minimal LVSI vs. 2 positive PAN groups, P = 0.0223 for no or one positive PAN group with nil or minimal LVSI vs. no or one positive PAN group with intermediate or prominent LVSI, P = 0.0388 for no or one positive PAN group with intermediate or prominent LVSI vs. >= 2 positive PAN groups). Conclusions. LVSI and number of positive PAN groups were independent prognostic factors for stage IIIc endometrial cancer patients. Postoperative therapy and follow-up modality need to be individualized according to LVSI and the number of positive PAN for stage life patients. New molecular markers to predict the Prognosis of endometrial cancer patients preoperatively should be found for individualization of treatment. New chemotherapy regimen including taxane needs to be considered as an adjuvant therapy for patients with node-positive endometrial cancer. (c) 2004 Elsevier Inc. All rights reserved.
• High dose three-dimensional conformal boost (3DCB) using an orthogonal diagnostic X-ray set-up for patients with gynecological malignancy: a new application of real-time tumor-tracking system

  R Yamamoto, A Yonesaka, S Nishioka, H Watari, T Hashimoto, D Uchida, H Taguchi, T Nishioka, B Miyasaka, N Sakuragi, H Shirato

  RADIOTHERAPY AND ONCOLOGY 73 (2) 219 - 222 0167-8140 2004/11 [Refereed][Not invited]
   

  The feasibility and accuracy of high dose three-dimensional conformal boost (3DCB) using three internal fiducial markers and a two-orthogonal X-ray set-up of the real-time tumor-tracking system on patients with gynecological malignacy were investigated in 10 patients. The standard deviation of the distribution of systematic deviations (Sigma) was reduced from 3.8, 4.6, and 4.9 mm in the manual setup to 2.3. 2.3 and 2.7 mm, in the set-up using the internal markers. The average standard deviation of the distribution of random deviations (sigma) was reduced from 3.7. 5.0, and 4.5 mm in the manual set-up to 3.3, 3.0, and 4.2 mm in the marker set-up. The appropriate PTV margin was estimated to be 10.2, 12.8, and 12.9 mm in the manual set-up and 6.9, 6.7, and 8.3 mm in the gold marker set-up, respectively, using the formula 2Sigma+0.7sigma. Set-up of the patients with three markers and two fluoroscopy is useful to reduce PTV margin and perform 3DCB. (C) 2004 Published by Elsevier Ireland Ltd.
• Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer

  H Negishi, M Takeda, T Fujimoto, Y Todo, Y Ebina, H Watari, R Yamamoto, H Minakami, N Sakuragi

  GYNECOLOGIC ONCOLOGY 94 (1) 161 - 166 0090-8258 2004/07 [Refereed][Not invited]
   

  Objective. We evaluated the primary sites of lymph node (LN) metastasis in patients during the early stage of ovarian cancer. Methods. Study 1: patients with clinical stage I and II common epithelial ovarian carcinoma (n=150) underwent systematic retroperitoneal LN dissection of the pelvic and paraaortic areas. The relationship between the incidence and location of LN metastasis and clinical and histological characteristics was examined. Study 2: we studied I I women with endometrial or fallopian tube tumors. At laparotomy, activated charcoal solution was injected into the unilateral cortex of the ovary. Ten minutes later, the retroperitoneal spaces were opened and charcoal uptake within the pelvic lymph node (PLN) and paraaortic node (PAN) as far as the level of renal vein was examined. Results. Study 1: The incidence of LN metastasis by stage was 6.5% (8/123) in stage I and 40.7% (11/27) in stage II. Among 19 patients with LN metastasis, 14 had only PAN, 2 had only pelvic LN, and 3 had both PAN and PLN metastases. Metastasis was limited to the ipsilateral side in 12 (63%) patients, but was bilateral in 5 (26%) and contralateral to the neoplastic ovary in 2 (11%). Positive peritoneal cytology was significantly (P<0.05) correlated with lymph node metastasis. Study 2: Lymphatic channels along the ovarian vessels were identified in all injected ovaries. Charcoal was deposited in the LN of all patients. The locations of these nodes included PAN in all patients, common iliac node in three, and external iliac node in one. Conclusion. PAN is the primary site of LN metastasis in ovarian cancer. Bilateral PAN dissections are necessary to determine the extent of tumors even in stage I ovarian carcinoma. (C) 2004 Elsevier Inc. All rights reserved.
• Prenatal trisomy 21 screening using the Lens culinaris agglutinin-reactive alpha-fetoprotein ratio.

  Yamamoto R, Minobe S, Ebina Y, Watari H, Kudo M, Henmi F, Satomura S, Fujimoto S, Minakami H, Sakuragi N

  Congenital anomalies 44 (2) 87 - 92 0914-3505 2004/06 [Refereed][Not invited]
  
• Cytological features of cervical smears in serous adenocarcinoma of the endometrium

  Y Todo, S Minobe, K Okamoto, M Takeda, Y Ebina, H Watari, M Terashima, M Kaneuchi, R Yamamoto, N Sakuragi

  JAPANESE JOURNAL OF CLINICAL ONCOLOGY 33 (12) 636 - 641 0368-2811 2003/12 [Refereed][Not invited]
   

  Objective: Serous adenocarcinoma (SAC) of the endometrium has a poor prognosis compared with that of typical endometrioid adenocarcinoma (EAC). The objective of this study was to determine whether SAC can be distinguished from EAC preoperatively by cervical or endometrial cytology. Study design: Cervical smears and endometrial smears obtained from 128 patients with endometrial carcinoma were reviewed. Histological types included 117 cases of EAC and 11 cases of SAC. The positive rates of cervical smears and those of endometrial smears in SAC and EAC cases were compared. Papillary clusters and bare nuclei of malignant cells in positive cervical smears were also investigated for their diagnostic significance in discriminating between EAC and SAC. Results: The positive rate of cervical smears in SAC was significantly higher than that in EAC (72.7 vs 27.4%, P < 0.05). Among cases with positive cervical smears, there were significantly more cases with papillary clusters and/or bare nuclei in cases of SAC than in cases of EAC. Conclusion: When endometrial carcinoma is clinically suspected and a cervical smear is positive, the predominance of either papillary clusters or features of bare nuclei of malignant cells in the smear may indicate the presence of SAC.
• A study on the microheterogeneity of alpha-fetoproteins produced by yolk sac and germ cell tumors

  R Yamamoto, T Ohkouchi, Y Wakui, S Minobe, H Watari, K Shimizu, S Satomura, N Sakuragi

  ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA 82 (9) 876 - 882 0001-6349 2003/09 [Refereed][Not invited]
   

  Background. It is generally believed that the lower the grade of differentiation of glycoprotein-producing cells, the more often modification by bisecting N -acetylglucosamine (GlcNAc) or fucose (Fuc) at the sugar chain of the glycoprotein or increase in branching of side chains occurs. We examined the characteristics of the alpha-fetoprotein (AFP) sugar chain stored in amniotic and exocoelomic fluid during 5-9 weeks of gestation and analyzed serum-derived AFP of patients with germ cell tumors. Methods. Total AFP concentrations in embryonic fluid at 5-9 weeks of gestation (n = 11) and serum of patients with germ cell tumors (n = 7) were measured using a radioimmunoassay (RIA) method. The percentages of AFPs reactive with Lens culinaris agglutinin (LCA), concanavalin A (Con A), erythroagglutinating phytohemagglutinin-E4 (E-PHA) and Ricinus communis agglutinin-120 (RCA 120) were obtained by lectin-affinity electrophoresis coupled with antibody-affinity blotting. Results. It was revealed that at 5-9 weeks of gestation, AFP variants that had been modified by the Fuc residue, which bound to the GlcNAc residue at the reducing end of the sugar chain, and bisecting GlcNAc residues gradually decreased as pregnancy advanced; however, the presence of N -acetylneuraminic acid (Neu5Ac) at the nonreducing ends changed little. Conclusions. It appears very likely that the changes in the relative amounts of AFP variants in the embryonic fluid during early pregnancy were due to differentiation of the yolk sac. The grade of differentiation of yolk sac tumors was very similar to that of the normal yolk sac at around 6 weeks of gestation.
• Lipopolysaccharide induces interleukin-8 production by human cervical smooth muscle cells

  M Watari, H Watari, T Fujimoto, H Yamada, J Nishihira, JF Strauss, S Fujimoto

  JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION 10 (2) 110 - 117 1071-5576 2003/02 [Refereed][Not invited]
   

  OBJECTIVE: We examined the effect of lipopolysaccharide (LPS), a component of the outer wall of gram-negative bacteria, on expression of the neutrophil chemoattractant interleukin-8 (IL-8) and the effects of IL-8 treatment on release Of matrix metabolizing enzymes in human cervical smooth muscle cells (CSMCs). METHODS: Human CSMCs were exposed to Escherichia coli LPS, and the expression of IL-8 mRNA was analyzed by Northern blotting. The IL-8 promoter activity was examined by dual luciferase assay, and the IL-8 concentration was assessed by enzyme-linked immunosorbent assay. We also treated the CSMCs with human IL-8 and examined the expression of matrix-degrading enzymes. RESULTS: E coli LPS (100 ng/mL) increased the expression of IL-8 mRNA 12.8-fold after 3 hours. This up-regulation was maintained for up to 24 hours. Lipopolysaccharide treatment produced a fivefold increase in IL-8 promoter activity in CSMCs transfected with an IL-8 promoter-reporter construct. IL-8 concentrations in conditioned medium of CSMC cultures treated with E coli LPS increased approximately 18-fold compared with the control cultures. Northern blot analysis and zymography revealed that exogenous human IL-8 had no significant effect on the expression of matrix metalloproteinase (MMP)-1, -3, and tissue inhibitor Of metalloproteinase (TIMP)-1 mRNAs, and on the secretion MMP-2 and -9 in CSMCs. CONCLUSION: We conclude that CSMCs respond to LPS with increased expression of IL-8 mRNA and secreted IL-8, and that expression of matrix metabolizing enzymes in CSMCs is not directly affected by IL-8. IL-8 produced by CSMCs in response to gram-negative infection may promote neutrophil invasion, and release of neutrophil matrix-degrading enzymes may participate in the matrix remodeling associated with parturition. Copyright (C) 2003 by the Society for Gynecologic Investigation.
• Sterols and intracellular vesicular trafficking: lessons from the study of NPC1

  JF Strauss, P Liu, LK Christenson, H Watari

  STEROIDS 67 (12) 947 - 951 0039-128X 2002/11 [Refereed][Not invited]
   

  Cholesterol is an important structural component of membranes as well as a precursor for steroid hormone, bile acid and regulatory oxysterol biosynthesis. Recent observations revealed that cholesterol plays an important role in signaling and the regulation of intracellular vesicular trafficking. Studies on Niemann-Pick type C disease, a fatal neuro-visceral cholesterol storage disorder, led to the elucidation of a sterol-modulated vesicular trafficking pathway. Mutations in the NPC1 gene, which cause the majority of cases of Niemann-Pick type C disease, result in the accumulation of free cholesterol in lysosomes and associated defects in glycolipid sorting. NPC1 has a sterol-sensing domain that presumably recognizes free sterols in the protein's environment and participates in the movement of cholesterol out of lysosomes. The compartment containing NPC1 is a subset of late endosomes; it is highly mobile, travels along microtubules, emitting flexible tubules. The movements of this compartment require an intact NPC1 sterol-sensing domain and are dramatically suppressed when free cholesterol accumulates in the late endosomes. Two other proteins involved in sterol trafficking enter into the NPC1 compartment, NPC2 also known as HE1, a secreted sterol-binding glycoprotein, and MLN64, a StAR-related lipid transfer (START) domain protein, which can bind cholesterol and promote its movement from donor to acceptor membranes. Mutations in NPC2 cause a rarer form of Niemann-Pick type C disease, establishing its importance in intracellular sterol movement. NPC2, NPC1 and MLN64 may act in an ordered sequence to sense cholesterol, effect sterol movement, and consequently, influence the process of vesicular trafficking. (C) 2002 Elsevier Science Inc. All rights reserved.
• Bax, Bcl-2, and p53 expression in endometrial cancer

  N Sakuragi, A Salah-eldin, H Watari, T Itoh, S Inoue, T Moriuchi, S Fujimoto

  GYNECOLOGIC ONCOLOGY 86 (3) 288 - 296 0090-8258 2002/09 [Refereed][Not invited]
   

  Background. It has not been fully clarified whether alteration of Bax and other apoptosis-relating proteins of Bcl-2 and p53 is involved in endometrial carcinogenesis. Methods. A total of 56 frozen tissues, which included 14 normal endometria, 13 endometrial hyperplasias (10 without atypia and 3 with atypia), and 29 endometrial carcinomas, were examined for the expression of Bax, Bcl-2, and p53 using immunohistochemistry. For Bax-negative cases, PCR-direct sequencing was performed for the bax gene. For cases with p53 overexpression, mutational analysis was performed for the p53 gene using a yeast functional assay and sequencing. Results. Both Bax and Bcl-2 were distinctly expressed in the normal proliferative phase endometrium. A decreased Bcl-2/Bax ratio in the secretory phase endometrial gland cells due to suppressed Bcl-2 expression was observed. Bax expression was positive in all 13 endometrial hyperplasias, while it was absent in 6 of 29 endometrial carcinomas (20.7%). Negative Bax expression in endometrial carcinoma was not related to tumor stage, histologic subtype, or other histopathologic prognostic factors. Bax expression showed no relationship to either p53 overexpression or Bcl-2 expression. In the DNA of 6 Bax-negative cases, we found a frameshift insertion mutation at codon 58 (AAG to CAAG) in the BH3 domain despite the absence of mutation in the (G)8 tract, suggesting that this codon may be another preferred target for box mutation other than the (G)8 tract. Mutational analysis was available for 7 of 10 cases with p53 overexpression, in which 5 cases were found to have a missense mutation and 2 cases had no mutation of the p53 gene. At least 10 of 29 (34.5%) cases of endometrial carcinoma were associated with sequence-verified mutation in the bax gene and/or p53 gene. Conclusions. The bax gene frameshift mutation appears to cause a loss of Bax expression in endometrial carcinoma. Codon 58 may be a preferred target of bax gene mutation in endometrial carcinomas. The bax gene mutation seems to occur in the early stage of the genesis of a subset of endometrial carcinomas. (C) 2002 Elsevier Science (USA).
• Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma

  T Ohkouchi, N Sakuragi, H Watari, E Nomura, Y Todo, H Yamada, S Fujimoto

  AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 187 (2) 353 - 359 0002-9378 2002/08 [Refereed][Not invited]
   

  OBJECTIVE: The purpose of this study was to clarify whether Bcl-2 and p53 have prognostic significance that is independent of lymph node metastasis and other conventional histopathologic factors in endometrial carcinoma. STUDY DESIGN: Immunohistochemistry for Bcl-2 and p53 expression was performed on the frozen sections of 102 cases that were treated with surgery, including pelvic and para-aortic lymphadenectomy. Cox regression analysis was used to determine the prognostic significance. RESULTS: By univariate analysis, both loss of Bcl-2 expression and p53 overexpression were related to patient survival. Lymph node metastasis, p53 overexpression, and nuclear grade were found to be independent prognostic factors (determined by multivariate analysis). The,estimated 5-year survival rate of patients with stage III/IV disease without p53 overexpression was 75.7%; the estimated 5-year survival rate for patients with p53 overexpression was only 40.4%. The difference was highly significant (P = .0053). CONCLUSION: Lymph node metastasis, p53 overexpression, and nuclear grade are independent prognostic factors for endometrial carcinoma. Bcl-2 may have little importance in the progression of endometrial carcinoma and is a less potent prognostic factor than is p53. A new treatment strategy is necessary for advanced stage endometrial carcinoma with p53 overexpression.
• Papillary squamous cell carcinoma of the uterine cervix: a report of two cases with human papillomavirus 16 DNA

  T Fujimoto, N Sakuragi, M Shimizu, H Watari, M Takeda, K Okamoto, E Nomura, R Yamamoto, K Okuyama, S Fujimoto

  ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA 81 (2) 176 - 178 0001-6349 2002/02 [Refereed][Not invited]
  

MISC

• 「それぞれの生」支持療法の工夫 嘔気対策・栄養管理 シスプラチン/パクリタキセル療法による嘔気・嘔吐・食欲不振に対する六君子湯の効果

  大西 俊介, 渡利 英道, 勘野 真紀, 大場 洋子, 竹内 聡, 宮路 天平, 小山田 隼佑, 野村 英司, 加藤 秀則, 杉山 徹, 浅香 正博, 櫻木 範明, 山口 拓洋, 上園 保仁, 岩瀬 哲  日本癌治療学会学術集会抄録集  55回-  WS5  -5  2017/10  [Not refereed][Not invited]
  
• BRCA陽性白金製剤感受性再発卵巣癌に対するolaparibの第III相試験 SOLO2

  田村 研治, 松本 光史, 中井 英勝, 榎本 隆之, 竹原 和宏, 齋藤 俊章, 渡利 英道, 渡辺 麻子, 藤原 恵一  日本癌治療学会学術集会抄録集  55回-  O10  -1  2017/10  [Not refereed][Not invited]
  
• 卵巣明細胞癌患者由来異種移植片モデルの樹立と特性解析

  朝野 拓史, 遠藤 大介, 國友 美穂子, 本田 弘平, 野村 俊之, 渡利 英道  日本癌治療学会学術集会抄録集  55回-  O11  -2  2017/10  [Not refereed][Not invited]
  
• 胃癌の子宮頸部転移が疑われた1例

  前田 悟郎, 武田 真人, 奥 聡, 朝野 拓史, 小林 由佳子, 石塚 泰也, 丸川 活司, 今井 一章, 遠藤 大介, 岡田 宏美, 三田村 卓, 渡利 英道, 畑中 佳奈子, 櫻木 範明, 松野 吉宏  日本臨床細胞学会雑誌  56-  (Suppl.2)  689  -689  2017/10  [Not refereed][Not invited]
  
• 子宮体部粘液性腺癌の2例

  小林 由佳子, 武田 真人, 奥 聡, 朝野 拓史, 前田 悟郎, 石塚 泰也, 丸川 活司, 岡田 宏美, 三田村 卓, 保坂 昌芳, 畑中 佳奈子, 佐川 正, 渡利 英道, 櫻木 範明, 松野 吉宏, 今井 一章  日本臨床細胞学会雑誌  56-  (Suppl.2)  718  -718  2017/10  [Not refereed][Not invited]
  
• 子宮頸部絨毛腺管状腺癌の1例

  奥 聡, 武田 真人, 朝野 拓史, 今井 一章, 小林 由佳子, 前田 悟郎, 石塚 泰也, 丸川 活司, 岡田 宏美, 三田村 卓, 保坂 昌芳, 佐川 正, 渡利 英道, 畑中 佳奈子, 松野 吉宏  日本臨床細胞学会雑誌  56-  (Suppl.2)  813  -813  2017/10  [Not refereed][Not invited]
  
• 再発卵巣癌の治療 長期生存を目指して

  渡利 英道  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  65回-  42  -42  2017/09  [Not refereed][Not invited]
  
• 卵巣明細胞癌患者由来異種移植片モデルの樹立と特性解析

  朝野 拓史, 遠藤 大介, 加藤 達矢, 金野 陽輔, 三田村 卓, 國友 美穂子, 本田 弘平, 野村 俊之, 渡利 英道, 櫻木 範明  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  65回-  56  -56  2017/09  [Not refereed][Not invited]
  
• Parasitic dissecting leiomyoma(DL)の1例

  石塚 泰也, 工藤 正尊, 藤井 タケル, 能代 究, 三田村 卓, 金野 陽輔, 加藤 達矢, 渡利 英道  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  65回-  100  -100  2017/09  [Not refereed][Not invited]
  
• ベセスダシステムとWHO新分類(2014)の整合性を考えた今後の子宮頸がん検診

  藤田 博正, 保坂 昌芳, 工藤 正隆, 渡利 英道, 櫻木 範明  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  65回-  103  -103  2017/09  [Not refereed][Not invited]
  
• 閉経後の外陰症例の治療経過の検討

  小林 由佳子, 武田 真人, 前田 悟郎, 山口 正博, 福本 俊, 小林 範子, 藤野 敬史, 渡利 英道, 工藤 正尊, 櫻木 範明  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  65回-  128  -128  2017/09  [Not refereed][Not invited]
  
• 悪性腹膜中皮腫の1例

  奥 聡, 武田 真人, 朝野 拓史, 小林 由佳子, 井平 圭, 野崎 綾子, 金野 陽輔, 加藤 達矢, 工藤 正尊, 渡利 英道, 清水 亜衣, 松野 吉宏  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  65回-  134  -134  2017/09  [Not refereed][Not invited]
  
• MRIによる子宮体癌と子宮癌肉腫の鑑別に関する検討

  常田 慧徳, 加藤 扶美, 朝野 拓史, 野崎 綾子, 井平 圭, 三田村 卓, 金野 陽輔, 加藤 達矢, 渡利 英道, 飯嶋 由紀, 西岡 井子, 真鍋 徳子, 工藤 與亮  日本医学放射線学会秋季臨床大会抄録集  53回-  S470  -S471  2017/08  [Not refereed][Not invited]
  
• 婦人科癌術後下肢リンパ浮腫患者に対する治療介入がQOLに及ぼす影響

  小林 範子, 藤野 敬史, 武田 真人, 渡利 英道, 青山 誠, 櫻木 範明  女性心身医学  22-  (1)  69  -69  2017/06  [Not refereed][Not invited]
  
• 当科におけるロボット支援腹腔鏡下子宮悪性腫瘍手術の初期導入成績について

  加藤 達矢, 工藤 正尊, 朝野 拓史, 嶋田 知紗, 野崎 綾子, 井平 圭, 金野 陽輔, 保坂 昌芳, 渡利 英道, 櫻木 範明  産婦人科手術  (28)  156  -156  2017/06  [Not refereed][Not invited]
  
• 子宮体癌2018年版・子宮頸癌2017年版 (第2章)【初回治療】に関して

  小林 裕明, 近藤 英司, 進 伸幸, 寺井 義人, 戸板 孝文, 新倉 仁, 渡利 英道, 河野 善明  日本婦人科腫瘍学会雑誌  35-  (3)  434  -434  2017/06  [Not refereed][Not invited]
  
• 子宮頸部円錐切除術前後におけるHPVタイピング検査の有用性の検討

  金野 陽輔, 朝野 拓史, 嶋田 知紗, 井平 圭, 加藤 達矢, 小林 範子, 武田 真人, 渡利 英道, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  35-  (3)  525  -525  2017/06  [Not refereed][Not invited]
  
• 卵巣明細胞癌患者由来異種移植片モデルの樹立と特性解析

  朝野 拓史, 渡利 英道, 遠藤 大介, 國友 美穂子, 本田 弘平, 野村 俊之, 畑中 豊, 畑中 佳奈子  日本婦人科腫瘍学会雑誌  35-  (3)  529  -529  2017/06  [Not refereed][Not invited]
  
• BRCA変異陽性PSR卵巣癌患者を対象としたolaparibの単独維持療法の第III相試験 SOLO-2

  松本 光史, 温泉川 真由, 中井 英勝, 榎本 隆之, 竹原 和宏, 齋藤 俊章, 渡利 英道, 渡辺 麻子, 藤原 恵一  日本婦人科腫瘍学会雑誌  35-  (3)  532  -532  2017/06  [Not refereed][Not invited]
  
• 腹水貯留原発不明癌の診断確定に腹水セルブロックが有用であった一例

  井平 圭, 朝野 拓史, 嶋田 知紗, 野崎 綾子, 遠藤 大介, 金野 陽輔, 加藤 達矢, 武田 真人, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  35-  (3)  615  -615  2017/06  [Not refereed][Not invited]
  
• 卵巣明細胞腺癌に対するcabozantinibの抗腫瘍効果についての検討

  中谷 真紀子, 渡利 英道, 王 磊, 畑中 豊, 畑中 佳奈子, 西原 広史, 朝野 拓史, 遠藤 大介, 三田村 卓, 董 培新, シャロン・ハンリー, 田中 伸哉, 櫻木 範明  日本婦人科腫瘍学会雑誌  35-  (3)  628  -628  2017/06  [Not refereed][Not invited]
  
• 化学療法耐性卵巣癌に対するEZH2阻害剤とpaclitaxelの相乗効果に関する検討

  遠藤 大介, 渡利 英道, 朝野 拓史, 嶋田 知紗, 井平 圭, 宇田 智浩, 金野 陽輔, 加藤 達矢, 小林 範子, 武田 真人, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  35-  (3)  633  -633  2017/06  [Not refereed][Not invited]
  
• 明細胞性卵巣癌におけるEZH2、ARID1Aの発現と予後についての検討

  野崎 綾子, 渡利 英道, 朝野 拓史, 小林 由佳子, 嶋田 知紗, 井平 圭, 遠藤 大介, 金野 陽輔, 加藤 達矢, 武田 真人, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  35-  (3)  642  -642  2017/06  [Not refereed][Not invited]
  
• 高悪性度子宮体癌と比較した子宮体部癌肉腫症例の臨床病理学的特徴について

  嶋田 知紗, 渡利 英道, 加藤 達矢, 野崎 綾子, 小林 由佳子, 朝野 拓史, 井平 圭, 金野 陽輔, 小林 範子, 武田 真人, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  35-  (3)  671  -671  2017/06  [Not refereed][Not invited]
  
• A case of parasitic leiomyoma following total laparoscopic hysterectomy without use of power morcellation: A case report

  Ishizuka Yasunari, Kudo Masataka, Ohara Yasuhiro, Yamazaki Hiroyuki, Ihira Kei, Uda Tomohiro, Nakatani Makiko, Kato Tatsuya, Watari Hidemichi, Sakuragi Noriaki  JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY  33-  (1)  131  -137  2017/04  [Not refereed][Not invited]
   

  Background: The number of gynecological laparoscopic procedures is increasing. Power morcellation has been widely employed to break up large uterine fibroids and remove fragments from the abdominal cavity. In recent years, several studies have reported parasitic leiomyoma (PM), resulting from the spread and growth of fibroid tissues in the abdominal cavity after the use of power morcellation for laparoscopic hysterectomy or myomectomy.

  Case: A 46-year-old para 1 woman had undergone total laparoscopic hysterectomy for a large uterine leiomyoma at the age of 41 without use of power morcellation. Fiftynine months later, she was found to have intrapelvic tumors. Following surgical resection they were diagnosed as iatrogenic PMs.

  Conclusions: It is possible that iatrogenic PM can occur even if power morcellation is not used. Surgeons must be careful to remove as many small fragments of fibroids as possible. We should be aware of the risk for iatrogenic PMs in all surgical procedures for uterine fibroids. To our knowledge, this is the first report of a case of iatrogenic PM after total laparoscopic hysterectomy without the use of power morcellation.

• 画像診断に苦慮したHHV8-unrelated primary effusion lymphoma-like lymphomaの1例

  中川 純一, 加藤 扶美, 三村 理恵, 藪崎 哲史, 坂本 圭太, 真鍋 徳子, 工藤 與亮, 菅野 宏美, 松野 吉宏, 豊嶋 崇徳, 金谷 穣, 渡利 英道, 櫻木 範明, 白土 博樹  Japanese Journal of Radiology  35-  (Suppl.)  3  -3  2017/02  [Not refereed][Not invited]
  
• 卵巣癌において化学療法後のオートタキシンの高発現は予後不良因子である

  金野 陽輔, 遠藤 大介, 朝野 拓史, 嶋田 知紗, 野崎 綾子, 井平 圭, 加藤 達矢, 小林 範子, 武田 真人, 渡利 英道, 工藤 正尊, 櫻木 範明  日本産科婦人科学会雑誌  69-  (2)  686  -686  2017/02  [Not refereed][Not invited]
  
• 卵巣明細胞腺癌患者由来異種移植片モデルの樹立と特性解析

  遠藤 大介, 渡利 英道, 本田 弘平, 國友 美穂子, 野村 俊之, 櫻木 範明  日本産科婦人科学会雑誌  69-  (2)  686  -686  2017/02  [Not refereed][Not invited]
  
• 卵巣明細胞性腺癌におけるEZH2、ARID1Aの発現と予後についての検討

  野崎 綾子, 渡利 英道, 朝野 拓史, 小林 由佳子, 嶋田 知紗, 井平 圭, 遠藤 大介, 金野 陽輔, 加藤 達矢, 武田 真人, 工藤 正尊, 櫻木 範明  日本産科婦人科学会雑誌  69-  (2)  687  -687  2017/02  [Not refereed][Not invited]
  
• シスプラチン/パクリタキセル併用化学療法を受ける子宮頸癌・体癌患者における嘔気・嘔吐に対する標準制吐療法と六君子湯併用制吐療法の第II相比較試験(JORTC-KMP02)

  嶋田 知紗, 渡利 英道, 大場 洋子, 山口 正博, 勘野 真紀, 朝野 拓史, 井平 圭, 野崎 綾子, 金野 陽輔, 加藤 達矢, 野村 英司, 櫻木 範明  日本産科婦人科学会雑誌  69-  (2)  922  -922  2017/02  [Not refereed][Not invited]
  
• 外陰および腟の疼痛症例の17例

  小林 由佳子, 武田 真人, 前田 悟郎, 山口 正博, 福本 俊, 嶋田 知紗, 保坂 昌芳, 小林 範子, 藤野 敬史, 渡利 英道, 工藤 正尊, 櫻木 範明  日本産科婦人科学会雑誌  69-  (2)  1035  -1035  2017/02  [Not refereed][Not invited]
  
• 黄体ホルモンが乳腺濃度へ及ぼす影響

  小林 範子, 藤野 敬史, 小林 由佳子, 武田 真人, 渡利 英道, 佐川 正, 櫻木 範明  日本産科婦人科学会雑誌  69-  (2)  1036  -1036  2017/02  [Not refereed][Not invited]
  
• 【婦人科診療の近未来】 子宮肉腫の初回治療・再発治療

  朝野 拓史, 渡利 英道  産婦人科の実際  65-  (12)  1657  -1664  2016/11  [Not refereed][Not invited]
  
• 子宮内腔に進展した大腸癌の1例

  奥 聡, 武田 真人, 小林 由佳子, 朝野 拓史, 前田 悟郎, 石塚 泰也, 三田村 卓, 渡利 英道, 丸川 活司, 櫻木 範明  日本臨床細胞学会雑誌  55-  (Suppl.2)  476  -476  2016/10  [Not refereed][Not invited]
  
• 大量の腹水貯留をきたしたLarge B cell lymphomaの1例

  小林 由佳子, 武田 真人, 丸川 活司, 朝野 拓史, 前田 悟郎, 石塚 泰也, 遠藤 大介, 岡田 宏美, 三田村 卓, 渡利 英道, 畑中 佳奈子, 櫻木 範明  日本臨床細胞学会雑誌  55-  (Suppl.2)  495  -495  2016/10  [Not refereed][Not invited]
  
• 腟原発リンパ上皮腫様癌の1例

  前田 悟郎, 武田 真人, 小林 由佳子, 朝野 拓史, 石塚 泰也, 岡田 宏美, 遠藤 大介, 三田村 卓, 渡利 英道, 丸川 活司, 櫻木 範明  日本臨床細胞学会雑誌  55-  (Suppl.2)  495  -495  2016/10  [Not refereed][Not invited]
  
• 子宮頸部Glassy cell carcinomaの1例

  石塚 泰也, 武田 真人, 丸川 活司, 朝野 拓史, 三田村 卓, 渡利 英道, 櫻木 範明  日本臨床細胞学会雑誌  55-  (Suppl.2)  506  -506  2016/10  [Not refereed][Not invited]
  
• 子宮肉腫に対する薬物療法の新展開

  渡利 英道  現代産婦人科  65-  (Suppl.)  S28  -S28  2016/09  [Not refereed][Not invited]
  
• 【思春期の悪性腫瘍治療と妊孕性】 思春期に好発する悪性腫瘍と治療戦略 婦人科領域 思春期・若年女性(AYA世代)の悪性卵巣胚細胞腫瘍の治療と妊孕性

  渡利 英道, 櫻木 範明  思春期学  34-  (3)  307  -311  2016/09  [Not refereed][Not invited]
  
• 類内膜癌G3および特殊組織型子宮体癌と比較した子宮体部癌肉腫症例の臨床病理学的特徴について

  朝野 拓史, 渡利 英道, 加藤 達矢, 野崎 綾子, 小林 由佳子, 嶋田 知紗, 井平 圭, 金野 陽輔, 小林 範子, 武田 真人, 工藤 正尊, 櫻木 範明  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  64回-  92  -92  2016/09  [Not refereed][Not invited]
  
• 当科における再発子宮体癌の再発様式と治療成績の検討

  朝野 拓史, 渡利 英道, 加藤 達矢, 福本 俊, 嶋田 知紗, 古田 祐, 金野 陽輔, 小林 範子, 武田 真人, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  34-  (3)  415  -415  2016/06  [Not refereed][Not invited]
  
• 子宮頸癌に対する広汎子宮全摘術後の補助化学療法の有用性についての後方視的検討

  嶋田 知紗, 加藤 達矢, 朝野 拓史, 山崎 博之, 井平 圭, 遠藤 大介, 福本 俊, 宇田 智浩, 中谷 真紀子, 古田 祐, 三田村 卓, 金野 陽輔, 武田 真人, 小林 範子, 工藤 正尊, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  34-  (3)  434  -434  2016/06  [Not refereed][Not invited]
  
• 子宮癌肉腫Stage IAに対する術後補助療法の有効性 多施設共同後方視研究JGOG2048Sによる検討

  原野 謙一, 平川 晃弘, 温泉川 真由, 中村 俊昭, 佐藤 豊実, 西川 忠曉, 青木 大輔, 伊藤 公彦, 伊藤 潔, 中西 透, 進 伸幸, 竹原 和宏, 渡部 洋, 渡利 英道, 齋藤 俊章  日本婦人科腫瘍学会雑誌  34-  (3)  437  -437  2016/06  [Not refereed][Not invited]
  
• 卵巣癌における化学療法前後のオートタキシンの発現変化と予後に関する検討

  金野 陽輔, 渡利 英道, 遠藤 大介, 朝野 拓史, 嶋田 知紗, 福本 俊, 古田 祐, 加藤 達矢, 小林 範子, 武田 真人, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  34-  (3)  505  -505  2016/06  [Not refereed][Not invited]
  
• 局所進行子宮頸癌に対する術前化学療法の治療効果に対する検討

  福本 俊, 稲葉 洋文, 木村 敬子, 山口 正博, 嶋田 知紗, 金野 陽輔, 加藤 達矢, 保阪 昌芳, 小林 範子, 武田 真人, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  60-  (1)  70  -70  2016/03  [Not refereed][Not invited]
  
• LGR7(Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 7:RXFP1)の卵巣癌における発現に関する検討

  石塚 泰也, 工藤 正尊, 宇田 智浩, 中谷 真紀子, 金野 陽輔, 加藤 達矢, 渡利 英道, 櫻木 範明  日本産科婦人科学会雑誌  68-  (2)  652  -652  2016/02  [Not refereed][Not invited]
  
• microRNA-363はLATS2の発現抑制を介して卵巣癌細胞のパクリタキセル耐性に関与する

  渡利 英道, ハッサン・モハメド, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  68-  (2)  653  -653  2016/02  [Not refereed][Not invited]
  
• 産婦人科におけるSLE症例の診療についての問題点

  良川 大寛, 武田 真人, 小林 由佳子, 岩城 豊, 山口 正博, 前田 悟郎, 福本 俊, 小林 範子, 藤野 敬史, 渡利 英道, 佐川 正, 櫻木 範明  日本産科婦人科学会雑誌  68-  (2)  677  -677  2016/02  [Not refereed][Not invited]
  
• 子宮頸癌に対する広汎子宮全摘術後の補助化学療法の有用性についての後方視的検討

  嶋田 知紗, 加藤 達矢, 渡利 英道, 福本 俊, 遠藤 大介, 井平 圭, 古田 祐, 金野 陽輔, 小林 範子, 武田 真人, 櫻木 範明  日本産科婦人科学会雑誌  68-  (2)  699  -699  2016/02  [Not refereed][Not invited]
  
• 最近経験したMRKH症候群4例 術前MRIと腹腔鏡所見の比較を中心に

  金野 陽輔, 保坂 昌芳, 嶋田 知紗, 福本 俊, 古田 祐, 加藤 達矢, 小林 範子, 武田 真人, 渡利 英道, 工藤 正尊, 櫻木 範明  日本産科婦人科学会雑誌  68-  (2)  814  -814  2016/02  [Not refereed][Not invited]
  
• 子宮体部平滑筋腫瘍の14例

  櫻井 愛美, 武田 真人, 福本 俊, 嶋田 知紗, 遠藤 大介, 古田 祐, 三田村 卓, 金野 陽輔, 加藤 達矢, 渡利 英道, 工藤 正尊, 櫻木 範明  日本産科婦人科学会雑誌  68-  (2)  894  -894  2016/02  [Not refereed][Not invited]
  
• 深い筋層浸潤を伴う子宮体癌におけるリンパ節転移の病理組織学的リスク因子解析

  齊藤 良玄, 渡利 英道, 嶋田 知紗, 福本 俊, 古田 祐, 金野 陽輔, 加藤 達矢, 小林 範子, 武田 真人, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  68-  (2)  895  -895  2016/02  [Not refereed][Not invited]
  
• 【婦人科がん治療の新機軸】 子宮体癌の化学療法と分子標的治療薬

  朝野 拓史, 渡利 英道  産科と婦人科  83-  (1)  39  -43  2016/01  [Not refereed][Not invited]
   

  子宮体癌に対する化学療法および分子標的治療に関する臨床試験をまとめた。現時点での標準化学療法レジメンは、術後補助化学療法ではAP療法、進行・再発癌ではそれに加えTAP療法やTC療法と考えられた。AP療法やTAP療法では毒性中止が高率である。しかし、分子標的薬単剤での効果は限定的であり、今後、新規レジメン(DP療法など)の検討およびTC療法とベバシズマブの併用療法の検討が期待される。(著者抄録)
• 【子宮頸癌治療の新たな選択肢】 子宮頸部扁平上皮癌に対する術後補助化学療法の展望

  渡利 英道  産婦人科の実際  64-  (13)  2037  -2042  2015/12  [Not refereed][Not invited]
  
• 当院における遺伝性乳がん・卵巣がん症候群の遺伝カウンセリングの現状

  柴田 有花, 細田 充主, 三田村 卓, 山田 崇弘, 矢部 一郎, 山下 啓子, 三田村 卓, 山田 崇弘, 渡利 英道, 櫻木 範明, 炭山 峰華  北海道外科雑誌  60-  (2)  231  -231  2015/12  [Not refereed][Not invited]
  
• ロボット支援腹腔鏡下子宮悪性腫瘍手術の導入初期成績について

  加藤 達矢, 工藤 正尊, 保坂 昌芳, 渡利 英道, 武田 真人, 金野 陽輔, 小林 範子, 櫻木 範明  日本外科系連合学会誌  40-  (5)  1063  -1063  2015/10  [Not refereed][Not invited]
  
• 子宮体部平滑筋肉腫の3例

  朝野 拓史, 武田 真人, 丸川 活司, 菅野 宏美, 畑中 佳奈子, 福本 俊, 井平 圭, 加藤 達矢, 保坂 昌芳, 渡利 英道, 櫻木 範明, 松野 吉宏  北海道臨床細胞学会会報  24-  53  -56  2015/10  [Not refereed][Not invited]
   

  過去5年の間に,まれな子宮体部平滑筋肉腫の3例を経験したので,その診断経過を報告する.(著者抄録)
• 子宮体部明細胞腺癌の診断経過についての検討

  井平 圭, 朝野 拓史, 丸川 活司, 石塚 泰也, 岡田 宏美, 遠藤 大介, 三田村 卓, 保坂 昌芳, 武田 真人, 渡利 英道, 佐川 正, 畑中 佳奈子, 松野 吉宏, 櫻木 範明  日本臨床細胞学会雑誌  54-  (Suppl.2)  558  -558  2015/10  [Not refereed][Not invited]
  
• 婦人科分野におけるセルブロックの有用性の検討

  前田 悟郎, 朝野 拓史, 丸川 活司, 石塚 泰也, 井平 圭, 遠藤 大介, 岡田 宏美, 三田村 卓, 保坂 昌芳, 武田 真人, 渡利 英道, 佐川 正, 畑中 佳奈子, 松野 吉宏, 櫻木 範明  日本臨床細胞学会雑誌  54-  (Suppl.2)  562  -562  2015/10  [Not refereed][Not invited]
  
• 子宮頸癌 卵巣癌を合併した子宮体部類内膜腺癌(triple cancer)の1例

  齊藤 良玄, 朝野 拓史, 丸川 活司, 石塚 泰也, 岡田 宏美, 井平 圭, 三田村 卓, 保坂 昌芳, 武田 真人, 遠藤 大介, 渡利 英道, 佐川 正, 櫻木 範明  日本臨床細胞学会雑誌  54-  (Suppl.2)  658  -658  2015/10  [Not refereed][Not invited]
  
• 子宮体部に発生した小細胞癌の一例

  古田 祐, 朝野 拓史, 丸川 活司, 石塚 泰也, 前田 悟郎, 遠藤 大介, 三田村 卓, 武田 真人, 岡田 宏美, 藤澤 孝志, 渡利 英道, 佐川 正, 畑中 佳奈子, 松野 吉宏, 櫻木 範明  日本臨床細胞学会雑誌  54-  (Suppl.2)  661  -661  2015/10  [Not refereed][Not invited]
  
• 卵巣癌/腹膜癌に対するbevacizumabの奏効率と有害事象 多施設での使用経験の報告

  山口 正博, 渡利 英道, 野村 英司, 涌井 之雄, 首藤 聡子, 見延 進一郎, 東 正樹, 櫻木 範明  日本癌治療学会誌  50-  (3)  701  -701  2015/09  [Not refereed][Not invited]
  
• 再発卵巣癌に対して長期間のBevacizumab投与を行った1例

  櫻井 愛美, 加藤 達矢, 嶋田 知紗, 斎藤 良玄, 福本 俊, 古田 裕, 渡利 英道, 櫻木 範明  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  63回-  61  -61  2015/09  [Not refereed][Not invited]
  
• 再発卵巣癌の予後因子についての検討

  金川 明功, 嶋田 知沙, 福本 俊, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 渡利 英道, 櫻木 範明  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  63回-  62  -62  2015/09  [Not refereed][Not invited]
  
• 子宮体部平滑筋腫瘍の7例

  藤井 タケル, 武田 真人, 岩城 豊, 福本 俊, 嶋田 知沙, 古田 拓, 齊藤 良玄, 金野 陽輔, 加藤 達矢, 片岡 宙門, 渡利 英道, 工藤 正尊, 櫻木 範明  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  63回-  91  -91  2015/09  [Not refereed][Not invited]
  
• 当科で施行した悪性腫瘍に対するロボット支援腹腔鏡下手術

  工藤 正尊, 加藤 達矢, 金野 陽輔, 保坂 昌芳, 渡利 英道, 櫻木 範明  日本産科婦人科内視鏡学会雑誌  31-  (Suppl.I)  255  -255  2015/08  [Not refereed][Not invited]
  
• ロボット支援腹腔鏡下広汎子宮頸部切除術後、早期に腹膜に再発を認めた1例

  石塚 泰也, 工藤 正尊, 加藤 達矢, 金野 陽輔, 保坂 昌芳, 渡利 英道, 櫻木 範明  日本産科婦人科内視鏡学会雑誌  31-  (Suppl.I)  263  -263  2015/08  [Not refereed][Not invited]
  
• 腹腔鏡下卵巣チョコレート嚢胞除去後にARTで妊娠するも帝切時に腹膜播種を認めた卵巣癌の1例

  中谷 真紀子, 工藤 正尊, 宇田 智浩, 石塚 泰也, 三田村 卓, 渡利 英道, 大河内 俊洋, 櫻木 範明  日本生殖医学会雑誌  60-  (3)  198  -198  2015/07  [Not refereed][Not invited]
  
• Mayer-Rokitansky-Kuster-Hauser症候群に対する腹腔鏡下のDavydov法造腟術

  保坂 昌芳, 山口 正博, 嶋田 知紗, 福本 俊, 井平 圭, 遠藤 大介, 宇田 智浩, 中谷 真紀子, 金野 陽輔, 加藤 達矢, 小林 範子, 武田 真人, 渡利 英道, 工藤 正尊, 櫻木 範明  日本生殖医学会雑誌  60-  (3)  198  -198  2015/07  [Not refereed][Not invited]
  
• 当科で行っている自律神経温存手技

  工藤 正尊, 加藤 達矢, 渡利 英道, 櫻木 範明  産婦人科手術  (26)  149  -149  2015/06  [Not refereed][Not invited]
  
• アンドロゲン不応症に伴う外陰部異常に対して女性化外陰形成術を施行した1例

  加藤 達矢, 守屋 仁彦, 山口 正博, 嶋田 知紗, 福本 俊, 三田村 卓, 金野 陽輔, 小田切 哲二, 保坂 昌芳, 小林 範子, 武田 真人, 渡利 英道, 工藤 正尊, 櫻木 範明  産婦人科手術  (26)  196  -196  2015/06  [Not refereed][Not invited]
  
• Mayer-Rokitansky-Kuster-Hauser症候群に対する腹腔鏡下Davydov法造腟術

  保坂 昌芳, 山口 正博, 前田 悟郎, 嶋田 知紗, 福本 俊, 井平 圭, 宇田 智浩, 北川 真紀子, 三田村 卓, 金野 陽輔, 加藤 達矢, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  産婦人科手術  (26)  198  -198  2015/06  [Not refereed][Not invited]
  
• 婦人科悪性腫瘍手術における合併症の管理と予防・軽減策について

  渡利 英道  日本婦人科腫瘍学会雑誌  33-  (3)  482  -482  2015/06  [Not refereed][Not invited]
  
• 症例報告 子宮平滑筋肉腫に対してPazopanibを使用した2例

  加藤 達矢, 櫻井 愛美, 山口 正博, 嶋田 知紗, 福本 俊, 三田村 卓, 金野 陽輔, 保坂 昌芳, 小林 範子, 武田 真人, 渡利 英道, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  33-  (3)  526  -526  2015/06  [Not refereed][Not invited]
  
• 症例報告 後腹膜原発腺肉腫の再発に対してpazopanibが奏功した一例

  山口 正博, 武田 真人, 加藤 達矢, 嶋田 知紗, 福本 俊, 金野 陽輔, 保坂 昌芳, 小林 範子, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  33-  (3)  526  -526  2015/06  [Not refereed][Not invited]
  
• 子宮頸がん基礎 子宮頸部異形成(CIN)の進展とIMP3、ZFP36発現との関連について

  嶋田 知紗, 保坂 昌芳, 渡利 英道, 山口 正博, 福本 俊, 遠藤 大介, 井平 圭, 金野 陽輔, 加藤 達矢, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  33-  (3)  532  -532  2015/06  [Not refereed][Not invited]
  
• 子宮頸がんNAC/手術 局所進行子宮頸癌に対する術前化学療法の治療効果に対する検討

  福本 俊, 稲葉 洋文, 木村 敬子, 山口 正博, 嶋田 知紗, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 小林 範子, 武田 真人, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本婦人科腫瘍学会雑誌  33-  (3)  536  -536  2015/06  [Not refereed][Not invited]
  
• 婦人科悪性腫瘍との鑑別診断に免疫組織化学的マーカー検索が有用であったと考えられた膵がんIVb期の1例

  蔵谷 美乃里, 三田村 卓, 渡利 英道, 山田 恭子, 加藤 達矢, 保坂 昌芳, 小林 範子, 武田 真人, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  33-  (3)  688  -693  2015/06  [Not refereed][Not invited]
   

  腹水貯留を伴う原発不明がんでは、子宮付属器悪性腫瘍や原発性腹膜がんが鑑別疾患に挙げられる。今回、CA125上昇のため婦人科悪性腫瘍との鑑別を要した膵がんIVb期の1症例を経験したので報告する。患者は69歳女性で、腹部膨満感を主訴に消化器内科を受診した。多量の腹水を認め、腹水細胞診で腺がん細胞が検出された。上下部消化管内視鏡検査で悪性所見を認めず、造影CT、PET-CTで腹腔内に播種病巣を疑うものの原発巣は不明であった。血清CA125高値(112U/ml)のため腹膜がんなどの婦人科悪性腫瘍が鑑別疾患に挙げられ当科へ紹介された。内診やエコー、骨盤MRIで悪性所見を認めなかった。腹水を再検したところ、免疫染色ではCK7陽性、CK20陰性、CEA陽性であり、漿液性腺がんよりも膵がんの可能性が示唆された。膵dynamic CTにて、造影CTやPET-CTでは明らかでなかった膵尾部腫瘤を認め膵がん原発のがん性腹膜炎と最終診断された。子宮付属器に異常所見を認めず多量の腹水貯留を伴う原発不明がんでは腹水細胞診の免疫組織化学的マーカー検索が診断に有用な場合があり、膵がんの可能性も念頭におく必要があると考えられた。(著者抄録)
• 放射線治療を多用しない子宮頸癌治療について

  渡利 英道  東北連合産科婦人科学会総会・学術講演会プログラム・抄録集  139回-  26  -26  2015/06  [Not refereed][Not invited]
  
• Mayer-Rokitansky-Kuster-Hauser症候群に対する腹腔鏡下Davydov法造腟術

  福本 俊, 保坂 昌芳, 嶋田 知紗, 井平 圭, 遠藤 大介, 宇田 智浩, 中谷 真紀子, 木村 敬子, 山口 正博, 金野 陽輔, 加藤 達矢, 工藤 正尊, 武田 真人, 渡利 英道, 櫻木 範明  日本外科系連合学会誌  40-  (3)  623  -623  2015/05  [Not refereed][Not invited]
  
• 血中IL-6が高値を示した悪性卵巣腫瘍の二症例

  細川 亜美, 飯沼 洋一郎, 小田切 哲二, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  北海道産科婦人科学会会誌  59-  (1)  162  -162  2015/03  [Not refereed][Not invited]
  
• 当科における子宮内避妊システムミレーナ52mgの使用経験

  蔵谷 美乃里, 飯沼 洋一郎, 小田切 哲二, 金野 陽輔, 首藤 聡子, 渡利 英道, 金内 優典, 櫻木 範明  北海道産科婦人科学会会誌  59-  (1)  184  -184  2015/03  [Not refereed][Not invited]
  
• 子宮頸部異形成(CIN)の進展とIMP3、ZFP36発現との関連について

  嶋田 知紗, 保坂 昌芳, 渡利 英道, 山口 正博, 福本 俊, 井平 圭, 遠藤 大介, 金野 陽輔, 加藤 達矢, 藤田 博正, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  67-  (2)  535  -535  2015/02  [Not refereed][Not invited]
  
• レーザー円錐切除術の術後経過の検討

  藤井 タケル, 武田 真人, 金野 陽輔, 三田村 卓, 加藤 達矢, 森脇 征史, 保坂 昌芳, 首藤 聡子, 岡元 一平, 渡利 英道, 工藤 正尊, 櫻木 範明  日本産科婦人科学会雑誌  67-  (2)  540  -540  2015/02  [Not refereed][Not invited]
  
• 長期女性ホルモン補充療法におけるエストロゲン投与量の検討

  福本 俊, 武田 真人, 山口 正博, 前田 悟郎, 嶋田 知紗, 小林 範子, 八重樫 稔, 渡利 英道, 工藤 正尊, 佐川 正, 藤野 敬史, 櫻木 範明  日本産科婦人科学会雑誌  67-  (2)  763  -763  2015/02  [Not refereed][Not invited]
  
• 子宮頸癌に対する自律神経温存広汎子宮全摘出術の忍容性についての検討

  加藤 達矢, 金内 優典, 山口 正博, 嶋田 知紗, 福本 俊, 金野 陽輔, 保坂 昌芳, 小林 範子, 武田 真人, 渡利 英道, 工藤 正尊, 櫻木 範明  日本産科婦人科学会雑誌  67-  (2)  833  -833  2015/02  [Not refereed][Not invited]
  
• 卵巣癌に対するベバシズマブの使用経験

  山口 正博, 渡利 英道, 嶋田 知紗, 福本 俊, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 小林 範子, 武田 真人, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  67-  (2)  862  -862  2015/02  [Not refereed][Not invited]
  
• Serous endometrial intraepithelial carcinoma(SEIC)の一例

  望月 抄苗, 丸川 活司, 合田 文, 清水 知浩, 渡部 涼子, 恩田 千景, 山谷 幸恵, 森谷 純, 石田 徹, 三田村 卓, 加藤 達矢, 高桑 恵美, 畑中 佳奈子, 渡利 英道, 三橋 智子, 櫻木 範明, 松野 吉宏  北海道臨床細胞学会会報  23-  34  -37  2014/10  [Not refereed][Not invited]
   

  漿液性子宮内膜上皮内癌serous endometrialintraepithelial carcinoma(以下SEIC)は,子宮内膜癌において,ホルモン非依存型とされる漿液性腺癌の初期病変と考えられている.今回我々は,SEICの一例を経験したので,その細胞像を中心に報告する.症例は60歳代女性.子宮がん検診にて,子宮腔内に10mm大のポリープ様病変が見出され,子宮内膜細胞診で異常細胞が認められたことから当院紹介受診となった.画像診断にて内膜の軽度肥厚を見るも,明らかな異常は認められなかった.しかし,子宮内膜細胞診では,萎縮内膜腺細胞を背景に,核腫大,クロマチン増量,核の大小不同を示す細胞集塊が認められた.一部に核小体著明,不規則重積性を示す細胞集塊がみられ,adenocarcinomaと診断されたため,子宮全摘および両側付属器切除術が施行された.切除検体では,萎縮内膜を背景に,内膜ポリープが存在し,内膜ポリープの一部に高度な異型を示す上皮様細胞が乳頭状に増殖する所見が認められた.これらの細胞は極性を失い,大小不同の目立つ腫大した核と,一部明瞭な核小体を有しており,免疫組織化学的にはER,WT-1陽性,p53強陽性と,漿液性腺癌の形質に近似していた.明らかな間質浸潤は認められず,以上を総合してSEICと診断された.高齢者の内膜細胞診において,萎縮内膜を背景に,核腫大,クロマチン増量,核の大小不同を示す細胞集塊を認めた場合は,SEICの可能性を考慮し精査することが必要であると思われる.(著者抄録)
• 後腹膜腔内発育した傍卵管嚢腫を腹腔鏡下に摘出した3例

  嶋田 知紗, 保坂 昌芳, 前田 悟郎, 山口 正博, 木村 敬子, 井平 圭, 遠藤 大介, 福本 俊, 宇田 智浩, 北川 真紀子, 三田村 卓, 金野 陽輔, 加藤 達矢, 小林 範子, 武田 真人, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科内視鏡学会雑誌  30-  (Suppl.I)  243  -243  2014/08  [Not refereed][Not invited]
  
• Mayer-Rokitansky-Kuster-Hauser症候群に対する腹腔鏡下Davydov法造腟術

  福本 俊, 保坂 昌芳, 前田 悟郎, 山口 正博, 木村 敬子, 嶋田 知紗, 井平 圭, 遠藤 大介, 宇田 智浩, 北川 真紀子, 三田村 卓, 金野 陽輔, 加藤 達矢, 小林 範子, 武田 真人, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科内視鏡学会雑誌  30-  (Suppl.I)  259  -259  2014/08  [Not refereed][Not invited]
  
• 【思春期女性のヘルスケア】 思春期の悪性腫瘍

  首藤 聡子, 能代 究, 木村 知美, 山口 正博, 小田切 哲二, 渡利 英道, 工藤 正尊, 櫻木 範明  HORMONE FRONTIER IN GYNECOLOGY  21-  (1)  67  -73  2014/03  [Not refereed][Not invited]
   

  思春期女子から若年成人女性において問題となる悪性腫瘍のうち、婦人科疾患である卵巣悪性胚細胞腫瘍、顆粒膜細胞腫および子宮頸癌に焦点を当て、疫学、病態、さらには妊孕性温存治療の実際について解説する。また、化学療法による卵巣機能障害の回避および妊孕性温存を目的としたGnRHアゴニスト投与に関する知見や患者の心理的側面についても言及する。(著者抄録)
• 【進行婦人科がんの集学的治療】 卵巣がん 進行卵巣がんの治療戦略 初回手術・術前化学療法どちらを選ぶか

  遠藤 大介, 渡利 英道, 櫻木 範明  臨床婦人科産科  67-  (11)  1146  -1153  2013/11  [Not refereed][Not invited]
   

  進行卵巣がんの予後因子として初回手術後の残存腫瘍径が重要であり,最大限の腫瘍減量のために術前化学療法が考慮される.術前化学療法後の腫瘍減量手術が予後の改善に寄与するかどうかに関して,新たな知見が得られてきている.いくつかの臨床試験の結果から,術前化学療法+腫瘍減量手術が標準治療の1つの選択肢として容認されていく可能性がある.(著者抄録)
• 【プロメテウス 婦人科がん最新医療】子宮体がんの手術療法 後腹膜リンパ節郭清

  渡利 英道, 保坂 昌芳, 三田村 卓, 加藤 達矢, 櫻木 範明  産婦人科の実際  62-  (12)  1779  -1783  2013/11  [Not refereed][Not invited]
  
• 血中IL-6が高値を示した悪性卵巣腫瘍の2症例

  細川 亜美, 飯沼 洋一郎, 小田切 哲二, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  61回-  49  -49  2013/09  [Not refereed][Not invited]
  
• 当科における子宮内避妊システムミレーナ52mgの使用経験

  蔵谷 美乃里, 飯沼 洋一郎, 小田切 哲二, 金野 陽輔, 首藤 聡子, 渡利 英道, 金内 優典, 櫻木 範明  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  61回-  74  -74  2013/09  [Not refereed][Not invited]
  
• 腹腔内出血をきたしたPEComaの一例

  小田切 哲二, 飯沼 洋一郎, 三田村 卓, 加藤 達矢, 小林 範子, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 工藤 正尊, 櫻木 範明  日本産科婦人科内視鏡学会雑誌  29-  (Suppl.I)  220  -220  2013/08  [Not refereed][Not invited]
  
• 腹腔鏡下婦人科悪性腫瘍手術における肺血栓塞栓症リスクの前方視的検討

  朝野 拓史, 服部 直也, 野村 英司, 渡利 英道  日本婦人科腫瘍学会雑誌  31-  (3)  434  -434  2013/06  [Not refereed][Not invited]
  
• 子宮内膜腺細胞におけるp53変異と漿液性子宮内膜腺癌へのがん化について

  藤田 博正, 佐々木 隆之, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  31-  (3)  464  -464  2013/06  [Not refereed][Not invited]
  
• 子宮頸部上皮内腫瘍および子宮頸癌におけるHPV16 E6 variantの解析

  首藤 聡子, 渡利 英道, 佐々木 隆之, 藤田 博正, 櫻木 範明  日本婦人科腫瘍学会雑誌  31-  (3)  490  -490  2013/06  [Not refereed][Not invited]
  
• PTCH1遺伝子の変異(c.2497delA)を確認した22歳女性のGorlin症候群

  三田村 卓, 小田切 哲二, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 山田 崇弘, 小林 範子, 武田 真人, 首藤 聡子, 渡利 英道, 金内 優典, 工藤 正尊, 宮下 俊之, 櫻木 範明  日本婦人科腫瘍学会雑誌  31-  (3)  500  -500  2013/06  [Not refereed][Not invited]
  
• 血清IL-6高値を呈した卵巣悪性腫瘍の2例

  飯沼 洋一郎, 小田切 哲二, 三田村 卓, 加藤 達矢, 小林 範子, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  31-  (3)  509  -509  2013/06  [Not refereed][Not invited]
  
• 腹腔鏡下婦人科悪性腫瘍手術における肺血栓塞栓症の発症リスクに関する前方視的検討

  朝野 拓史, 光部 兼六郎, 服部 直也, 渡利 英道, 吉井 一樹, 金野 陽輔, 勘野 真紀, 野村 英司, 工藤 正尊, 櫻木 範明  産婦人科手術  (24)  161  -161  2013/05  [Not refereed][Not invited]
  
• 婦人科悪性腫瘍術後患者に対する大建中湯の使用経験について

  首藤 聡子, 山田 恭子, 三田村 卓, 小田切 哲二, 加藤 達矢, 小林 範子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  産婦人科漢方研究のあゆみ  (30)  66  -71  2013/04  [Not refereed][Not invited]
   

  2003年〜2012年の間に婦人科悪性腫瘍に対する手術を受けた患者367例(平均年齢51.5±12.4歳)を対象に、これらを大動脈周囲リンパ節および骨盤内リンパ節郭清を施行した239例をPLX+PALX群、骨盤内リンパ節郭清のみを施行した128例をPLX群として、術後3〜7日目に大建中湯エキス製剤(15g/日)を投与し、イレウス予防効果について検討した。その結果、1)子宮頸癌による広汎子宮全摘術の多いPLX群ではPLX+PALX群と比較して平均年齢・BMIが有意に低かった。2)悪性腫瘍手術後のイレウス発症率は全体で18.0%、PLX+PALX群で16.7%、PLX群で20.3%と両群の発症率に差は認められなかった。3)イレウス発症までの期間を大建中湯内服の有無で比較すると、内服群で有意に発症時期の遅延が認められた。4)PLX+PALX群、PLX群の、それぞれにおけるイレウス発症の有無と大建中湯内服の有無の比較では大建中湯内服はイレウス発症を有意に低下させることはなかった。以上より、大建中湯は傍大動脈リンパ節を含むリンパ節郭清症例において早期発症のイレウスを予防する可能性が示唆された。
• 帝王切開創部より発生したと考えられる明細胞腺癌の1例

  遠藤 大介, 金野 陽輔, 首藤 聡子, 小田切 哲二, 加藤 達矢, 小林 範子, 武田 真人, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  57-  (1)  112  -112  2013/03  [Not refereed][Not invited]
  
• 3T MRIによる子宮体癌の評価

  三村 理恵, 加藤 扶美, 真鍋 徳子, 小野寺 祐也, 寺江 聡, 金内 優典, 渡利 英道, 櫻木 範明, 白土 博樹  Japanese Journal of Radiology  31-  (Suppl.I)  16  -16  2013/02  [Not refereed][Not invited]
  
• 子宮体癌診断・治療update

  渡利 英道  日本産科婦人科学会雑誌  65-  (2)  422  -422  2013/02  [Not refereed][Not invited]
  
• PTCH1遺伝子の変異(c.2497delA)を確認した22歳女性のGorlin症候群 症例報告

  蔵谷 美乃里, 三田村 卓, 小田切 哲二, 加藤 達矢, 山田 崇弘, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  65-  (2)  520  -520  2013/02  [Not refereed][Not invited]
  
• 当科における子宮内膜異型増殖症/類内膜腺癌に対する妊孕性温存治療

  遠藤 浅香, 工藤 正尊, 保坂 昌芳, 首藤 聡子, 武田 真人, 小林 範子, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  65-  (2)  573  -573  2013/02  [Not refereed][Not invited]
  
• 子宮体癌3C1期における傍大動脈リンパ節occult metastasisの検討

  嶋田 知紗, 藤堂 幸治, 大場 洋子, 見延 進一郎, 岡元 一平, 加藤 秀則, 渡利 英道, 櫻木 範明  日本産科婦人科学会雑誌  65-  (2)  856  -856  2013/02  [Not refereed][Not invited]
  
• 当科における消化管原発転移性卵巣腫瘍症例の検討

  大原 康弘, 首藤 聡子, 遠藤 大介, 三田村 卓, 小田切 哲二, 加藤 達矢, 小林 範子, 武田 真人, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  65-  (2)  966  -966  2013/02  [Not refereed][Not invited]
  
• 10.子宮体癌診断・治療update(専攻医教育プログラム,公益社団法人日本産科婦人科学会第65回学術講演会)

  渡利 英道  日本産科婦人科學會雜誌  65-  (2)  422  -422  2013/02/01  [Not refereed][Not invited]
  
• 【婦人科がん手術の最前線】 子宮体がん 子宮体がんにおけるリンパ節郭清術の意義とその手技

  保坂 昌芳, 金内 優典, 渡利 英道  産婦人科の実際  62-  (1)  39  -43  2013/01  [Not refereed][Not invited]
  
• Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis

  KARAAYVAZ Mihriban, JIA Nan, JU Jingfang  北海道醫學雜誌 = Acta medica Hokkaidonensia  87-  (6)  265  -265  2012/11/01  [Not refereed][Not invited]
  
• 婦人科悪性腫瘍と妊孕能温存(その2) 当科における非上皮性卵巣悪性腫瘍と妊孕能温存治療 胚細胞腫瘍を中心として

  首藤 聡子, 三田村 卓, 小田切 哲二, 金野 陽輔, 加藤 達矢, 小林 範子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明, 岡元 一平, 藤堂 幸治, 加藤 秀則  日本婦人科腫瘍学会雑誌  30-  (4)  592  -592  2012/10  [Not refereed][Not invited]
  
• 当科における子宮内膜異型増殖症/類内膜腺癌に対する妊孕性温存治療

  遠藤 浅香, 工藤 正尊, 保坂 昌芳, 首藤 聡子, 武田 真人, 小林 範子, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  60回-  73  -73  2012/09  [Not refereed][Not invited]
  
• 婦人科悪性腫瘍との鑑別を要した膵癌IVb期の1例

  蔵谷 美乃里, 三田村 卓, 加藤 達矢, 保坂 昌芳, 小林 範子, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  60回-  79  -79  2012/09  [Not refereed][Not invited]
  
• 胆管癌卵巣転移の2例

  大原 康弘, 遠藤 大介, 金野 陽輔, 小田切 哲二, 首藤 聡子, 小林 範子, 武田 真人, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  北日本産科婦人科学会総会・学術講演会プログラム・抄録集  60回-  109  -109  2012/09  [Not refereed][Not invited]
  
• 腹腔鏡下婦人科悪性腫瘍手術における肺血栓塞栓症リスクの前方視的検討

  朝野 拓史, 光部 兼六郎, 服部 直也, 渡利 英道, 福本 俊, 山田 恭子, 勘野 真紀, 野村 英司, 工藤 正尊, 櫻木 範明  日本産科婦人科内視鏡学会雑誌  28-  (1)  103  -103  2012/08  [Not refereed][Not invited]
  
• 重症子宮内膜症術後に尿管腟瘻を来し、腹腔鏡下膀胱尿管新吻合術を行った1例

  宇田 智浩, 工藤 正尊, 井平 圭, 小田切 哲二, 加藤 達矢, 保坂 昌芳, 西 信也, 渡利 英道, 金内 優典, 櫻木 範明  日本産科婦人科内視鏡学会雑誌  28-  (1)  286  -286  2012/08  [Not refereed][Not invited]
  
• 若年女性における骨の管理 無月経 原発性無月経女性に対する女性ホルモン補充療法の長期的影響と骨代謝の特徴

  小林 範子, 武田 真人, 三田村 卓, 小田切 哲二, 加藤 達矢, 首藤 聡子, 渡利 英道, 金内 優典, 古田 伊都子, 藤野 敬史, 水上 尚典, 櫻木 範明  Osteoporosis Japan  20-  (3)  508  -511  2012/07  [Not refereed][Not invited]
   

  Kaufmann療法を中心としたホルモン補充療法(HRT)を行った原発性無月経患者45例を対象に、腰椎骨密度(BMD、BMD Z-score)と骨代謝マーカー(uNTX、BAP)の経時的変化について後方視的に検討した。結果、治療前後でBMDは0.76±1.0→0.85±1.0g/cm2、BMD Z-scoreは-2.4±1.0→-1.5±0.9と有意に改善していた。uNTXは80.3±66.0→45.5±23.7nMBCE/mMCrと有意に低下していたが、治療後も基準値より高値にとどまっていた。BAPは31.0±18.2→26.4±11.1U/Lで有意な変化は認められなかった。HRT施行年数別に「10年未満群」「10年以上20年未満群」「20年以上群」に分けて各指標の変化を比較したところ、BMDの変化は3群間に有意差を認めなかったが、施行年数が長くなるほどBMD Z-scoreは増加してゼロに近づいていき、uNTXは基準値内まで低下していた。
• 卵巣漿液性腺癌において、microRNA-31の発現によりpaclitaxel感受性が変化する

  三田村 卓, 渡利 英道, 遠藤 大介, 田中 理恵子, 中谷 真紀子, 小田切 哲二, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 小林 範子, 首藤 聡子, 武田 真人, 金内 優典, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  30-  (3)  398  -398  2012/06  [Not refereed][Not invited]
  
• 子宮体癌における術前リスクアセスメント導入の提言

  明石 大輔, 藤堂 幸治, 見延 進一郎, 岡元 一平, 加藤 秀則, 晴山 仁志, 服部 理文, 東 正樹, 鈴木 賀博, 片岡 宙門, 涌井 之雄, 渡利 英道, 金内 優典, 櫻木 範明  日本婦人科腫瘍学会雑誌  30-  (3)  448  -448  2012/06  [Not refereed][Not invited]
  
• 術中DVT予防が関与すると考えられた広汎子宮全摘術後横紋筋融解症3例の検討

  首藤 聡子, 金野 陽輔, 遠藤 大介, 三田村 卓, 小田切 哲二, 加藤 達矢, 小林 範子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本婦人科腫瘍学会雑誌  30-  (3)  472  -472  2012/06  [Not refereed][Not invited]
  
• 【婦人科がん診療に役立つ緩和医療の実践】 当院における緩和ケアチームへの産婦人科のかかわり(1)

  首藤 聡子, 渡利 英道, 田巻 知宏, 櫻木 範明  産婦人科の実際  61-  (5)  751  -755  2012/05  [Not refereed][Not invited]
  
• 婦人科腫瘍専門医資格について

  渡利 英道  関東連合産科婦人科学会誌  49-  (2)  265  -265  2012/05  [Not refereed][Not invited]
  
• 子宮頸部に進展した肺原発腺癌の一例

  朝野 拓史, 武田 真人, 丸川 活司, 渡利 英道, 金内 優典, 山田 洋介, 久保田 佳奈子, 佐川 正, 松野 吉宏, 櫻木 範明  日本臨床細胞学会雑誌  51-  (Suppl.1)  392  -392  2012/03  [Not refereed][Not invited]
  
• 低悪性度子宮内膜間質肉腫の一例

  石塚 泰也, 武田 真人, 三田村 卓, 加藤 達矢, 宮越 里絵, 丸川 活司, 渡利 英道, 金内 優典, 三橋 智子, 櫻木 範明  日本臨床細胞学会雑誌  51-  (Suppl.1)  408  -408  2012/03  [Not refereed][Not invited]
  
• 上皮性卵巣癌の予後因子に関する臨床病理学的検討

  遠藤 大介, 渡利 英道, 三田村 卓, 金野 陽輔, 小田切 哲二, 加藤 達矢, 小林 範子, 首藤 聡子, 武田 真人, Hanley Sharon, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  56-  (1)  43  -48  2012/03  [Not refereed][Not invited]
   

  初回手術を行った上皮性卵巣癌158例、卵管癌4例、腹膜癌1例の計163例を対象に、neoadjuvant chemotherapy(NAC)と手術完遂度の影響を解析した。組織型は漿液性腺癌77例(47.2%)、明細胞腺癌44例(26.9%)、類内膜腺癌26例(15.9%)、粘液性腺癌16例(9.8%)、進行期はI期55例(33.7%)、II期15例(9.2%)、III期71例(43.6%)、IV期22例(13.5%)、観察期間は中央値48ヵ月であった。進行期別5年生存率はI期90.4%、II期78.0%、III期60.7%、IV期38.9%であった。III・IV期93例中NAC施行49例、うちinterval debulking surgery(IDS)施行は42例、optimal surgery達成率は71.4%、Primary debulking surgery(PDS)施行は44例、optimal surgery達成率は75%であった。5年生存率は、NACの有無別でNAC+IDS 50.3%、PDS 61.9%と有意差なく、初回手術別でoptimal surgery 71.5%、suboptimal surgery 16.5%と有意差が認められた。多変量解析では手術完遂度のみが有意な予後因子であった。
• 外陰癌とCIN3が合併しともにHPV31型陽性であった1症例

  武田 真人, 金野 陽輔, 首藤 聡子, 小田切 哲二, 加藤 達矢, 保坂 昌芳, 小林 範子, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  56-  (1)  67  -68  2012/03  [Not refereed][Not invited]
  
• アメーバ腟炎の1例

  朝野 拓史, 山口 正博, 金野 陽輔, 小田切 哲二, 加藤 達矢, 保坂 昌芳, 小林 範子, 首藤 聡子, 武田 真人, 久保田 佳奈子, 古田 伊都子, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  56-  (1)  68  -68  2012/03  [Not refereed][Not invited]
  
• 子宮腺筋症に合併した粘液性腺癌と異所性異型腺管の症例について

  小田切 哲二, 渡利 英道, 金野 陽輔, 保坂 昌芳, 加藤 達矢, 小林 範子, 首藤 聡子, 武田 真人, 金内 優典, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  56-  (1)  72  -72  2012/03  [Not refereed][Not invited]
  
• 非典型的な画像所見を呈し、診断に苦慮した卵巣癌の1例

  山口 正博, 朝野 拓史, 金野 陽輔, 小田切 哲二, 加藤 達矢, 保坂 昌芳, 小林 範子, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  56-  (1)  76  -76  2012/03  [Not refereed][Not invited]
  
• FIGO2008新進行期分類に基づいた子宮体癌の予後についての検討

  渡利 英道, 三田村 卓, 小田切 哲二, 金野 陽輔, 加藤 達矢, 小林 範子, 首藤 聡子, 武田 真人, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  64-  (2)  425  -425  2012/02  [Not refereed][Not invited]
  
• 子宮体癌における傍大動脈リンパ節転移および鼠径上節転移の詳細について

  小田切 哲二, 渡利 英道, 金野 陽輔, 三田村 卓, 加藤 達矢, 小林 範子, 首藤 聡子, 武田 真人, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  64-  (2)  427  -427  2012/02  [Not refereed][Not invited]
  
• 婦人科癌術後リンパ浮腫発症予防に、術後早期からの患者教育は有効である

  小林 範子, 藤野 敬史, 小田切 哲二, 金野 陽輔, 加藤 達矢, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  64-  (2)  448  -448  2012/02  [Not refereed][Not invited]
  
• microRNA-31の発現低下は、レセプターチロシンキナーゼMETの発現を介して卵巣癌のタキサン耐性を引き起こす

  三田村 卓, 渡利 英道, 加藤 達矢, 保坂 昌芳, 小林 範子, 武田 真人, 首藤 聡子, 金内 優典, 工藤 正尊, 水上 尚典, 田中 伸哉, 櫻木 範明  日本産科婦人科学会雑誌  64-  (2)  597  -597  2012/02  [Not refereed][Not invited]
  
• 上皮性卵巣癌におけるNACの治療成績について

  遠藤 大介, 渡利 英道, 金野 陽輔, 首藤 聡子, 小田切 哲二, 加藤 達矢, 小林 範子, 武田 真人, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  64-  (2)  620  -620  2012/02  [Not refereed][Not invited]
  
• 低用量エストロゲン補充療法の効果と安全性

  武田 真人, 大場 洋子, 小林 範子, 古田 伊都子, 渡利 英道, 金内 優典, 工藤 正尊, 佐川 正, 藤野 敬史, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  64-  (2)  666  -666  2012/02  [Not refereed][Not invited]
  
• 子宮頸癌に対する術前化学療法後自律神経温存広汎子宮全摘術の治療効果に対する検討

  金野 陽輔, 小田切 哲二, 加藤 達矢, 保坂 昌芳, 小林 範子, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  64-  (2)  778  -778  2012/02  [Not refereed][Not invited]
  
• 当科における子宮頸癌手術症例のリンパ節転移に関する検討

  加藤 達矢, 金内 優典, 三田村 卓, 金野 陽輔, 小田切 哲二, 小林 範子, 首藤 聡子, 武田 真人, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  64-  (2)  780  -780  2012/02  [Not refereed][Not invited]
  
• 3T MRIを用いた子宮体癌の深達度評価

  三村 理恵, 加藤 扶美, 真鍋 徳子, 山, 小野寺 祐也, 寺江 聡, 金内 優典, 渡利 英道, 櫻木 範明, 白土 博樹  日本医学放射線学会学術集会抄録集  71回-  S310  -S310  2012/02  [Not refereed][Not invited]
  
• 子宮体癌に合併しヘパリン療法が奏効した無菌性血栓性心内膜炎の1例

  横山 しのぶ, 山田 聡, 加賀 早苗, 小田切 哲二, 西野 久雄, 岩野 弘幸, 西田 睦, 澁谷 斉, 重松 明男, 渡利 英道, 小野塚 久夫, 清水 力, 三神 大世, 筒井 裕之  超音波医学  38-  (6)  677  -677  2011/11  [Not refereed][Not invited]
  
• LEGHの6例

  加藤 達矢, 武田 真人, 山田 洋介, 首藤 聡子, 渡利 英道, 金内 優典, 丸川 活司, 久保田 佳奈子, 松野 吉宏, 櫻木 範明  日本臨床細胞学会雑誌  50-  (Suppl.2)  561  -561  2011/09  [Not refereed][Not invited]
  
• 外陰Paget病の1例

  遠藤 大介, 武田 真人, 中谷 真紀子, 藤堂 幸治, 渡利 英道, 金内 優典, 丸川 活司, 久保田 佳奈子, 佐川 正, 櫻木 範明  日本臨床細胞学会雑誌  50-  (Suppl.2)  575  -575  2011/09  [Not refereed][Not invited]
  
• 【これだけは知っておきたい思春期のヘルスケア】思春期女子と悪性腫瘍 治療と妊孕性温存

  首藤 聡子, 三田村 卓, 遠藤 大介, 金野 陽輔, 小田切 哲二, 加藤 達矢, 武田 真人, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  産婦人科治療  103-  (2)  187  -192  2011/08  [Not refereed][Not invited]
   

  思春期女子から若年成人女性において問題となる婦人科悪性腫瘍のうち、卵巣悪性胚細胞腫瘍、顆粒膜細胞腫および子宮頸癌に焦点をあて、疫学、病態、さらには妊孕性温存治療の実際につき解説する。また、思春期女子での発症がまれとされる子宮体癌症例の治療経験にふれ、最後に化学療法による卵巣機能障害の回避および妊孕性温存のための生殖医療技術の応用についても言及する。(著者抄録)
• 子宮頸癌に対する自律神経温存広汎子宮全摘出術の認容性についての検討

  加藤 達矢, 金内 優典, 武田 真人, 金野 陽輔, 小田切 哲二, 保坂 昌芳, 小林 範子, 首藤 聡子, 渡利 英道, 櫻木 範明  日本外科系連合学会誌  36-  (4)  739  -739  2011/08  [Not refereed][Not invited]
  
• 【卵巣がん 最新の治療戦略】 初回治療 進行卵巣癌の手術 Neo-adjuvant chemotherapyの有用性

  保坂 昌芳, 渡利 英道, 櫻木 範明  臨床婦人科産科  65-  (7)  862  -865  2011/07  [Not refereed][Not invited]
  
• 子宮頸癌における卵巣温存の意義 骨密度における観点から

  小林 範子, 武田 真人, 小田切 哲二, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 渡利 英道, 金内 優典, 藤野 敬史, 櫻木 範明  Osteoporosis Japan  19-  (3)  489  -492  2011/07  [Not refereed][Not invited]
   

  子宮頸癌根治手術症例における卵巣の意義を明らかにするため、治療後の長期的な骨密度に及ぼす影響について検討した。子宮頸癌の診断で広汎子宮全摘術を受けた症例で、術前後にDEXA法で骨密度を測定した90例を対象とした。後方視的に術前後の骨密度(L2-4BMD)の変化を検討した。L2-4BMD変化率(術前後)は卵巣温存群-1.2%、卵巣摘出群-12.4%と、卵巣摘出群では卵巣温存群に比べて骨密度が大きく低下した。卵巣温存群21例中17例で、術後観察期間中に卵巣機能は保たれた。卵巣摘出群において、手術時の閉経の有無でL2-4BMD(術後)を比較すると、卵巣温存群で良好であった。観察期間は卵巣温存群5.0±2.8年、卵巣摘出群4.6±3.0年で、卵巣温存群では卵巣に再発転移を認めなかった。
• 神経温存広汎子宮全摘術 子宮頸癌に対する自律神経温存広汎子宮全摘出術の治療効果についての検討

  金内 優典, 加藤 達矢, 武田 真人, 金野 陽輔, 遠藤 大介, 小田切 哲二, 保坂 昌芳, 小林 範子, 首藤 聡子, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  29-  (3)  471  -471  2011/06  [Not refereed][Not invited]
  
• 下肢リンパ浮腫の予防と管理 子宮頸癌術後における下肢リンパ浮腫のリスク因子に関する検討

  大場 洋子, 藤堂 幸治, 小林 範子, 金内 優典, 渡利 英道, 武田 真人, 首藤 聡子, 工藤 正尊, 加藤 秀則, 櫻木 範明  日本婦人科腫瘍学会雑誌  29-  (3)  496  -496  2011/06  [Not refereed][Not invited]
  
• 下肢リンパ浮腫の予防と管理 婦人科癌術後下肢リンパ浮腫患者に対する治療介入がQOLに及ぼす影響

  小林 範子, 藤野 敬史, 中山 紀子, 小田切 哲二, 加藤 達矢, 保坂 昌芳, 武田 真人, 首藤 聡子, 渡利 英道, 金内 優典, 青山 誠, 櫻木 範明  日本婦人科腫瘍学会雑誌  29-  (3)  496  -496  2011/06  [Not refereed][Not invited]
  
• 抗癌剤耐性 卵巣漿液性腺癌において、microRNA-31の発現によりpaclitaxel感受性が変化する

  三田村 卓, 渡利 英道, 小田切 哲二, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 小林 範子, 首藤 聡子, 武田 真人, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本婦人科腫瘍学会雑誌  29-  (3)  497  -497  2011/06  [Not refereed][Not invited]
  
• 新規バイオマーカーの探索 子宮体癌リンパ節転移バイオマーカーの探索

  首藤 聡子, 金野 陽輔, 小田切 哲二, 加藤 達矢, 保坂 昌芳, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本婦人科腫瘍学会雑誌  29-  (3)  500  -500  2011/06  [Not refereed][Not invited]
  
• 子宮頸癌の術後補助療法としてのtaxan/platinum併用化学療法の有用性について

  金野 陽輔, 保坂 昌芳, 小田切 哲二, 加藤 達矢, 小林 範子, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本婦人科腫瘍学会雑誌  29-  (3)  524  -524  2011/06  [Not refereed][Not invited]
  
• 進行・再発婦人科がんにおける消化管閉塞に対するオクトレオチドの有用性について

  小田切 哲二, 渡利 英道, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 小林 範子, 首藤 聡子, 武田 真人, 金内 優典, 櫻木 範明  日本婦人科腫瘍学会雑誌  29-  (3)  561  -561  2011/06  [Not refereed][Not invited]
  
• 電気刺激ナビゲーション併用自律神経温存と広汎子宮全摘術後の膀胱機能

  加藤 達矢, 保坂 昌芳, 小田切 哲二, 金野 陽輔, 小林 範子, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本外科系連合学会誌  36-  (3)  553  -553  2011/05  [Not refereed][Not invited]
  
• 子宮体部悪性腫瘍治療後の再発症例に対する予後因子についての検討

  小田切 哲二, 渡利 英道, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 小林 範子, 首藤 聡子, 武田 真人, 金内 優典, 櫻木 範明  日本外科系連合学会誌  36-  (3)  553  -553  2011/05  [Not refereed][Not invited]
  
• 【婦人科内分泌療法 病態の理解と正しい診断に基づく対処・治療のポイント】 腫瘍・類腫瘍 子宮体癌の内分泌療法

  保坂 昌芳, 渡利 英道, 櫻木 範明  臨床婦人科産科  65-  (4)  597  -601  2011/04  [Not refereed][Not invited]
  
• 腟原発リンパ上皮腫瘍癌Lymphoepithelioma-like carcinomaの1例

  三田村 卓, 保坂 昌芳, 武田 真人, 渡利 英道, 首藤 聡子, 木川 聖美, 小林 範子, 西 信也, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  55-  (1)  103  -103  2011/03  [Not refereed][Not invited]
  
• 細胞診陽性者におけるヒト・パピローマ・ウイルス(HPV)型分析の有用性および新しい経過観察指針作成について

  藤田 博正, 佐々木 隆之, 保坂 昌芳, 蝦名 康彦, 渡利 英道, 櫻木 範明  北海道産科婦人科学会会誌  55-  (1)  153  -154  2011/03  [Not refereed][Not invited]
  
• 円錐切除後子宮頸管狭窄に対するナイチノールステント留置の試み

  前田 悟郎, 首藤 聡子, 木川 聖美, 三田村 卓, 保坂 昌芳, 武田 真人, 蝦名 康彦, 渡利 英道, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  55-  (1)  154  -155  2011/03  [Not refereed][Not invited]
  
• 【産婦人科救急マニュアル】 婦人科領域 術中アクシデント 開腹手術

  渡利 英道, 櫻木 範明  産科と婦人科  78-  (Suppl.)  251  -256  2011/03  [Not refereed][Not invited]
  
• 子宮頸部神経内分泌腫瘍の一例

  石塚 泰也, 武田 真人, 保坂 昌芳, 渡利 英道, 金内 優典, 丸川 活司, 山田 洋介, 久保田 佳奈子, 松野 吉宏, 櫻木 範明  日本臨床細胞学会雑誌  50-  (Suppl.1)  207  -207  2011/03  [Not refereed][Not invited]
  
• 赤痢アメーバ腟炎の1例

  朝野 拓史, 武田 真人, 山名 幸恵, 三田村 卓, 加藤 達矢, 渡利 英道, 金内 優典, 久保田 佳奈子, 松野 吉宏, 櫻木 範明  日本臨床細胞学会雑誌  50-  (Suppl.1)  213  -213  2011/03  [Not refereed][Not invited]
  
• 子宮体部の明細胞腺癌、漿液性腺癌、粘液性腺癌症例における細胞診

  金野 陽輔, 武田 真人, 三田村 卓, 保坂 昌芳, 丸川 活司, 渡利 英道, 金内 優典, 山田 洋介, 久保田 佳奈子, 櫻木 範明  日本臨床細胞学会雑誌  50-  (Suppl.1)  267  -267  2011/03  [Not refereed][Not invited]
  
• 卵管癌の10例

  福本 俊, 武田 真人, 丸川 活司, 三田村 卓, 保坂 昌芳, 首藤 聡子, 渡利 英道, 金内 優典, 久保田 佳奈子, 櫻木 範明  日本臨床細胞学会雑誌  50-  (Suppl.1)  274  -274  2011/03  [Not refereed][Not invited]
  
• 子宮体癌IIIc期の予後因子解析

  鈴木 賀博, 藤堂 幸治, 中谷 真紀子, 大場 洋子, 見延 進一郎, 岡元 一平, 加藤 秀則, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本産科婦人科学会雑誌  63-  (2)  447  -447  2011/02  [Not refereed][Not invited]
  
• アメーバ腟炎の1例

  朝野 拓史, 山口 正博, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 古田 伊都子, 武田 真人, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  63-  (2)  719  -719  2011/02  [Not refereed][Not invited]
  
• アポトーシス抑制タンパクClusterinと子宮頸癌の放射線治療効果について

  渡利 英道, 三田村 卓, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 小林 範子, 首藤 聡子, 武田 真人, 金内 優典, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  63-  (2)  748  -748  2011/02  [Not refereed][Not invited]
  
• 子宮頸癌の術後補助療法としてのtaxan/platinum併用化学療法の有用性について

  保坂 昌芳, 渡利 英道, 金野 陽輔, 小田切 哲二, 加藤 達矢, 小林 範子, 首藤 聡子, 武田 真人, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  63-  (2)  776  -776  2011/02  [Not refereed][Not invited]
  
• 子宮体癌リンパ節転移バイオマーカーの探索

  首藤 聡子, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 武田 真人, 渡利 英道, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  63-  (2)  793  -793  2011/02  [Not refereed][Not invited]
  
• 子宮体癌手術における傍大動脈リンパ節郭清と周術期合併症に関する後方視的解析

  金野 陽輔, 藤堂 幸治, 見延 進一郎, 加藤 秀則, 岡元 一平, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本産科婦人科学会雑誌  63-  (2)  831  -831  2011/02  [Not refereed][Not invited]
  
• 婦人科癌術後リンパ浮腫に対して、発症早期からの介入は進行を予防できる

  小林 範子, 藤野 敬史, 大場 洋子, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  63-  (2)  877  -877  2011/02  [Not refereed][Not invited]
  
• 腹腔鏡下子宮内膜症手術で診断された虫垂子宮内膜症12症例の検討

  加藤 達矢, 工藤 正尊, 明石 大輔, 木川 聖美, 小田切 哲二, 金野 陽輔, 保坂 昌芳, 首藤 聡子, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  63-  (2)  897  -897  2011/02  [Not refereed][Not invited]
  
• ASC-US、ASC-H、moderate dysplasiaの細胞所見とHPV

  福本 俊, 武田 真人, 首藤 聡子, 森脇 征史, 岡元 一平, 渡利 英道, 金内 優典, 丸川 活司, 石川 誠, 櫻木 範明  日本臨床細胞学会雑誌  49-  (Suppl.2)  639  -639  2010/09  [Not refereed][Not invited]
  
• 子宮体部癌肉腫19例の検討

  石塚 泰也, 武田 真人, 三田村 卓, 加藤 達矢, 小田 泰也, 保坂 昌芳, 渡利 英道, 金内 優典, 久保田 佳奈子, 櫻木 範明  日本臨床細胞学会雑誌  49-  (Suppl.2)  650  -650  2010/09  [Not refereed][Not invited]
  
• 当科で経験した外陰および腟の腺癌

  金野 陽輔, 武田 真人, 保坂 昌芳, 三田村 卓, 加藤 達矢, 首藤 聡子, 羽賀 博典, 渡利 英道, 金内 優典, 櫻木 範明  日本臨床細胞学会雑誌  49-  (Suppl.2)  699  -699  2010/09  [Not refereed][Not invited]
  
• 卵管移行上皮癌の一例

  小林 由佳子, 武田 真人, 中谷 真紀子, 三田村 卓, 保坂 昌芳, 渡利 英道, 金内 優典, 久保田 佳奈子, 松野 吉宏, 櫻木 範明  日本臨床細胞学会雑誌  49-  (Suppl.2)  700  -700  2010/09  [Not refereed][Not invited]
  
• 当科で子宮頸癌に対して施行した腹腔鏡下広汎子宮全摘(LRH)および骨盤リンパ節郭清の安全性や広汎性についての検討

  保坂 昌芳, 工藤 正尊, 森脇 征史, 三田村 卓, 加藤 達矢, 首藤 聡子, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本産科婦人科内視鏡学会雑誌  26-  (1)  65  -65  2010/07  [Not refereed][Not invited]
  
• 【産婦人科画像診断のセカンドチョイス】 婦人科画像診断 どこまで可能か 子宮頸癌の膀胱・直腸浸潤の判定

  武田 真人, 加藤 扶美, 首藤 聡子, 渡利 英道, 金内 優典, 尾松 徳彦, 櫻木 範明  臨床婦人科産科  64-  (6)  951  -957  2010/06  [Not refereed][Not invited]
  
• 広汎子宮全摘術に合併した横紋筋融解症の2例

  木川 聖美, 三田村 卓, 保坂 昌芳, 武田 真人, 首藤 聡子, 小林 範子, 渡利 英道, 金内 優典, 櫻木 範明  産婦人科手術  (21)  161  -161  2010/06  [Not refereed][Not invited]
  
• 卵巣がん治療ガイドライン2010年版について 卵巣がん治療ガイドライン 上皮性悪性卵巣腫瘍(概論・卵巣癌の治療・手術療法)

  大道 正英, 田畑 務, 寺井 義人, 八幡 哲郎, 渡利 英道, 岡本 愛光, 佐藤 豊実  日本婦人科腫瘍学会雑誌  28-  (3)  279  -279  2010/06  [Not refereed][Not invited]
  
• 卵巣癌細胞におけるmicro RNA発現とパクリタキセル耐性との関連について

  渡利 英道, ハッサン・モハメド, 三田村 卓, 保坂 昌芳, 金内 優典, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  28-  (3)  288  -288  2010/06  [Not refereed][Not invited]
  
• ASCUS、LSIL、HSIL例におけるHPV検出と頸癌早期発見のための個別化管理の可能性

  保坂 昌芳, 藤田 博正, 金野 陽輔, 小田切 哲二, 加藤 達矢, 小林 範子, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本婦人科腫瘍学会雑誌  28-  (3)  292  -292  2010/06  [Not refereed][Not invited]
  
• 電気刺激ナビゲーション併用自律神経温存と広汎子宮全摘術後の膀胱機能

  加藤 達矢, 保坂 昌芳, 金野 陽輔, 小田切 哲二, 小林 範子, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本婦人科腫瘍学会雑誌  28-  (3)  301  -301  2010/06  [Not refereed][Not invited]
  
• 子宮頸部病変におけるヒト・パピローマ・ウイルス(HPV)型分析の有用性

  藤田 博正, 保坂 昌芳, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  28-  (3)  333  -333  2010/06  [Not refereed][Not invited]
  
• 子宮体部悪性腫瘍治療後の再発症例に対する予後因子についての検討

  小田切 哲二, 渡利 英道, 金野 陽輔, 保坂 昌芳, 大場 洋子, 小林 範子, 首藤 聡子, 武田 真人, 金内 優典, 櫻木 範明  日本婦人科腫瘍学会雑誌  28-  (3)  339  -339  2010/06  [Not refereed][Not invited]
  
• 子宮体癌における外鼠径(大腿上)リンパ節転移頻度

  見延 進一郎, 藤堂 幸治, 加藤 秀則, 岡元 一平, 鈴木 賀博, 保坂 昌芳, 首藤 聡子, 西 信也, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本婦人科腫瘍学会雑誌  28-  (3)  341  -341  2010/06  [Not refereed][Not invited]
  
• 婦人科癌術後リンパ浮腫に対する外来での集中複合的理学療法の短期・長期的治療成績

  小林 範子, 藤野 敬史, 大場 洋子, 金野 陽輔, 小田切 哲二, 保坂 昌芳, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本婦人科腫瘍学会雑誌  28-  (3)  349  -349  2010/06  [Not refereed][Not invited]
  
• HPV31感染を背景としたCIN3合併外陰癌の1症例

  金野 陽輔, 首藤 聡子, 小田切 哲二, 保坂 昌芳, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本婦人科腫瘍学会雑誌  28-  (3)  354  -354  2010/06  [Not refereed][Not invited]
  
• 【産婦人科診療 pros and cons】婦人科腫瘍 子宮体癌Ib期相当に対する傍大動脈リンパ節郭清 行うか、行わないか

  渡利 英道, 藤堂 幸治, 首藤 聡子, 三田村 卓, 小田切 哲二, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 大場 洋子, 小林 範子, 武田 真人, 金内 優典, 櫻木 範明  産婦人科の実際  59-  (3)  497  -503  2010/03  [Not refereed][Not invited]
  
• 術前化学療法を施行した子宮頸癌症例におけるアポトーシス抑制蛋白clusterinの発現と治療反応性および予後因子との関連

  加藤 達矢, 渡利 英道, 鹿沼 達哉, 太田 陽子, 中谷 真紀子, 三田村 卓, 保坂 昌芳, 首藤 聡子, 武田 真人, 蝦名 康彦, 金内 優典, 工藤 正尊, 峯岸 敬, 櫻木 範明  北海道産科婦人科学会会誌  54-  (1)  70  -70  2010/03  [Not refereed][Not invited]
  
• 子宮体癌におけるリンパ節郭清省略の試み

  三田村 卓, 中谷 真紀子, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 武田 真人, 蝦名 康彦, 金内 優典, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  54-  (1)  73  -73  2010/03  [Not refereed][Not invited]
  
• 卵巣癌癌性胸膜炎に対するパクリタキセル胸腔内投与

  中谷 真紀子, 三田村 卓, 保坂 昌芳, 武田 真人, 渡利 英道, 加藤 達矢, 首藤 聡子, 蝦名 康彦, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  54-  (1)  84  -84  2010/03  [Not refereed][Not invited]
  
• 高リスク子宮体癌における傍大動脈リンパ節郭清および術後補助化学療法の意義

  鈴木 賀博, 藤堂 幸治, 青柳 有紀子, 見延 進一郎, 加藤 秀則, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本産科婦人科学会雑誌  62-  (2)  618  -618  2010/02  [Not refereed][Not invited]
  
• 子宮頸部細胞診ASCUS、LSILにおけるハイリスクHPVの分布および進展との関連

  保坂 昌芳, 藤田 博正, 三田村 卓, 金野 陽輔, 小田切 哲二, 首藤 聡子, 西 信也, 武田 真人, 渡利 英道, 金内 優典, 工藤 正尊, 櫻木 範明  日本産科婦人科学会雑誌  62-  (2)  676  -676  2010/02  [Not refereed][Not invited]
  
• 円錐切除後子宮頸管狭窄に対するナイチノールステント留置を施行した2症例

  首藤 聡子, 三田村 卓, 保坂 昌芳, 武田 真人, 渡利 英道, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  62-  (2)  680  -680  2010/02  [Not refereed][Not invited]
  
• 卵巣癌細胞におけるマイクロRNA発現とパクリタキセル耐性との関連について

  渡利 英道, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  62-  (2)  691  -691  2010/02  [Not refereed][Not invited]
  
• アポトーシス抑制タンパクClusterinを分子標的とした卵巣癌細胞におけるpaclitaxel耐性克服の試み

  三田村 卓, 渡利 英道, 木川 聖美, 保坂 昌芳, 首藤 聡子, 武田 真人, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  62-  (2)  692  -692  2010/02  [Not refereed][Not invited]
  
• Feasibility of endoscopic radical and modified radical hysterectomy combined with pelvic lymphadenectomy

  HOSAKA Masayoshi, KUDO Masataka, AKASHI Daisuke, MITAMURA Takashi, KATO Tatsuya, MORIWAKI Masashi, SUDO Satoko, TAKEDA Mahito, EBINA Yasuhiko, WATARI Hidemichi, KANEUCHI Yoshinori, SAKURAGI Noriaki  JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY  25-  (2)  432  -437  2009/12/01  [Not refereed][Not invited]
   

  <B>Objectives:</B> The purpose of this study was to determine the feasibility and radicality of endoscopic radical hysterectomy (ERH) and endoscopic modified radical hysterectomy (EmRH) combined with pelvic lymphadenectomy (ELND) in invasive cervical cancer patients.<BR><B>Methods:</B> Five patients with invasive cervical cancer underwent ERH or EmRH between May 2003 and March 2007 at Hokkaido University Hospital. Two patients with stage I a adenocarcinoma underwent an EmRH, and two patients with stage I b1 and one patient with stage II a underwent an ERH. All patients gave their informed consent to this experimental procedure before surgery.<BR><B>Results:</B> The median age of patients was 39 years (range, 33-45 years), and the median body mass index was 20.2 kg/m<SUP>2</SUP> (range, 18.5-23.7 kg/m<SUP>2</SUP>). The maximum tumor diameter was 20mm in 1 patient, and ≤10mm in 4 patients. The pathologic subtype was squamous cell carcinoma in 2 patients, and adenocarcinoma in 3 patients. The median operative time was 734 min (range, 583-974 min), the median blood loss was 890 ml(range, 280-2650 ml), the median number of lymph nodes removed was 77 (range, 47-103), and the median length of vaginal cuff removed was 20mm(range, 10-25mm). The median duration of hospitalization post-operatively was 16 days (range, 13-23 days). A post-surgical infection occurred in one patient, but no severe complications were noted. There were no relapses after a mean follow-up period of 31.8 months (range, 15-71 months).<BR><B>Conclusions:</B> An ERH or EmRH with ELND is feasible and might be beneficial for early invasive cervical cancer.
• 卵巣癌治療の新たな展開 10年後を見据えて PETを用いた症例選択により行なう再発卵巣癌腫瘍減量手術は、生存期間延長に寄与する

  蝦名 康彦, 三田村 卓, 保坂 昌芳, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本癌治療学会誌  44-  (2)  294  -294  2009/09  [Not refereed][Not invited]
  
• 進行・再発婦人科癌患者の消化管閉塞に対するオクトレオチドの有効性と安全性について

  渡利 英道, 田中 理恵子, 木川 聖美, 三田村 卓, 保坂 昌芳, 首藤 聡子, 武田 真人, 蝦名 康彦, 金内 優典, 櫻木 範明  日本癌治療学会誌  44-  (2)  525  -525  2009/09  [Not refereed][Not invited]
  
• 婦人科腫瘍への内視鏡下手術のアプローチ 子宮頸癌に対する内視鏡手術

  工藤 正尊, 保坂 昌芳, 森脇 征史, 三田村 卓, 武田 真人, 首藤 聡子, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 金内 優典, 櫻木 範明, 野村 英司, 光部 兼六郎  日本産科婦人科内視鏡学会雑誌  25-  (1)  52  -52  2009/09  [Not refereed][Not invited]
  
• 抗NMDA(N-methyl-D-asparete)受容体脳炎を発症した卵巣成熟嚢胞性奇形腫の1例

  保坂 昌芳, 工藤 正尊, 木川 聖美, 三田村 卓, 首藤 聡子, 武田 真人, 蝦名 康彦, 渡利 英道, 金内 優典, 櫻木 範明  日本産科婦人科内視鏡学会雑誌  25-  (1)  175  -175  2009/09  [Not refereed][Not invited]
  
• 婦人科系

  保坂 昌芳, 蝦名 康彦, 木川 聖美, 三田村 卓, 加藤 達矢, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 櫻木 範明  日本臨床細胞学会北海道支部会報  18-  58  -60  2009/09  [Not refereed][Not invited]
  
• 【子宮疾患・子宮内膜症の臨床 基礎・臨床研究のアップデート】 感染症・炎症性疾患 子宮腟部びらん

  金内 優典, 武田 真人, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本臨床  67-  (増刊5 子宮疾患・子宮内膜症の臨床)  335  -338  2009/08  [Not refereed][Not invited]
  
• 子宮頸癌における北大式系統的自律神経温存広汎子宮全摘術後の膀胱機能について

  保坂 昌芳, 藤堂 幸治, 小田 泰也, 三田村 卓, 加藤 達矢, 首藤 聡子, 武田 真人, 蝦名 康彦, 渡利 英道, 金内 優典, 櫻木 範明  産婦人科の実際  58-  (8)  1227  -1232  2009/08  [Not refereed][Not invited]
   

  著者らが広汎子宮全摘術を行った子宮頸癌患者で、少なくとも片側の自律神経膀胱枝を温存できた60例を温存群、両側とも温存できなかった5例を非温存群とし、術前術後の尿流動態検査(UDS)用いた膀胱機能を比較検討した。その結果、最大蓄尿時膀胱コンプライアンス、最大尿流速度、排尿時最大腹圧、排尿時最大排尿筋圧、残尿のいずれも、温存群が非温存群と比べ有意に良好であった。
• 上皮性卵巣癌におけるp53変異とその予後に与える影響(Mutations of p53 in epithelial ovarian cancers and its effect on prognosis)

  鈴木 友希子, 多田 光宏, 金内 優典, 蝦名 康彦, 渡利 英道, 半田 康, 加藤 秀則, 櫻木 範明, 浜田 淳一, 守内 哲也  日本癌学会総会記事  68回-  329  -329  2009/08  [Not refereed][Not invited]
  
• 子宮体癌に対する傍大動脈リンパ節郭清ならびに術後化学療法とFIGO IIIc期の治療成績

  渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌 = The journal of the Japan Society of Gynecologic Oncology  27-  (3)  388  -391  2009/06/25  [Not refereed][Not invited]
  
• 系統的自律神経温存広汎子宮全摘出術 北海道大学術式

  金内 優典, 保坂 昌芳, 藤堂 幸治, 三田村 卓, 加藤 達矢, 首藤 聡子, 武田 真人, 蝦名 康彦, 渡利 英道, 櫻木 範明  産婦人科治療  98-  (6)  1026  -1033  2009/06  [Not refereed][Not invited]
  
• Cyr61高発現とリンパ節転移は子宮体癌の独立予後因子である

  渡利 英道, 田中 理恵子, 三田村 卓, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 武田 真人, 蝦名 康彦, 金内 優典, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  27-  (3)  282  -282  2009/06  [Not refereed][Not invited]
  
• 卵巣癌に対するパクリタキセル胸腔内投与時の薬物動態

  三田村 卓, 保坂 昌芳, 首藤 聡子, 武田 真人, 蝦名 康彦, 渡利 英道, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本婦人科腫瘍学会雑誌  27-  (3)  291  -291  2009/06  [Not refereed][Not invited]
  
• 卵巣癌再発に対して、FDG-PETを用いた症例選択により行なうSDSは、生存期間延長に寄与する

  蝦名 康彦, 三田村 卓, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  27-  (3)  308  -308  2009/06  [Not refereed][Not invited]
  
• 子宮体癌リンパ節転移バイオマーカーの探索

  首藤 聡子, 三田村 卓, 加藤 達矢, 保坂 昌芳, 武田 真人, 蝦名 康彦, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明  日本婦人科腫瘍学会雑誌  27-  (3)  313  -313  2009/06  [Not refereed][Not invited]
  
• 進行・再発婦人科癌患者における消化管閉塞に対するオクトレオチドの有効性と安全性についての検討

  保坂 昌芳, 渡利 英道, 田中 理恵子, 三田村 卓, 加藤 達矢, 首藤 聡子, 武田 真人, 蝦名 康彦, 金内 優典, 櫻木 範明  日本婦人科腫瘍学会雑誌  27-  (3)  322  -322  2009/06  [Not refereed][Not invited]
  
• 子宮体癌手術に傍大動脈リンパ節郭清は必要か? 私はこうしている 子宮体癌に対する傍大動脈リンパ節郭清ならびに術後化学療法とFIGO IIIc期の治療成績

  渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  27-  (3)  388  -391  2009/06  [Not refereed][Not invited]
  
• 腹腔鏡下広汎性子宮頸部摘出術を行った3症例

  金内 優典, 三田村 卓, 首藤 聡子, 中谷 真紀子, 加藤 達矢, 保坂 昌芳, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 櫻木 範明, 加藤 秀則, 半田 康, 木川 聖美, 野村 英司, 光部 兼六郎  産婦人科手術  (20)  161  -161  2009/06  [Not refereed][Not invited]
  
• 婦人科領域における腹腔鏡手術の最先端 子宮筋腫核出術はつり上げ法か気腹法か 当科で施行した気腹法による腹腔鏡下子宮筋腫核出術

  工藤 正尊, 加藤 達矢, 金野 陽輔, 西 信也, 首藤 聡子, 保坂 昌芳, 森脇 征史, 三田村 卓, 武田 真人, 蝦名 康彦, 渡利 英道, 金内 優典, 櫻木 範明  日本外科系連合学会誌  34-  (3)  444  -444  2009/05  [Not refereed][Not invited]
  
• 各科悪性腫瘍に対する外科的療法とコメディカルのかかわり方 婦人科悪性腫瘍に対して手術治療を受けた患者への術後指導の取り組み

  金内 優典, 宮川 純子, 三田村 卓, 保坂 昌芳, 首藤 聡子, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 新岡 郁子, 山本 英津子, 水上 尚典, 櫻木 範明  日本外科系連合学会誌  34-  (3)  473  -473  2009/05  [Not refereed][Not invited]
  
• 日本における子宮頸がん検診のあり方 ベセスダシステムの導入をめぐって ヒトパピローマウイルス(HPV)型判定を取り入れた異形成経過観察指針作成について

  藤田 博正, 佐々木 隆之, 清野 邦義, 白川 洋三, 日野 順子, 安孫子 光春, 保坂 昌芳, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本臨床細胞学会雑誌  48-  (Suppl.1)  94  -94  2009/03  [Not refereed][Not invited]
  
• 術前化学療法を施行した子宮頸癌症例におけるアポトーシス抑制蛋白clusterinの発現と治療反応性および予後因子との関連

  中谷 真紀子, 渡利 英道, 鹿沼 達哉, 保坂 昌芳, 首藤 聡子, 武田 真人, 蝦名 康彦, 金内 優典, 工藤 正尊, 峯岸 敬, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  61-  (2)  435  -435  2009/02  [Not refereed][Not invited]
  
• 子宮体癌におけるリンパ節転移の術前、術中評価

  三田村 卓, 中谷 真紀子, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 武田 真人, 蝦名 康彦, 渡利 英道, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  61-  (2)  454  -454  2009/02  [Not refereed][Not invited]
  
• 婦人科癌に対するドセタキセル腹腔内投与の薬物動態と副作用についての研究

  金内 優典, 加藤 秀則, 半田 康, 三田村 卓, 首藤 聡子, 木川 聖美, 加藤 達矢, 保坂 昌芳, 蝦名 康彦, 渡利 英道, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  61-  (2)  465  -465  2009/02  [Not refereed][Not invited]
  
• 卵巣癌再発に対して、FDG-PETを用いた症例選択により行なうSecondary debulking surgeryは、生存期間延長に寄与する

  蝦名 康彦, 三田村 卓, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  61-  (2)  658  -658  2009/02  [Not refereed][Not invited]
  
• 子宮頸部腺癌の手術治療成績

  加藤 達矢, 武田 真人, 中谷 真紀子, 三田村 卓, 保坂 昌芳, 首藤 聡子, 蝦名 康彦, 渡利 英道, 金内 優典, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  61-  (2)  668  -668  2009/02  [Not refereed][Not invited]
  
• 子宮頸癌におけるリンパ節転移例の予後因子についての検討

  小島 崇史, 保坂 昌芳, 三田村 卓, 森脇 征史, 原 洋子, 藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  53-  (1)  51  -52  2009/01  [Not refereed][Not invited]
  
• 子宮頸癌におけるアポトーシス関連蛋白clusterinの発現と予後因子としての有用性に関する臨床病理学的検討

  保坂 昌芳, 渡利 英道, 太田 陽子, 小島 崇史, 三田村 卓, 森脇 征史, 原 洋子, 藤堂 幸治, 武田 真人, 蝦名 康彦, 工藤 正尊, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  53-  (1)  61  -61  2009/01  [Not refereed][Not invited]
  
• 子宮温存治療を試みた14歳子宮体癌の1例

  三田村 卓, 藤堂 幸治, 小島 崇史, 森脇 征史, 原 洋子, 保坂 昌芳, 武田 真人, 渡利 英道, 櫻木 範明  北海道産科婦人科学会会誌  53-  (1)  63  -63  2009/01  [Not refereed][Not invited]
  
• 子宮体癌に対する傍大動脈リンパ節郭清ならびに術後補助化学療法とFIGO IIIc期の治療成績

  渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌 = The journal of the Japan Society of Gynecologic Oncology  26-  (4)  2008/10/25  [Not refereed][Not invited]
  
• 【婦人科がん診療のリスクマネージメント】手術療法の問題点 子宮頸癌の手術

  蝦名 康彦, 三田村 卓, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 武田 真人, 渡利 英道, 金内 優典, 工藤 正尊, 櫻木 範明  産婦人科の実際  57-  (11)  1726  -1733  2008/10  [Not refereed][Not invited]
  
• 術前化学療法を施行した子宮頸癌症例におけるアポトーシス抑制蛋白clusterinの発現と治療反応性および予後因子との関連

  渡利 英道, 鹿沼 達哉, 大田 陽子, 三田村 卓, 加藤 達矢, 保坂 昌芳, 藤堂 幸治, 首藤 聡子, 武田 真人, 蝦名 康彦, 峯岸 敬, 櫻木 範明  日本癌治療学会誌  43-  (2)  814  -814  2008/10  [Not refereed][Not invited]
  
• 子宮体癌手術に傍大動脈リンパ節郭清は必要か? 私はこうしている 子宮体癌に対する傍大動脈リンパ節郭清ならびに術後補助化学療法とFIGO III c期の治療成績

  渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  26-  (4)  449  -449  2008/10  [Not refereed][Not invited]
  
• AP-2 子宮頸癌発生過程とHPV感染様式の関連についての基礎検討(子宮頸部,グローバル時代の細胞診,第47回日本臨床細胞学会秋期大会)

  西脇 森衛, 松澤 聡, 齋藤 梢, 山本 智宏, 奥山 雅美, 石川 誠, 渡利 英道, 櫻木 範明, 高木 芳武, 近藤 信夫  日本臨床細胞学会雑誌  47-  (2)  2008/09/22  [Not refereed][Not invited]
  
• P-301 子宮頸部悪性黒色腫の一例(子宮頸部(11),グローバル時代の細胞診,第47回日本臨床細胞学会秋期大会)

  佐々木 尚子, 武田 真人, 三田村 卓, 保坂 昌芳, 蝦名 康彦, 渡利 英道, 櫻木 範明, 松野 吉宏, 久保田 佳奈子, 山田 洋介  日本臨床細胞学会雑誌  47-  (2)  2008/09/22  [Not refereed][Not invited]
  
• P-299 乳癌の子宮頸部転移の一例(子宮頸部(11),グローバル時代の細胞診,第47回日本臨床細胞学会秋期大会)

  加藤 達矢, 武田 真人, 保坂 昌芳, 三田村 卓, 蝦名 康彦, 渡利 英道, 櫻木 範明, 松野 吉宏, 久保田 佳奈子, 山田 洋介  日本臨床細胞学会雑誌  47-  (2)  2008/09/22  [Not refereed][Not invited]
  
• 子宮頸癌発生過程とHPV感染様式の関連についての基礎検討

  西脇 森衛, 松澤 聡, 齋藤 梢, 山本 智宏, 奥山 雅美, 石川 誠, 渡利 英道, 櫻木 範明, 高木 芳武, 近藤 信夫  日本臨床細胞学会雑誌  47-  (Suppl.2)  461  -461  2008/09  [Not refereed][Not invited]
  
• 乳癌の子宮頸部転移の一例

  加藤 達矢, 武田 真人, 保坂 昌芳, 三田村 卓, 蝦名 康彦, 渡利 英道, 櫻木 範明, 松野 吉宏, 久保田 佳奈子, 山田 洋介  日本臨床細胞学会雑誌  47-  (Suppl.2)  629  -629  2008/09  [Not refereed][Not invited]
  
• 子宮頸部悪性黒色腫の一例

  佐々木 尚子, 武田 真人, 三田村 卓, 保坂 昌芳, 蝦名 康彦, 渡利 英道, 櫻木 範明, 松野 吉宏, 久保田 佳奈子, 山田 洋介  日本臨床細胞学会雑誌  47-  (Suppl.2)  630  -630  2008/09  [Not refereed][Not invited]
  
• 当科における浸潤子宮頸癌に対する鏡視下手術

  工藤 正尊, 保坂 昌芳, 森脇 征史, 藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 水上 尚典, 櫻木 範明  産婦人科手術  (19)  179  -179  2008/08  [Not refereed][Not invited]
  
• 広汎子宮全摘術後の持続的な蓄尿コンプライアンス低下に影響を及ぼす因子の解析

  藤堂 幸治, 森脇 征史, 保坂 昌芳, 原 洋子, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 櫻木 範明  日本外科系連合学会誌  33-  (4)  711  -711  2008/08  [Not refereed][Not invited]
  
• 当科で子宮頸癌に対して施行した腹腔鏡下広汎子宮全摘(LRH)および骨盤リンパ節郭清の5例について

  保坂 昌芳, 工藤 正尊, 森脇 征史, 三田村 卓, 加藤 達矢, 首藤 聡子, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本産科婦人科内視鏡学会雑誌  24-  (1)  123  -123  2008/07  [Not refereed][Not invited]
  
• Total Laparoscopic Myomectomy : Application for Uterine Submucosal Myoma

  MORIWAKI Masashi, KUDO Masataka, SUDO Satoko, NISHI Shinya, KATO Tatsuya, WADA Shinichiro, MITSUBE Kenrokuro, HOSAKA Masayoshi, TODO Yukiharu, EBINA Yasuhiko, WATARI Hidemichi, OKOUCHI Toshihiro, MINAKAMI Hisanori, SAKURAGI Noriaki  JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY  24-  (1)  204  -208  2008/07/01  [Not refereed][Not invited]
   

  Background: Submucosal myoma has been treated with hysteroscopic transcervical resection (TCR) . However, in cases of unstalked submucosal myoma over 3cm in diameter, TCR could lead to not only extended operation time but also extensive thermal damage on endometrium by electrocoagulation. In this study, we validated the feasibility and utility of total Laparoscopic approach for submucosal myoma treatment.<BR>Materials and Methods: Total laparoscopic myomectomy (TLM) was performed on 12 women with submucosal myoma. Our TLM procedure was as follows: a balloon catheter was detained in the uterine cavity to evaluate the degree of submucosal projection by sonohysterography. Culdotomy was performed to set acrylic vaginal pipe into intraperitoneal cavity as a larger access port. After intramyometrial injection of vasopressin, a transverse incision was made to extract myomas. As myomectomy progressed, endometrium filled with indigocarmine through a detained balloon catheter appeared transparent-blue bulge, which helped easy recognition of endometrial injury. Uterine wall was sutured layer by layer without tucking the endometrium into myometrium. The enucleated nodules were removed via a vaginal pipe.<BR>Results: The median size of dominant submucosal myomas was 5cm, the median blood loss was 120ml and the median operating time was 162 minutes. There was no correlation between the degree of submucosal projection and endometrial defect. Minimal endometrial damage was observed and one of 3 infertile patients was pregnant after surgery.<BR>Conclusion: TLM was feasible in the cases of submucosal myoma as well as intramural and subserosal myomas.
• Clusterinを分子標的とした上皮性卵巣癌細胞におけるパクリタキセル感受性増強効果についての検討

  渡利 英道, Mohamed Hassan, 三田村 卓, 保坂 昌芳, 首藤 聡子, 藤堂 幸治, 武田 真人, 蝦名 康彦, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  26-  (3)  265  -265  2008/06  [Not refereed][Not invited]
  
• アポトーシス抑制蛋白clusterinと子宮頸癌の術前化学療法反応性ならびに予後との関連

  保坂 昌芳, 渡利 英道, 鹿沼 達哉, 太田 陽子, 三田村 卓, 首藤 聡子, 武田 真人, 蝦名 康彦, 峰岸 敬, 櫻木 範明  日本婦人科腫瘍学会雑誌  26-  (3)  276  -276  2008/06  [Not refereed][Not invited]
  
• 14歳の子宮体癌症例の診断と治療

  三田村 卓, 保坂 昌芳, 藤堂 幸治, 首藤 聡子, 武田 真人, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  26-  (3)  284  -284  2008/06  [Not refereed][Not invited]
  
• 肺動脈に進展した子宮筋腫術後のintravenous leiomyomatosisの1例

  小田 泰也, 蝦名 康彦, 原 洋子, 保坂 昌芳, 小林 範子, 藤堂 幸治, 荒木 直人, 武田 真人, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明, 日下 剛  日本産科婦人科学会東北連合地方部会誌  (55)  62  -62  2008/06  [Not refereed][Not invited]
  
• 後腹膜に発生し付属器腫瘍との鑑別を要したmalignant peripheral sheath tumorの1例

  荒木 直人, 武田 真人, 小田 泰也, 保坂 昌芳, 小林 範子, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会東北連合地方部会誌  (55)  70  -70  2008/06  [Not refereed][Not invited]
  
• Docetaxel/Gemcitabine療法が奏功した再発子宮内膜間質肉腫の1例

  中谷 真紀子, 蝦名 康彦, 森脇 征史, 保坂 昌芳, 原 洋子, 荒木 直人, 藤堂 幸治, 武田 真人, 渡利 英道, 工藤 正尊, 櫻木 範明, 小田 泰也  日本産科婦人科学会東北連合地方部会誌  (55)  182  -183  2008/06  [Not refereed][Not invited]
  
• カルボプラチンの過敏症発現後にシスプラチンの脱感作療法でプラチナを投与し得た卵巣漿液性腺癌3症例

  保坂 昌芳, 渡利 英道, 森脇 征史, 原 洋子, 荒木 直人, 藤堂 幸治, 武田 真人, 蝦名 康彦, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会東北連合地方部会誌  (55)  191  -191  2008/06  [Not refereed][Not invited]
  
• 当科におけるGemcitabineを用いた婦人科再発癌の治療経験

  蝦名 康彦, 森脇 征史, 原 洋子, 保坂 昌芳, 荒木 直人, 藤堂 幸治, 武田 真人, 渡利 英道, 工藤 正尊, 櫻木 範明  日本産科婦人科学会東北連合地方部会誌  (55)  196  -196  2008/06  [Not refereed][Not invited]
  
• 当科における婦人科悪性腫瘍に対する鏡視下手術

  工藤 正尊, 保坂 昌芳, 藤堂 幸治, 森脇 征史, 原 洋子, 荒木 直人, 武田 真人, 蝦名 康彦, 渡利 英道, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会東北連合地方部会誌  (55)  198  -198  2008/06  [Not refereed][Not invited]
  
• 【快適な術後経過のための工夫と対応】 リンパ節郭清術後のドレナージ

  藤堂 幸治, 森脇 征史, 保坂 昌芳, 原 洋子, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 櫻木 範明  産科と婦人科  75-  (2)  176  -181  2008/02  [Not refereed][Not invited]
  
• アポトーシス関連蛋白clusterinを分子標的とした上皮性卵巣癌におけるパクリタキセル感受性増強効果についての検討

  渡利 英道, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  60-  (2)  563  -563  2008/02  [Not refereed][Not invited]
  
• 神経温存広汎子宮全摘後の膀胱機能の検討

  保坂 昌芳, 藤堂 幸治, 小島 崇史, 三田村 卓, 森脇 征史, 大場 洋子, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  60-  (2)  614  -614  2008/02  [Not refereed][Not invited]
  
• 広汎子宮全摘術後の持続的な蓄尿機能低下に影響を及ぼす因子の解析

  三田村 卓, 藤堂 幸治, 小島 崇史, 森脇 征史, 保坂 昌芳, 大場 洋子, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  60-  (2)  623  -623  2008/02  [Not refereed][Not invited]
  
• 子宮頸癌におけるリンパ節転移例の予後因子についての検討

  小島 崇史, 保坂 昌芳, 三田村 卓, 森脇 征史, 大場 洋子, 藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  60-  (2)  623  -623  2008/02  [Not refereed][Not invited]
  
• 小児頭大の筋腫核を経腟的に回収しえた腹腔鏡下筋腫核出術の1例

  保坂 昌芳, 工藤 正尊, 森脇 征史, 原 洋子, 荒木 直人, 藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  52-  (1)  34  -35  2008/01  [Not refereed][Not invited]
  
• 子宮脱手術後の腟断端脱に対して行ったlaparoscopic sacral colopexy

  藤堂 幸治, 森脇 征史, 保坂 昌芳, 原 洋子, 荒木 直人, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  52-  (1)  35  -35  2008/01  [Not refereed][Not invited]
  
• 卵巣硬化性間質性腫瘍の一例

  荒木 直人, 武田 真人, 森脇 征史, 原 洋子, 保坂 昌芳, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 工藤 正尊, 山田 秀人, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  52-  (1)  44  -45  2008/01  [Not refereed][Not invited]
  
• 研修医からの質問Q&A 子宮頸部上皮内腺癌の治療は円錐切除で十分なのでしょうか?

  渡利 英道, 櫻木 範明  臨床腫瘍プラクティス  3-  (4)  438  -439  2007/11  [Not refereed][Not invited]
  
• 【産婦人科診療Data Book】 子宮体癌全般

  渡利 英道, 櫻木 範明  産婦人科の実際  56-  (11)  1733  -1736  2007/10  [Not refereed][Not invited]
  
• 303 細胞診で診断の得られなかった子宮頸部コンジローマ様癌症例(子宮頸部4(11),一般演題,第46回日本臨床細胞学会秋期大会)

  三田村 卓, 武田 真人, 森脇 征史, 保坂 昌芳, 原 洋子, 藤堂 幸治, 渡利 英道, 櫻木 範明, 伊藤 智雄, 久保田 佳奈子  日本臨床細胞学会雑誌  46-  (2)  2007/09/22  [Not refereed][Not invited]
  
• Carboplatinの急性過敏反応発症後にCisplatinを用いた脱感作療法でプラチナを再投与し得た卵巣癌3症例

  保坂 昌芳, 蝦名 康彦, 森脇 征史, 原 洋子, 荒木 直人, 藤堂 幸治, 武田 真人, 渡利 英道, 櫻木 範明  癌と化学療法  34-  (9)  1505  -1508  2007/09  [Not refereed][Not invited]
   

  卵巣癌の標準化学療法はpaclitaxel/carboplatin併用療法である。このregimenは初回治療はもとより、症例によっては再発時にも用いられる。そのため、投与回数が重なった時にcarboplatinの急性過敏症反応を起こすことがある。最近、われわれはcarboplatinによる急性過敏症反応を3症例経験した。症状は頻脈、胸部苦悶感、呼吸困難などであった。そのような症例に対しcisplatinを用いた脱感作療法を行ったところ、全例にプラチナ製剤の再投与が可能であった。この方法は安全で、プラチナ感受性のある症例には有用であると考えられたので報告する。(著者抄録)
• 細胞診で診断の得られなかった子宮頸部コンジローマ様癌症例

  三田村 卓, 武田 真人, 森脇 征史, 保坂 昌芳, 原 洋子, 藤堂 幸治, 渡利 英道, 櫻木 範明, 伊藤 智雄, 久保田 佳奈子  日本臨床細胞学会雑誌  46-  (Suppl.2)  563  -563  2007/09  [Not refereed][Not invited]
  
• 子宮頸部adenosarcomaの1例

  保坂 昌芳, 武田 真人, 小田 泰也, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  51-  (1)  38  -39  2007/06  [Not refereed][Not invited]
  
• 肺動脈に進展した子宮筋腫術後のintravenous leiomyomatosisの1例

  小田 泰也, 蝦名 康彦, 原 洋子, 保坂 昌芳, 藤堂 幸治, 荒木 直人, 武田 真人, 渡利 英道, 水上 尚典, 櫻木 範明, 日下 剛  北海道産科婦人科学会会誌  51-  (1)  43  -43  2007/06  [Not refereed][Not invited]
  
• 骨盤外科における機能温存を目指した手術手技の改良 広汎子宮全摘術における効果的自律神経温存法の確立と鏡視下手術導入の検討

  櫻木 範明, 藤堂 幸治, 渡利 英道, 蝦名 康彦, 武田 真人, 保坂 昌芳, 森脇 征史, 原 洋子, 工藤 正尊  日本外科系連合学会誌  32-  (3)  444  -444  2007/06  [Not refereed][Not invited]
  
• 婦人科悪性腫瘍における妊孕性温存手術 当科でおこなった浸潤子宮頸癌に対する子宮温存手術(円錐切除と鏡視下リンパ節郭清)

  工藤 正尊, 森脇 征史, 保坂 昌芳, 藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 水上 尚典, 櫻木 範明  日本外科系連合学会誌  32-  (3)  515  -515  2007/06  [Not refereed][Not invited]
  
• 子宮脱手術後の腟断端脱に対して行った腹腔鏡下腟仙骨固定術

  藤堂 幸治, 森脇 征史, 原 洋子, 保坂 昌芳, 荒木 直人, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  産婦人科手術  (18)  203  -203  2007/06  [Not refereed][Not invited]
  
• 骨盤の局所解剖と機能温存手術 膀胱機能温存を目指した系統的自律神経温存広汎子宮全摘術および術後管理について

  藤堂 幸治, 森脇 征史, 保坂 昌芳, 原 洋子, 武田 真人, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  25-  (3)  188  -189  2007/06  [Not refereed][Not invited]
  
• 子宮頸部扁平上皮癌small size症例における病理組織学的予後因子と手術法の検討

  武田 真人, 森脇 征史, 保坂 昌芳, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  25-  (3)  229  -229  2007/06  [Not refereed][Not invited]
  
• 系統的骨盤・傍大動脈リンパ節郭清を含む手術療法と術後化学療法による子宮体癌治療後の再発様式

  渡利 英道, 森脇 征史, 保坂 昌芳, 原 洋子, 荒木 直人, 藤堂 幸治, 武田 真人, 蝦名 康彦, 工藤 正尊, 櫻木 範明  日本婦人科腫瘍学会雑誌  25-  (3)  256  -256  2007/06  [Not refereed][Not invited]
  
• 広汎子宮全摘術における系統的自律神経温存法と術後膀胱機能の解析

  藤堂 幸治, 保坂 昌芳, 小田 泰也, 原 洋子, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 櫻木 範明  日本女性骨盤底医学会誌  4-  (1)  143  -149  2007/05  [Not refereed][Not invited]
   

  目的:我々は広汎子宮全摘術に下腹神経、骨盤内臓神経、骨盤神経叢およびその膀胱枝の系統的温存を併用してきた。骨盤神経叢子宮枝を選択的に切断し骨盤神経叢と傍腟結合織を分離させる手技が重要である。我々の行う術式の有用性を尿流動態学的検査で検証する。方法:対象は広汎子宮全摘術を行った子宮頸癌49例でA群:系統的自律神経温存を行った43例(1b1期17例、1b2期10例、2a期4例、2b期12例)、B群:系統的自律神経温存を行わなかった6例(1b1期4例、2b期2例)である。術前、術後1、3、6、12ヵ月の各時点において最大尿意時膀胱コンプライアンス(Cves)、最大尿流量率(MFR)、最大尿流量時腹腔内圧(PabdQmax)、最大尿流量時排尿筋圧(PdetQmax)、残尿量(Resid)を求めた。各パラメータの経時的推移はrepeated measure one-way ANOVAで解析し、有意差ありと判定された場合にFisher's protected least significant difference法を用いて各時点間の有意差を検討した。尿意についても評価を行った。成績:年齢、進行期分布、腫瘍径、切除腟長は両群間で差を認めなかった。A群においてCves、MFR、Residは術前と術後12ヵ月の間に差を認めなかった。PabdQmaxは手術により増加、PdetQmaxは低下したが、B群と比較してその影響は有意に小さいことが示された。A群で尿意の異常を認めた例は7%に過ぎなかったが、B群の67%で尿意が減弱した。結論:骨盤神経叢子宮枝を選択的に切断し、骨盤神経叢と傍腟結合織の分離を行う系統的自律神経温存法は切除腟長を縮小することなく膀胱機能温存を可能とするために重要な手技である。(著者抄録)
• 粘膜下筋腫に対する全腹腔鏡下筋腫核出術

  森脇 征史, 工藤 正尊, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 西 信也, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 田中 信一, 大河内 俊洋, 水上 尚典, 櫻木 範明  日本産科婦人科内視鏡学会雑誌  22-  (2)  309  -309  2007/03  [Not refereed][Not invited]
  
• 【婦人科手術とQOL】 広汎性子宮全摘術と機能温存

  森脇 征史, 渡利 英道, 蝦名 康彦, 武田 真人, 藤堂 幸治, 保坂 昌芳, 原 洋子, 荒木 直人, 工藤 正尊, 櫻木 範明  産婦人科治療  94-  (3)  249  -255  2007/03  [Not refereed][Not invited]
   

  わが国の浸潤頸癌罹患率は減少してきているが、若年女性では近年の増加傾向が指摘されている。子宮頸癌治療において長期間にわたるQOL維持に対する考慮が重要である。頸癌では卵巣転移はまれである。卵巣温存を希望する若年女性頸癌、とくに扁平上皮癌においては卵巣を温存することが標準治療と考えられる。腟短縮防止も機能温存広汎子宮全摘術における重要な問題であり、いくつかの腟短縮防止法が報告されている。妊孕能温存を希望する若年女性のIa2〜Ib1期頸癌では、欧米諸国を中心として経腟的あるいは経腹的なradical trachelectomyによる子宮温存治療の報告があるが、現時点では研究的治療とみなされる。(著者抄録)
• 子宮頸癌におけるアポトーシス関連蛋白clusterinの発現と予後因子としての有用性に関する臨床病理学的検討

  渡利 英道, 森脇 征史, 保坂 昌芳, 原 洋子, 荒木 直人, 藤堂 幸治, 武田 真人, 蝦名 康彦, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  59-  (2)  366  -366  2007/02  [Not refereed][Not invited]
  
• リンパ浮腫の複合的理学療法に対する治療効果についての検討

  原 洋子, 小林 範子, 藤野 敬史, 森脇 征史, 保坂 昌芳, 荒木 直人, 藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  59-  (2)  419  -419  2007/02  [Not refereed][Not invited]
  
• 子宮頸癌術後補助治療としての放射線療法と化学療法の検討

  保坂 昌芳, 武田 真人, 森脇 征史, 原 洋子, 荒木 直人, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  59-  (2)  575  -575  2007/02  [Not refereed][Not invited]
  
• 子宮頸部扁平上皮癌(3cm未満)の子宮外進展とそれに関連する病理組織学的予後因子の検討

  武田 真人, 荒木 直人, 森脇 征史, 原 洋子, 保坂 昌芳, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  59-  (2)  581  -581  2007/02  [Not refereed][Not invited]
  
• 腹腔鏡下子宮筋腫核出術における筋腫核の経腟的回収についての検討

  森脇 征史, 工藤 正尊, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 西 信也, 藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  59-  (2)  643  -643  2007/02  [Not refereed][Not invited]
  
• 【子宮内膜癌】 子宮内膜癌と遺伝子異常

  渡利 英道, 櫻木 範明  HORMONE FRONTIER IN GYNECOLOGY  13-  (4)  347  -352  2006/12  [Not refereed][Not invited]
   

  子宮内膜癌(体癌)は、エストロゲン依存性で比較的予後良好な癌(type1)と、エストロゲン非依存性で予後不良な癌(type2)に大別され、おのおのの遺伝子異常にも相違があることが明らかとなりつつある。今後ますます子宮体癌に対する分子生物学的研究が発展し、その成果に基づいた分子標的治療などを導入した新しい治療法の開発によって、さらなる子宮体癌の治療成績の向上を目指さなければならない。(著者抄録)
• P-181 DNAアレイによる子宮頸部擦過細胞診検体および浸潤癌組織検体におけるHPVの検出(婦人科(子宮頸部)-(9),一般演題・示説,第45回 日本臨床細胞学会秋期大会)

  森脇 征史, 渡利 英道, 道又 理恵, 石津 明洋, 小田 秦也, 保坂 昌芳, 藤堂 幸治, 武田 真人, 蝦名 康彦, 櫻木 範明  日本臨床細胞学会雑誌  45-  (2)  2006/09/22  [Not refereed][Not invited]
  
• DNAアレイによる子宮頸部擦過細胞診検体および浸潤癌組織検体におけるHPVの検出

  森脇 征史, 渡利 英道, 道又 理恵, 石津 明洋, 小田 泰也, 保坂 昌芳, 藤堂 幸治, 武田 真人, 蝦名 康彦, 櫻木 範明  日本臨床細胞学会雑誌  45-  (Suppl.2)  503  -503  2006/09  [Not refereed][Not invited]
  
• 悪性卵巣腫瘍(境界悪性腫瘍を含む)に対する妊孕能温存治療の臨床的検討

  保坂 昌芳, 山本 律, 岡元 一平, 小田 泰也, 藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 櫻木 範明  産婦人科の実際  55-  (8)  1297  -1304  2006/08  [Not refereed][Not invited]
   

  1988〜2001年に妊孕能温存治療を行った悪性卵巣腫瘍50例を対象とし,治療成績,卵巣機能への影響を検討した.初回手術は患側附属器摘出49例,両側腫瘍核出1例であり,片側附属器摘出例中46例に対側卵巣楔状切除,21例に大網切除,17例に後腹膜リンパ節摘出を施行した.33例に術後化学療法を施行し,etoposideを5回以上投与した群では排卵回復までの期間は有意に遅延していた.CAP療法を6コース施行した漿液性腺癌1例では卵巣機能が廃絶した.妊娠を希望した21例中,妊娠は8例に認めた.手術治療のみでも高い治癒率が期待できるIa期,grade 1の上皮性悪性腫瘍や境界悪性腫瘍,抗癌剤感受性の高い悪性胚細胞腫瘍例において,治療が過剰にならないことが妊娠率向上につながると考えられた
• HPV感染と子宮頸癌 メンブレンアレイシステムを用いた子宮頸部細胞診検体および浸潤癌組織検体からのHPV検出

  渡利 英道, 武田 真人, 小田 泰也, 保坂 昌芳, 藤堂 幸治, 蝦名 康彦, 櫻木 範明  日本婦人科腫瘍学会雑誌  24-  (3)  213  -213  2006/06  [Not refereed][Not invited]
  
• 子宮頸部腺癌における血清腫瘍マーカー値・腫瘍径とリンパ節転移との関連について

  保坂 昌芳, 武田 真人, 中郷 賢二郎, 小田 泰也, 小林 範子, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  50-  (1)  106  -107  2006/06  [Not refereed][Not invited]
  
• 子宮体癌III c期の病理組織学的予後因子についての検討

  小田 泰也, 渡利 英道, 藤堂 幸治, 保坂 昌芳, 中郷 賢二郎, 小林 範子, 武田 真人, 蝦名 康彦, 山本 律, 水上 尚典, 櫻木 範明  北海道産科婦人科学会会誌  50-  (1)  113  -113  2006/06  [Not refereed][Not invited]
  
• 子宮頸癌の広汎子宮全摘術後ハイリスク症例に対する補助療法の検討

  保坂 昌芳, 武田 真人, 小田 泰也, 原 洋子, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  24-  (3)  300  -300  2006/06  [Not refereed][Not invited]
  
• 子宮体癌手術におけるリンパ節郭清の個別化 術前リンパ節転移予測スコア妥当性の研究

  藤堂 幸治, 小田 泰也, 保坂 昌芳, 武田 真人, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  24-  (3)  305  -305  2006/06  [Not refereed][Not invited]
  
• 【子宮体癌治療の最新トピックス】 進行期評価と治療方針の決定

  渡利 英道, 櫻木 範明  産婦人科の実際  55-  (5)  745  -751  2006/05  [Not refereed][Not invited]
  
• 【産婦人科 インフォームド・コンセントの実際】 婦人科(悪性腫瘍) 子宮体がん 手術療法

  渡利 英道, 櫻木 範明  産科と婦人科  73-  (Suppl.)  317  -324  2006/03  [Not refereed][Not invited]
  
• DNA array法による子宮頸部細胞診検体および子宮頸部浸潤癌組織検体中のヒトパピローマウイルス(HPV)の検出

  渡利 英道, 小田 泰也, 保坂 昌芳, 原 洋子, 荒木 直人, 藤堂 幸治, 武田 真人, 蝦名 康彦, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  58-  (2)  374  -374  2006/02  [Not refereed][Not invited]
  
• 変異型p53の機能を回復するCP-31398はp53遺伝子ドミナントネガティブ変異依存性体癌細胞増殖および浸潤の亢進を抑制する

  董 培新, 渡利 英道, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  58-  (2)  400  -400  2006/02  [Not refereed][Not invited]
  
• Weekly paclitaxel/5-fluorouracil併用療法を用いplatinum-free intervalを考慮した再発・抵抗性卵巣漿液性腺癌に対する治療成績

  保坂 昌芳, 渡利 英道, 小田 泰也, 原 洋子, 荒木 直人, 藤堂 幸治, 武田 真人, 蝦名 康彦, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  58-  (2)  431  -431  2006/02  [Not refereed][Not invited]
  
• 子宮頸部扁平上皮癌における術前検査とNAC

  武田 真人, 小田 泰也, 原 洋子, 保坂 昌芳, 荒木 直人, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  58-  (2)  592  -592  2006/02  [Not refereed][Not invited]
  
• 子宮頸癌に対するRetroperitoneal approachによる鏡視下リンパ節郭清

  工藤 正尊, 保坂 昌芳, 藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  58-  (2)  602  -602  2006/02  [Not refereed][Not invited]
  
• 子宮体癌手術におけるリンパ節郭清術適応の個別化 術前リンパ節転移予測スコア(LNM score)のValidation Study

  藤堂 幸治, 小田 泰也, 保坂 昌芳, 原 洋子, 荒木 直人, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  58-  (2)  606  -606  2006/02  [Not refereed][Not invited]
  
• 再発卵巣癌の手術治療計画におけるFDG-PETの有用性と限界について

  小田 泰也, 蝦名 康彦, 原 洋子, 保坂 昌芳, 藤堂 幸治, 荒木 直人, 武田 真人, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  58-  (2)  627  -627  2006/02  [Not refereed][Not invited]
  
• 婦人科癌再発診断におけるFDG-PETの有用性と限界に関する検討

  蝦名 康彦, 小田 泰也, 保坂 正芳, 原 洋子, 藤堂 幸治, 荒木 直人, 武田 真人, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌 = The journal of the Japan Society of Gynecologic Oncology  24-  (1)  53  -58  2006/01/25  [Not refereed][Not invited]
  
• 婦人科悪性腫瘍の臨床におけるPETの有効性とその限界 婦人科癌再発診断におけるFDG-PETの有用性と限界に関する検討

  蝦名 康彦, 小田 泰也, 保坂 正芳, 原 洋子, 藤堂 幸治, 荒木 直人, 武田 真人, 渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  24-  (1)  53  -58  2006/01  [Not refereed][Not invited]
   

  婦人科癌再発診断におけるFDG-PETの有用性と限界に関して検討した.対象は,婦人科癌治療後経過観察中の87例(平均56.5歳)で,原疾患は卵巣癌71例,子宮体癌11例,子宮頸癌5例であった.1)87例中55例(63.2%)が再発と診断され,FDG-PETならびにCT,腫瘍マーカーでの診断成績は,感度・特異度・正診率など全てでFDG-PETが最も良い成績であった.2)疾患別では,PETは卵巣癌では感度・特異度とも最も良かったが,子宮体癌ではCTが最もよく,子宮頸癌では感度は腫瘍マーカーと,特異度はCTと同程度であった.3)PET所見が治療方針に影響を与えたのは87例中58例(66.7%)であり,再発腫瘍摘出術を行った20例中19例がPET陽性であった.4)PET偽陰性は6例(卵巣癌3例,子宮体癌2例,子宮頸癌1例),偽陽性は3例(全例卵巣癌)であった.5)血清CA125値が腫瘍マーカーとなり得る74例では,CA125中央値はPET陰性例11.5U/mlに比し陽性例72.0U/mlと有意に高く,CA125値が20U/mlを超える症例ではPET陽性例が多く,再発例の頻度が高かった
• 子宮頸管熟化におけるエラスチン分解酵素(serine protease)カテプシンSの役割

  渡利 道子, 山田 秀人, 菅藤 満恵, 西田 竜太郎, 森川 守, 島田 茂樹, 片岡 宙門, 平山 恵美, 渡利 英道, 山田 俊, 櫻木 範明, 水上 尚典  北海道産科婦人科学会会誌  49-  (1)  32  -33  2006/01  [Not refereed][Not invited]
  
• 卵巣原発扁平上皮癌の1例

  寺島 瑞恵, 藤堂 幸治, 明石 大輔, 見延 進一郎, 小林 範子, 藤本 俊郎, 蝦名 康彦, 渡利 英道, 山本 律, 櫻木 範明  北海道産科婦人科学会会誌  49-  (1)  38  -38  2006/01  [Not refereed][Not invited]
  
• ヒト子宮頸部平滑筋細胞におけるThrombinの作用について

  渡利 道子, 赤石 理奈, 平野 加奈, 森川 守, 小林 範子, 片岡 宙門, 平山 恵美, 渡利 英道, 山田 秀人, 奥山 和彦, 水上 尚典  北海道産科婦人科学会会誌  48-  (1)  27  -27  2005/12  [Not refereed][Not invited]
  
• Liquid-phase binding assayを用いたフコシル化アルファーフェトプロテイン分画測定による,胎児21トリソミー検出法に関する検討

  見延 進一郎, 山本 律, 古山 有紀子, 石川 聡司, 小山 貴弘, 藤本 俊郎, 武田 真人, 渡利 英道, 根岸 広明, 櫻木 範明, 奥山 和彦, 水上 尚典  北海道産科婦人科学会会誌  48-  (1)  28  -29  2005/12  [Not refereed][Not invited]
  
• 鎖肛を伴った先天性腟欠損症の2症例

  小山 貴弘, 藤本 俊郎, 見延 進一郎, 武田 真人, 渡利 英道, 根岸 広明, 山本 律, 櫻木 範明  北海道産科婦人科学会会誌  48-  (1)  35  -36  2005/12  [Not refereed][Not invited]
  
• 当科で経験した卵管原発性類内膜腺癌症例の検討

  古山 有紀子, 見延 進一郎, 山本 律, 石川 聡司, 小山 貴弘, 藤本 俊郎, 武田 真人, 渡利 英道, 根岸 広明, 櫻木 範明  北海道産科婦人科学会会誌  48-  (1)  42  -43  2005/12  [Not refereed][Not invited]
  
• 原発性卵管癌3例の臨床的検討

  石川 聡司, 武田 真人, 見延 進一郎, 藤本 俊郎, 渡利 英道, 根岸 広明, 山本 律, 櫻木 範明  北海道産科婦人科学会会誌  48-  (1)  43  -43  2005/12  [Not refereed][Not invited]
  
• 子宮頸部腺癌における血清腫瘍マーカー値・腫瘍径とリンパ節転移との関連について

  保坂 昌芳, 武田 真人, 中郷 賢二郎, 小田 泰也, 小林 範子, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会東北連合地方部会誌  (53)  78  -78  2005/11  [Not refereed][Not invited]
  
• 子宮体癌III c期の病理組織学的予後因子についての検討

  小田 泰也, 渡利 英道, 藤堂 幸治, 保坂 昌芳, 中郷 賢二郎, 小林 範子, 武田 真人, 蝦名 康彦, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会東北連合地方部会誌  (53)  83  -83  2005/11  [Not refereed][Not invited]
  
• 子宮体癌に対する傍大動脈リンパ節郭清を含む手術治療成績について

  渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌 = The journal of the Japan Society of Gynecologic Oncology  23-  (4)  497  -502  2005/10/25  [Not refereed][Not invited]
  
• 子宮体癌の集学的治療 子宮体癌に対する傍大動脈リンパ節郭清を含む手術治療成績について

  渡利 英道, 櫻木 範明  日本婦人科腫瘍学会雑誌  23-  (4)  497  -502  2005/10  [Not refereed][Not invited]
   

  傍大動脈リンパ節郭清を含む根治手術を行った子宮体癌326例(平均55.8歳)の成績を報告した.FIGO進行期別の累積5年生存率(292例)はI期96.9%,II期87.7%,III期84.5%,IV期10.3%で,亜分類ではIa期100%,Ib期97.8%,Ic期92.3%,IIa期88.9%,IIb期87.1%,IIIa期95.0%,IIIc期73.8%,IVb期10.3%,組織型別では類内膜腺癌91.0%,特殊型53.8%であった.多変量解析による独立した予後因子は,「組織型」「核異型度」「脈管侵襲」「リンパ節転移」であった.次に,リンパ節転移陽性55例について「傍大動脈リンパ節転移の有無」を含め検討したところ,「腹膜転移」「脈管侵襲」が独立した予後因子であり,これら2因子により予後が層別化され,腹膜転移を有する症例の予後は極めて不良であった.腹膜転移を有しないリンパ節転移陽性44例での検討では,「脈管侵襲」と「傍大動脈リンパ節転移部位数」が独立した予後因子であり,これらの組み合わせにより予後層別化が可能であった
• リンパ節転移陽性例の予後因子とp53遺伝子変異解析に基づいた子宮体癌治療の個別化に向けての検討

  渡利 英道, 櫻木 範明  日本癌学会総会記事  64回-  66  -66  2005/09  [Not refereed][Not invited]
  
• DNAアレイ法を用いた子宮頸癌症例のHPVジェノタイピング

  道又 理恵, 尾川 直樹, 石津 明洋, 渡利 英道, 鈴木 昭, 外丸 詩野, 櫻木 範明, 笠原 正典, 吉木 敬  日本癌学会総会記事  64回-  93  -93  2005/09  [Not refereed][Not invited]
  
• 個別化治療への最先端研究 婦人科がん p53遺伝子変異解析に基づいた子宮体癌治療の個別化に向けての検討

  渡利 英道, 董 培新, 濱田 淳一, 多田 光宏, 守内 哲也, 櫻木 範明  日本癌学会総会記事  64回-  131  -132  2005/09  [Not refereed][Not invited]
  
• DNA array法を用いた子宮頸部浸潤癌組織中ヒトパピローマウイルス(HPV)の検出

  渡利 英道, 道又 理恵, 石津 明洋, 安田 元昭, 櫻木 範明  日本癌治療学会誌  40-  (2)  534  -534  2005/09  [Not refereed][Not invited]
  
• ヒト子宮頸部平滑筋細胞に対するLPSの作用について

  渡利 道子, 木川 聖美, 森川 守, 小林 範子, 片岡 宙門, 平山 恵美, 山田 秀人, 奥山 和彦, 渡利 英道, 藤本 聖一郎, 水上 尚典, 西平 順  北海道産科婦人科学会会誌  47-  (1)  37  -37  2005/09  [Not refereed][Not invited]
  
• 婦人科癌再発診断におけるFDG-PETの有用性と限界に関する検討

  蝦名 康彦, 保坂 正芳, 藤堂 幸治, 武田 真人, 渡利 英道, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌 = The journal of the Japan Society of Gynecologic Oncology  23-  (3)  335  -335  2005/06/25  [Not refereed][Not invited]
  
• 卵巣癌におけるセンチネルリンパ節の検討

  渡利 英道, 山本 律, 櫻木 範明, 根岸 広明  日本婦人科腫瘍学会雑誌 = The journal of the Japan Society of Gynecologic Oncology  23-  (3)  336  -336  2005/06/25  [Not refereed][Not invited]
  
• DNAarray法による子宮頸癌検体中ヒトパピローマウイルスの検出

  保坂 昌芳, 渡利 英道, 藤堂 幸治, 武田 真人, 蝦名 康彦, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  23-  (3)  352  -352  2005/06  [Not refereed][Not invited]
  
• 子宮体癌におけるCyr61の発現について

  渡利 英道, 熊 桜, 保坂 昌芳, 藤堂 幸治, 武田 真人, 蝦名 康彦, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  23-  (3)  354  -354  2005/06  [Not refereed][Not invited]
  
• 当科で経験した婦人科悪性腫瘍の脳転移症例の検討

  小田 泰也, 武田 真人, 保坂 昌芳, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  23-  (3)  356  -356  2005/06  [Not refereed][Not invited]
  
• 再発・抵抗性卵巣癌に対するweekly paclitaxel/5-fluorouracil併用療法のfeasibility study

  中郷 賢二郎, 渡利 英道, 小田 泰也, 保坂 昌芳, 藤堂 幸治, 武田 真人, 蝦名 康彦, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  23-  (3)  365  -365  2005/06  [Not refereed][Not invited]
  
• 当科における子宮頸部Bulky扁平上皮癌に対する広汎子宮全摘手術療法の治療成績

  武田 真人, 小田 泰也, 保坂 昌芳, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  23-  (3)  374  -374  2005/06  [Not refereed][Not invited]
  
• 妊娠中に子宮頸部悪性腺腫の合併を疑った症例

  藤堂 幸治, 保坂 昌芳, 武田 真人, 蝦名 康彦, 渡利 英道, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  23-  (3)  387  -387  2005/06  [Not refereed][Not invited]
  
• 広汎子宮全摘術における膀胱機能温存法

  藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 山本 律, 工藤 正尊, 水上 尚典, 櫻木 範明  産婦人科手術  (16)  138  -138  2005/06  [Not refereed][Not invited]
  
• 当科で経験した子宮体部癌肉腫の3例(子宮体部5, 第46回日本臨床細胞学会総会(春期大会))

  小田 秦也, 武田 真人, 保坂 昌芳, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 櫻木 範明, 太田 聡, 伊藤 智雄  日本臨床細胞学会雑誌  44-  (1)  2005/03/22  [Not refereed][Not invited]
  
• 当科で経験した卵管癌の4例(卵巣3, 第46回日本臨床細胞学会総会(春期大会))

  石川 聡司, 武田 真人, 小田 秦也, 保坂 昌芳, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 櫻木 範明, 太田 聡, 伊藤 智雄  日本臨床細胞学会雑誌  44-  (1)  2005/03/22  [Not refereed][Not invited]
  
• 初期卵巣癌 (Tl/T2) 症例における腹腔細胞診とリンパ節転移との関連(卵巣, 第46回日本臨床細胞学会総会(春期大会))

  蝦名 康彦, 小田 泰也, 保坂 昌芳, 藤堂 幸治, 武田 真人, 渡利 英道, 山本 律, 櫻木 範明  日本臨床細胞学会雑誌  44-  (1)  2005/03/22  [Not refereed][Not invited]
  
• 当科で経験した子宮体部癌肉腫の3例

  小田 泰也, 武田 真人, 保坂 昌芳, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 櫻木 範明, 太田 聡, 伊藤 智雄  日本臨床細胞学会雑誌  44-  (Suppl.1)  135  -135  2005/03  [Not refereed][Not invited]
  
• 当科で経験した卵管癌の4例

  石川 聡司, 武田 真人, 小田 泰也, 保坂 昌芳, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 櫻木 範明, 太田 聡, 伊藤 智雄  日本臨床細胞学会雑誌  44-  (Suppl.1)  144  -144  2005/03  [Not refereed][Not invited]
  
• 初期卵巣癌(T1/T2)症例における腹腔細胞診とリンパ節転移との関連

  蝦名 康彦, 小田 泰也, 保坂 昌芳, 藤堂 幸治, 武田 真人, 渡利 英道, 山本 律, 櫻木 範明  日本臨床細胞学会雑誌  44-  (Suppl.1)  201  -201  2005/03  [Not refereed][Not invited]
  
• 広汎子宮全摘術における新しい系統的自律神経温存法と術後膀胱機能の解析

  藤堂 幸治, 武田 真人, 小林 範子, 蝦名 康彦, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  57-  (2)  422  -422  2005/02  [Not refereed][Not invited]
  
• 当科におけるBulky子宮頸部扁平上皮癌に対する広汎子宮全摘手術療法の治療成績

  武田 真人, 小田 泰也, 保坂 昌芳, 小林 範子, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  57-  (2)  423  -423  2005/02  [Not refereed][Not invited]
  
• p53癌抑制遺伝子のdominant negative変異は進行子宮体癌の予後因子である

  董 培新, 渡利 英道, 蝦名 康彦, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  57-  (2)  448  -448  2005/02  [Not refereed][Not invited]
  
• 再発・抵抗性卵巣癌に対するweekly paclitaxel/5-fluorouracil併用療法のfeasibility study

  渡利 英道, 小田 泰也, 根岸 広明, 山村 満恵, 保坂 昌芳, 小林 範子, 藤堂 幸治, 武田 真人, 蝦名 康彦, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  57-  (2)  455  -455  2005/02  [Not refereed][Not invited]
  
• 卵巣悪性腫瘍(境界悪性腫瘍を含む)に対する妊孕能温存治療の臨床的検討

  保坂 昌芳, 山本 律, 小田 泰也, 小林 範子, 藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  57-  (2)  619  -619  2005/02  [Not refereed][Not invited]
  
• 婦人科癌再発症例の治療方針決定に際してFDG-PETは有用か?

  蝦名 康彦, 小田 泰也, 保坂 昌芳, 小林 範子, 藤堂 幸治, 武田 真人, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  57-  (2)  633  -633  2005/02  [Not refereed][Not invited]
  
• 子宮体癌の集学的治療 子宮体癌に対する傍大動脈リンパ節郭清を含む手術治療成績について

  渡利 英道, 涌井 之雄, 山下 幸紀, 櫻木 範明  日本婦人科腫瘍学会雑誌  22-  (4)  303  -303  2004/10  [Not refereed][Not invited]
  
• 158 当科で経験した子宮頸部乳頭状扁平上皮癌の2例(子宮頸部6)

  保坂 昌芳, 武田 真人, 小田 秦也, 見延 進一郎, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 櫻木 範明, 太田 聡, 伊藤 智雄  日本臨床細胞学会雑誌  43-  (2)  2004/09/22  [Not refereed][Not invited]
  
• 189 子宮体部小細胞癌の一例(子宮体部9)

  藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 山本 律, 櫻木 範明  日本臨床細胞学会雑誌  43-  (2)  2004/09/22  [Not refereed][Not invited]
  
• 癌治療とクリニカルPET 卵巣癌再発診断におけるFDG-PETの有用性に関する検討

  蝦名 康彦, 中郷 賢二郎, 小田 泰也, 小林 範子, 藤堂 幸治, 武田 真人, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本癌治療学会誌  39-  (2)  401  -401  2004/09  [Not refereed][Not invited]
  
• 脈管侵襲と傍大動脈リンパ節転移部位数による子宮体癌III c期の予後層別化

  渡利 英道, 藤堂 幸治, 保坂 昌芳, 中郷 賢二郎, 小田 泰也, 小林 範子, 武田 真人, 蝦名 康彦, 山本 律, 水上 尚典, 櫻木 範明  日本癌治療学会誌  39-  (2)  851  -851  2004/09  [Not refereed][Not invited]
  
• 当科で経験した子宮頸部乳頭状扁平上皮癌の2例

  保坂 昌芳, 武田 真人, 小田 泰也, 見延 進一郎, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 櫻木 範明, 太田 聡, 伊藤 智雄  日本臨床細胞学会雑誌  43-  (Suppl.2)  481  -481  2004/09  [Not refereed][Not invited]
  
• 子宮体部小細胞癌の一例

  藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 山本 律, 櫻木 範明  日本臨床細胞学会雑誌  43-  (Suppl.2)  497  -497  2004/09  [Not refereed][Not invited]
  
• 系統的自律神経温存広汎子宮全摘術と術前・術後の尿流動態学的検討

  藤堂 幸治, 佐々木 瑞恵, 小林 範子, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 山本 律, 櫻木 範明  日本外科系連合学会誌  29-  (3)  593  -593  2004/06  [Not refereed][Not invited]
  
• 当科で経験した子宮頸部乳頭状扁平上皮癌の4例

  武田 真人, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  22-  (3)  211  -211  2004/06  [Not refereed][Not invited]
  
• 脈管侵襲と傍大動脈リンパ節転移部位数は子宮体癌IIIc期の予後因子である

  渡利 英道, 藤堂 幸治, 武田 真人, 蝦名 康彦, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  22-  (3)  227  -227  2004/06  [Not refereed][Not invited]
  
• 卵巣癌再発診断におけるFDG-PETの有用性に関する検討

  蝦名 康彦, 藤堂 幸治, 武田 真人, 渡利 英道, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  22-  (3)  233  -233  2004/06  [Not refereed][Not invited]
  
• 小腸原発Gastrointestinal stromal tumor(GIST)の一例

  藤堂 幸治, 武田 真人, 蝦名 康彦, 渡利 英道, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  22-  (3)  246  -246  2004/06  [Not refereed][Not invited]
  
• S3-3 初期卵巣癌(T1/T2)症例における腹腔細胞診とリンパ節転移との関連(シンポジウム3 : (卵巣がんにおける細胞診の現状と問題点)

  蝦名 康彦, 藤堂 幸治, 武田 真人, 渡利 英道, 山本 律, 櫻木 範明  日本臨床細胞学会雑誌  43-  (1)  2004/05/22  [Not refereed][Not invited]
  
• 48 DNA array法による子宮頸部擦過細胞診検体中ヒトパピローマウイルスの検出(子宮頸部 2)

  渡利 英道, 松並 平晋, 道又 理恵, 白川 洋三, 清野 邦義, 藤田 博正, 山本 律, 櫻木 範明  日本臨床細胞学会雑誌  43-  (1)  2004/05/22  [Not refereed][Not invited]
  
• 初期卵巣癌(T1/T2)症例における腹腔細胞診とリンパ節転移との関連

  蝦名 康彦, 藤堂 幸治, 武田 真人, 渡利 英道, 山本 律, 櫻木 範明  日本臨床細胞学会雑誌  43-  (Suppl.1)  95  -95  2004/05  [Not refereed][Not invited]
  
• DNA array法による子宮頸部擦過細胞診検体中ヒトパピローマウイルスの検出

  渡利 英道, 松並 平晋, 道又 理恵, 白川 洋三, 清野 邦義, 藤田 博正, 山本 律, 櫻木 範明  日本臨床細胞学会雑誌  43-  (Suppl.1)  158  -158  2004/05  [Not refereed][Not invited]
  
• 系統的自律神経温存広汎子宮全摘術と術前・術後の尿流動態学的検討

  藤堂 幸治, 寺島 瑞恵, 小林 範子, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本ウロギネコロジー研究会誌  1-  (1)  37  -37  2004/05  [Not refereed][Not invited]
  
• 【産婦人科手術時の合併症軽減のために】 子宮内膜症での子宮全摘術

  渡利 英道, 櫻木 範明  産婦人科の実際  53-  (3)  369  -375  2004/03  [Not refereed][Not invited]
   

  子宮内膜症合併時の子宮全摘術の際の留意点について概説した.この場合,子宮内膜症による骨盤内の癒着によって子宮と周囲組織との関係が正常の解剖と異なる状態であることを念頭において手術を進めなければならない.そのためには,広汎子宮全摘術の際に行う手術操作に習熟しておく必要がある.又,尿路系の損傷や腸管の損傷が発生した場合に対処できる技術を身につけておくべきであるが,状況によっては外科や泌尿器科に協力を要請することを躊躇すべきではない
• DNA array法による子宮頸部細胞診検体中ヒトパピローマウイルスの検出

  渡利 英道, 山本 律, 水上 尚典, 櫻木 範明, 安田 元昭, 柴田 健一郎, 白田 勝利, 西村 訓弘, 白川 洋三, 藤田 博正  日本産科婦人科学会東北連合地方部会誌  (51)  108  -108  2004/03  [Not refereed][Not invited]
  
• 直腸子宮内膜症に発生した類内膜腺癌に子宮体部類内膜腺癌を同時発生した一例

  藤堂 幸治, 寺島 瑞恵, 明石 大輔, 見延 進一郎, 小林 範子, 藤本 俊郎, 武田 真人, 蝦名 康彦, 渡利 英道, 山本 律, 櫻木 範明  日本産科婦人科学会東北連合地方部会誌  (51)  113  -114  2004/03  [Not refereed][Not invited]
  
• 卵巣腫瘍との鑑別が困難であった小腸Gastrointestinal stromal tumor(GIST)の二症例

  寺島 瑞恵, 藤堂 幸治, 小林 範子, 見延 進一郎, 藤本 俊郎, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会東北連合地方部会誌  (51)  119  -119  2004/03  [Not refereed][Not invited]
  
• 卵巣癌再発におけるFDG-PETの有用性

  明石 大輔, 蝦名 康彦, 小林 範子, 見延 進一郎, 藤本 俊郎, 藤堂 幸治, 武田 真人, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会東北連合地方部会誌  (51)  122  -122  2004/03  [Not refereed][Not invited]
  
• 卵巣癌再発診断におけるFDG-PETの有用性に関する検討

  蝦名 康彦, 明石 大輔, 寺島 瑞恵, 小林 範子, 池田 研, 藤堂 幸治, 武田 真人, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  56-  (2)  312  -312  2004/02  [Not refereed][Not invited]
  
• DNA array法による子宮頸部擦過細胞診検体中ヒトパピローマウイルスの検出

  渡利 英道, 安田 元昭, 白田 勝利, 西村 訓弘, 藤田 博正, 柴田 健一郎, 藤堂 幸治, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  56-  (2)  345  -345  2004/02  [Not refereed][Not invited]
  
• 子宮体癌組織型とp53癌抑制遺伝子変異の機能的variationとの関連

  山本 律, 藤堂 幸治, 渡利 英道, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  56-  (2)  362  -362  2004/02  [Not refereed][Not invited]
  
• II-IV期卵巣癌の組織型,GST-pi,MDR-1,p53発現の予後因子としての意義

  池田 研, 酒井 慶一郎, 晴山 仁志, 津村 宣彦, 石崎 善昭, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  56-  (2)  371  -371  2004/02  [Not refereed][Not invited]
  
• 系統的自律神経温存広汎子宮全摘術と術前・術後の尿流動態学的検討

  藤堂 幸治, 寺島 瑞恵, 明石 大輔, 小林 範子, 池田 研, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  56-  (2)  390  -390  2004/02  [Not refereed][Not invited]
  
• 子宮頸部腺癌における血清腫瘍マーカー値・腫瘍径とリンパ節転移との関連について

  武田 真人, 明石 大輔, 寺島 瑞恵, 小林 範子, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  56-  (2)  550  -550  2004/02  [Not refereed][Not invited]
  
• 初期卵巣癌におけるリンパ節転移について

  根岸 広明, 武田 真人, 藤本 俊郎, 見延 進一郎, 小林 範子, 渡利 英道, 蝦名 康彦, 山本 律, 津村 宣彦, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  56-  (2)  581  -581  2004/02  [Not refereed][Not invited]
  
• 21-22.初期卵巣癌におけるリンパ節転移について(第102群 卵巣腫瘍13)(一般演題)

  根岸 広明, 武田 真人, 藤本 俊郎, 見延 進一郎, 小林 範子, 渡利 英道, 蝦名 康彦, 山本 律, 津村 宣彦, 水上 尚典, 櫻木 範明  日本産科婦人科學會雜誌  56-  (2)  581  -581  2004/02/01  [Not refereed][Not invited]
  
• 1-33.DNA array法による子宮頚部擦過細胞診検体中ヒトパピローマウイルスの検出(第3群 子宮頸部悪性腫瘍3)(一般演題)

  渡利 英道, 安田 元昭, 白田 勝利, 西村 訓弘, 藤田 博正, 柴田 健一郎, 藤堂 幸治, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科學會雜誌  56-  (2)  345  -345  2004  [Not refereed][Not invited]
  
• 152.子宮頸部小細胞癌2例の検討(子宮頸部8)(第42回日本臨床細胞学会秋期大会)

  藤本 俊郎, 見延 進一郎, 武田 真人, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 櫻本 範明  日本臨床細胞学会雑誌  42-  (2)  2003/09/22  [Not refereed][Not invited]
  
• 159.子宮頸部に浸潤した急性骨髄性白血病の一例(子宮頸部9)(第42回日本臨床細胞学会秋期大会)

  武田 真人, 太田 聡, 伊藤 智雄, 見延 進一郎, 藤堂 幸治, 藤本 俊郎, 蝦名 康彦, 渡利 英道, 榎本 範明  日本臨床細胞学会雑誌  42-  (2)  2003/09/22  [Not refereed][Not invited]
  
• 345.卵巣原発扁平上皮癌の一例(卵巣1)(第42回日本臨床細胞学会秋期大会)

  藤堂 幸治, 蝦名 康彦, 寺島 瑞恵, 藤本 俊郎, 武田 真人, 渡利 英道, 櫻木 範明  日本臨床細胞学会雑誌  42-  (2)  2003/09/22  [Not refereed][Not invited]
  
• 357.卵巣腫瘍との鑑別が困難であった小腸原発gastrointestinal stromal tumor(GIST)の一例(卵巣3)(第42回日本臨床細胞学会秋期大会)

  寺島 瑞恵, 藤堂 幸治, 藤本 俊郎, 武田 真人, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本臨床細胞学会雑誌  42-  (2)  2003/09/22  [Not refereed][Not invited]
  
• 子宮頸部小細胞癌2例の検討

  藤本 俊郎, 見延 進一郎, 武田 真人, 藤堂 幸治, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本臨床細胞学会雑誌  42-  (Suppl.2)  417  -417  2003/09  [Not refereed][Not invited]
  
• 子宮頸部に浸潤した急性骨髄性白血病の一例

  武田 真人, 太田 聡, 伊藤 智雄, 見延 進一郎, 藤堂 幸治, 藤本 俊郎, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本臨床細胞学会雑誌  42-  (Suppl.2)  421  -421  2003/09  [Not refereed][Not invited]
  
• 卵巣原発扁平上皮癌の一例

  藤堂 幸治, 蝦名 康彦, 寺島 瑞恵, 藤本 俊郎, 武田 真人, 渡利 英道, 櫻木 範明  日本臨床細胞学会雑誌  42-  (Suppl.2)  514  -514  2003/09  [Not refereed][Not invited]
  
• 卵巣腫瘍との鑑別が困難であった小腸原発gastrointestinal stromal tumor(GIST)の一例

  寺島 瑞恵, 藤堂 幸治, 藤本 俊郎, 武田 真人, 蝦名 康彦, 渡利 英道, 櫻木 範明  日本臨床細胞学会雑誌  42-  (Suppl.2)  520  -520  2003/09  [Not refereed][Not invited]
  
• 卵巣悪性腫瘍(境界悪性腫瘍を含む)における妊孕能温存症例の臨床的検討

  山本 律, 見延 進一郎, 小林 範子, 藤本 俊郎, 武田 真人, 蝦名 康彦, 渡利 英道, 工藤 正尊, 岡元 一平, 晴山 仁志, 水上 尚典, 櫻木 範明  日本癌治療学会誌  38-  (2)  241  -241  2003/09  [Not refereed][Not invited]
  
• 子宮頸部初期浸潤癌における脈管侵襲及びリンパ節転移の検討

  蝦名 康彦, 岡元 一平, 小林 範子, 藤堂 幸治, 藤本 俊郎, 見延 進一郎, 武田 真人, 渡利 英道, 山本 律, 水上 尚典, 櫻木 範明  日本癌治療学会誌  38-  (2)  372  -372  2003/09  [Not refereed][Not invited]
  
• 子宮体癌リンパ節転移陽性例の予後因子

  渡利 英道, 藤堂 幸治, 見延 進一郎, 小林 範子, 藤本 俊郎, 武田 真人, 蝦名 康彦, 工藤 正尊, 山本 律, 水上 尚典, 櫻木 範明  日本癌治療学会誌  38-  (2)  709  -709  2003/09  [Not refereed][Not invited]
  
• 【子宮内膜癌のライフサイエンス'03】 子宮体部類内膜腺癌におけるマトリックスメタロプロテアーゼ(MMP)-1プロモーター遺伝子多型と病理組織学的予後因子との関連について

  渡利 英道, 藤本 俊郎, 藤堂 幸治, 櫻木 範明  産婦人科の世界  55-  (8)  921  -928  2003/08  [Not refereed][Not invited]
   

  マトリックスメタロプロテアーゼ(MMP)-1プロモーター遺伝子1G/2G多型と子宮体部類内膜腺癌の病理組織学的予後因子との関連を解析し,1G/2G多型が子宮体癌の新たな予後因子となる可能性について検討を行った.MMP-1プロモーター遺伝子多型が子宮体部類内膜腺癌の予後因子となりうることが示唆された
• DNAアレイ法を用いたヒトパピローマウイルスの網羅的検出法

  安田 元昭, 白田 勝利, 西村 訓弘, 岩澤 晶彦, 渡利 英道, 櫻木 範明, 柴田 健一郎  日本癌学会総会記事  62回-  290  -290  2003/08  [Not refereed][Not invited]
  
• 子宮頸部扁平上皮癌における血清腫瘍マーカー値・腫瘍径とリンパ節転移との関連についての検討

  武田 真人, 藤本 俊郎, 蝦名 康彦, 渡利 英道, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌 = The journal of the Japan Society of Gynecologic Oncology  21-  (3)  2003/06/25  [Not refereed][Not invited]
  
• 腫瘍マーカーは婦人科腫瘍の診断と治療にどのくらい有益か? 子宮頸部扁平上皮癌における血清腫瘍マーカー値・腫瘍径とリンパ節転移との関連についての検討

  武田 真人, 藤本 俊郎, 蝦名 康彦, 渡利 英道, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  21-  (3)  169  -169  2003/06  [Not refereed][Not invited]
  
• 子宮体癌における傍大動脈リンパ節転移の予測

  藤堂 幸治, 藤本 俊郎, 武田 真人, 渡利 英道, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  21-  (3)  201  -201  2003/06  [Not refereed][Not invited]
  
• 初期卵巣癌におけるリンパ節転移について

  根岸 広明, 武田 真人, 藤本 俊郎, 見延 進一郎, 小林 範子, 渡利 英道, 山本 律, 櫻木 範明  日本婦人科腫瘍学会雑誌  21-  (3)  202  -202  2003/06  [Not refereed][Not invited]
  
• 自律神経温存広汎子宮全摘術後の排尿機能

  藤堂 幸治, 藤本 俊郎, 武田 真人, 蛯名 康彦, 渡利 英道, 山本 律, 桑原 道弥, 櫻木 範明  日本外科系連合学会誌  28-  (3)  575  -575  2003/05  [Not refereed][Not invited]
  
• 子宮頸部扁平上皮癌における血清腫瘍マーカー値・腫瘍径とリンパ節移転との関連について

  西田 竜太郎, 武田 真人, 石川 聡司, 見延 進一郎, 藤本 俊郎, 渡利 英道, 根岸 広明, 山本 律, 櫻木 範明  日本産科婦人科学会東北連合地方部会報  (50)  78  -78  2003/05  [Not refereed][Not invited]
  
• 鎖肛を伴った先天性腟欠損症の2症例

  小山 貴弘, 藤本 俊郎, 見延 進一郎, 武田 真人, 渡利 英道, 根岸 広明, 山本 律, 櫻木 範明  日本産科婦人科学会東北連合地方部会報  (50)  83  -84  2003/05  [Not refereed][Not invited]
  
• 原発性卵管癌3例の臨床的検討

  石川 聡司, 武田 真人, 渡利 英道, 見延 進一郎, 藤本 俊郎, 根岸 広明, 山本 律, 櫻木 範明  日本産科婦人科学会東北連合地方部会報  (50)  123  -124  2003/05  [Not refereed][Not invited]
  
• 当科で経験した卵管原発性類内膜腺癌の1症例

  古山 有紀子, 見延 進一郎, 山本 律, 石川 聡司, 小山 貴弘, 藤本 俊郎, 武田 真人, 渡利 英道, 根岸 広明, 櫻木 範明  日本産科婦人科学会東北連合地方部会報  (50)  124  -124  2003/05  [Not refereed][Not invited]
  
• 子宮体部類内膜腺癌におけるマトリックスメタロプロテアーゼ(MMP)-1プロモーター遺伝子多型と病理学的予後因子との関連について

  渡利 英道, 藤本 俊郎, 藤堂 幸治, 石川 聡司, 見延 進一郎, 小林 範子, 武田 真人, 根岸 広明, 山本 律, 水上 尚典, 櫻木 範明  日本産科婦人科学会雑誌  55-  (2)  190  -190  2003/02  [Not refereed][Not invited]
  
• ヒト子宮頸部平滑筋細胞(CSMC)とヒト白血球由来細胞(THP-1)におけるトロンビンの作用について

  渡利 道子, 赤石 理奈, 平野 加奈, 森川 守, 片岡 宙門, 藤本 俊郎, 平山 恵美, 渡利 英道, 山田 秀人, 奥山 和彦, 櫻木 範明, 水上 尚典  日本産科婦人科学会雑誌  55-  (2)  229  -229  2003/02  [Not refereed][Not invited]
  
• 婦人科悪性腫瘍に対する動体追跡照射の試み

  山本 律, 見延 進一郎, 小林 範子, 藤本 俊郎, 武田 真人, 渡利 英道, 根岸 広明, 櫻木 範明  日本産科婦人科学会雑誌  55-  (2)  399  -399  2003/02  [Not refereed][Not invited]
  
• 子宮体癌におけるp53,MDR-1,GST-pi発現の検討 組織型との関連

  藤堂 幸治, 武田 真人, 岡元 一平, 渡利 英道, 山本 律, 櫻木 範明, 藤本 征一郎  日本婦人科腫瘍学会雑誌  20-  (3)  365  -365  2002/06  [Not refereed][Not invited]
  
• Lipopolysaccharide(LPS)はヒト子宮頸部平滑筋細胞におけるInterleukin-8(IL-8)の発現・誘導を促進する

  渡利 道子, 渡利 英道, 山田 秀人, 西平 順, 奥山 和彦, 水上 尚典, 藤本 征一郎  日本産科婦人科学会雑誌  54-  (2)  257  -257  2002/02  [Not refereed][Not invited]
  
• 妊娠中に発症した急性突発性末梢性顔面神経麻痺の3症例

  川上 博史, 渡利 英道, 横尾 洋一, 大久保 仁, 高後 亮  日本産科婦人科学会東北連合地方部会報  (48)  112  -112  2001/03  [Not refereed][Not invited]
  
• プロゲステロンによるNiemann-Pick C1(NPC1)遺伝子の発現増加

  渡利 英道, ストラウス・ジェローム  日本産科婦人科学会雑誌  53-  (2)  258  -258  2001/02  [Not refereed][Not invited]
  
• Niemann-Pick type C1遺伝子産物(NPC1)の構造と機能について

  渡利 英道, Strauss III Jerome F, 藤本 征一郎  日本産科婦人科学会雑誌  52-  (2)  513  -513  2000/02  [Not refereed][Not invited]
  
• 【卵巣における性ステロイド代謝とその調節因子】 ステロイド産生急性調節性(StAR)蛋白質のステロイドホルモン産生における役割

  菅原 照夫, 渡利 英道, 藤本 征一郎  産科と婦人科  65-  (3)  292  -299  1998/03  [Not refereed][Not invited]
  
• 子宮体癌におけるゲルゾリン発現の免疫組織学的検討

  晴山 仁志, 渡利 英道, 古屋 充子, 香城 恒麿, 山本 律, 藤野 敬史, 牧野田 知, 藤本 征一郎, 葛巻 暹  北海道産科婦人科学会会誌  41-  (1)  33  -33  1997/03  [Not refereed][Not invited]
  
• 妊娠中 感染 サイトメガロウイルス

  渡利 英道, 松本 憲則, 藤本 征一郎  周産期医学  26-  (増刊)  96  -99  1996/11  [Not refereed][Not invited]
  
• 若年妊娠の産科学的問題点

  渡利 英道, 藤本 俊郎, 藤本 裕子  産婦人科の世界  48-  (9)  807  -813  1996/09  [Not refereed][Not invited]
  
• 子宮頸部の小細胞癌の1例 : 第35回日本臨床細胞学会秋季大会 : 子宮頸部V

  蝦名 康彦, 晴山 仁志, 古屋 充子, 八重樫 稔, 渡利 英道, 香城 恒麿, 十亀 真志, 牧野田 知, 藤本 征一郎, 荒川 三紀雄, 藤田 美悧, 井上 和秋  日本臨床細胞学会雑誌  35-  (2)  356  -356  1996/09  [Not refereed][Not invited]
  
• Fetal cystic hygromaの臨床的検討

  渡利 英道, 金内 優典, 山田 秀人  産婦人科の実際  45-  (5)  571  -577  1996/05  [Not refereed][Not invited]
   

  当科で最近経験したfetal cystic hygromaの11症例を臨床的に検討した. 1)正常核型を有する症例が1/3を占めていること, 2)他の先天奇形の合併率が必ずしも高くないこと,等が確認された.したがって,fetal cystic hygromaの管理については,画一的なターミネーションには問題があり,妊娠早期の超音波診断及び染色体分析,胎児水腫ならびに他の先天奇形の合併について評価することによってその予後を判定し,個別的に管理することの必要性が感じられた
• 若年妊娠

  渡利 英道, 山田 崇弘, 斉藤 千奈美  産婦人科の実際  44-  (11)  1620  -1625  1995/10  [Not refereed][Not invited]
  
• Roles of ras Genes on Biological Properties of Human Choriocarcinoma Cells

  Watari Hidemichi  The Hokkaido journal of medical science  70-  (4)  623  -634  1995/07  [Not refereed][Not invited]
   

  ヒト絨毛癌細胞株CC1にv-H-ras,v-K-rasを導入して各々の発現クローンを樹立し,その形質の変化を対照クローンと比較検討した. 1)v-H-ras発現クローンにおいてのみNa+-K+-ATPase活性の上昇に基づくと考えられるドーム形成が観察され,H-rasが絨毛細胞におけるNa+-K+-ATPaseを介した経細胞性輸送機構に促進的に作用する可能性がはじめて示唆された. 2)v-K-ras発現クローンが有意に高いhCG分泌能を示したことから,K-rasが妊娠維持機構に重要な役割を担っている可能性が推察された
• 産婦人科薬物療法の実際 妊娠悪阻の治療

  岸田 達朗, 渡利 英道, 晴山 仁志  産婦人科治療  70-  (5)  576  -582  1995/05  [Not refereed][Not invited]
  
• v-K-ras癌遺伝子導入によるヒト絨毛性ゴナドトロピンβの分泌増加

  渡利 英道  日本産科婦人科学会雑誌  47-  (Suppl.)  248  -248  1995/02  [Not refereed][Not invited]
  
• H-ras癌遺伝子によるヒト絨毛癌細胞株CC 1のドーム形成

  渡利 英道  日本癌学会総会記事  53回-  192  -192  1994/10  [Not refereed][Not invited]
  
• 妊娠後期におけるCefodizime(CDZM)の経胎盤移行性について

  花谷 馨, 渡利 英道, 岸田 達朗  産婦人科の世界  46-  (5)  385  -391  1994/05  [Not refereed][Not invited]
  
• 妊娠診断補助薬『シュアーステップhCG』と『HCGテストパックプラス』の臨床的比較検討 妊娠,絨毛性疾患,続発性無月経症例よりの臨床検体を用いて

  武田 直毅, 八重樫 稔, 渡利 英道  産科と婦人科  61-  (4)  569  -572  1994/04  [Not refereed][Not invited]
  
• 羊水産生機序に関する最近の知見

  渡利 英道, 晴山 仁志, 藤本 征一郎  産科と婦人科  61-  (2)  201  -206  1994/02  [Not refereed][Not invited]
  
• H-ras癌遺伝子導入によるヒト絨毛癌細胞株CC1の形態変化について

  渡利 英道  日本産科婦人科学会雑誌  46-  (Suppl.)  272  -272  1994/02  [Not refereed][Not invited]
  
• 産婦人科における痛み 流産と痛み

  渡利 英道, 田中 俊誠, 藤本 征一郎  産婦人科の実際  41-  (10)  1491  -1494  1992/09  [Not refereed][Not invited]
  
• 女性と味覚

  渡利 英道, 和泉 宏弥, 田中 俊誠  臨床婦人科産科  46-  (1)  115  -119  1992/01  [Not refereed][Not invited]
   

  健康非妊娠婦人群280名,特記すべき疾患をもたない正常妊娠婦人群1061名,ならびに合併疾患を認めない45歳より55歳までの更年期婦人群27名について調べた.1)黄体期では卵胞期と比べ明らかに味覚感受性は低下し,感受性に周期性のあることが認められた.また,健康男子と比較すると塩味をのぞき月経周期のいかんによらず感受性は低下し,塩味だけは黄体期に限り男子より低下していることが認められた.2)妊娠に際しては,妊娠3ヵ月で急激な感受性の低下がみられ,漸次回復し妊娠5ヵ月より黄体期にみられる感受性の範囲を推移するが,塩,酸味に限り妊娠9ヵ月で再び軽度感受性の低下する傾向が認められた
• 周産期医学 妊娠中 喘息合併妊娠

  田中 俊誠, 渡利 英道, 藤本 征一郎  周産期医学  21-  (増刊)  131  -138  1991/12  [Not refereed][Not invited]
  
• 出産年齢をめぐって 若年妊娠の予後 産科学的考察

  渡利 英道, 田中 俊誠, 藤本 征一郎  周産期医学  21-  (12)  1751  -1756  1991/12  [Not refereed][Not invited]
  
• 次回妊娠へのアドバイス 妊娠悪阻

  渡利 英道, 田中 俊誠, 藤本 征一郎  産婦人科の実際  39-  (10)  1419  -1426  1990/09  [Not refereed][Not invited]
  
• 初診 性機能の異常 月経異常

  藤野 敬史, 田中 俊誠, 渡利 英道  綜合臨床  39-  (増刊)  1461  -1466  1990/05  [Not refereed][Not invited]